

# MINISTRY OF HEALTH ERITREA

# NATIONAL MASTER PLAN FOR NEGELECTED TROPICAL DISEASES 2015-2020

# **Table of Contents**

| Acronyms  |
|---|
| List of Figures   |
| Forward 6   |
| Acknowledgment7   |
| List of contributors:   |
| INTRODUCTION  |
| PART 1: SITUATION ANALYSIS11  |
| 1.1 Country Profile   |
| 1.1.1 Administrative, demographic and community structures11                        |
| 1.1.2 Geographic characteristics  |
| 1.1.3 Socio-economic status and indicators17  |
| 1.1.4Transportation and communication17   |
| 1.2 Health System Situation Analysis  |
| 1.2.1 Health System Goals & Priorities18  |
| 1.2.2 Analysis of the overall Health System 19                                      |
| 1.3 NTD Situation Analysis  |
| 1.3.1 Epidemiology and burden of disease24  |
| 1.3.2 NTD programme implementation67  |
| 1.3.3 Gaps and Priorities   |
| PART 2: NTD STRATEGIC AGENDA  |
| 2.1. Overall NTD Programme Vision, Mission and Goals73                              |
| 2.2. Guiding principles and strategic priorities73                                  |
| 2.3 NATIONAL NTD PROGRAMME GOALS, OBJECTIVES, STRATEGIES AND TARGETS                |
| 2.4 National Milestones   |
| PART 3: OPERATIONAL FRAMEWORK82   |
| 3.1 Scaling up access to NTD Interventions, treatment and service delivery capacity |
| 3.1.1 Scaling up preventive chemotherapy interventions                              |
| 3.1.2 Scaling up NTD Case management Interventions                                  |
| 3.3Pharcovigilance in NTD control activities  |

| 3.4 Strengthening Capacity at National Level for NTD programme management and implementation 94  |
|--|
| 3.5 Enhancing planning for results, Resource Mobilization and Financial Sustainability           |
| 3.6 Strengthening Government Ownership, Advocacy, Coordination and Partnerships                  |
| 3.8. Post intervention surveillance and integration within Primary Health Care                   |
| Contact addresses:   |
| PART 2: OPERATIONAL FRAMEWORK  |
| Annex 2. 1: Package of Preventive Chemotherapy (PCT) - Mass drug administration (MDA)117         |
| Annex 2.2: Package of Case management (CM) and chronic care                                      |
| Annex 2. 3: PCT algorithm 1118   |
| Annex 2.4: PCT algorithm 2   |
| Annex 2.5: Algorithm for Co-endemicity of CM-NTDs (Lepros y and Leishmaniasis) in Eritrea 119    |
| Annex 2.6 Package of Transmission control - vector/reservoir control                             |
| Annex 2.7: Package of Improvement of Environment, Supply of safe drinking water, sanitation, and |
| operational research   |
| Annex 2.8: "WHAT to do" by sub zoba (operational unit) by operational package                    |
| Annex 2.9: Drug estimates and logistics123   |
| Annex 2.10: Drug forecasting and logistics   |
| Annex 2.11: Summary of progressive scale up and phase out of PCT interventions package           |
| Annex 2.12: Results framework for the WHO-HQ-AFRO-APOC Strategic Plan, 2015–2020 125             |
| Bibliography127  |

# Acronyms

| ADR   | Adverse drug reactions                               |
|-------|--|
| AFRO  | World Health Organization Regional Office for Africa |
| AIDS  | Acquired Immunodeficiency Syndrome                   |
| APOC  | African Programme for Onchocerciasis Control         |
| ARI   | Acute Respiratory Infections                         |
| CDC   | Communicable Disease Control                         |
| CLS   | Clinical Laboratory Science                          |
| СМ    | Case management                                      |
| DF    | Dengue Fever   |
| DKB   | Debubawi Keih Bahri Zone                             |
| DSS   | Decision Support System                              |
| HF    | Health Facility                                      |
| HSSDP | Health Sector Strategic and Development Plan         |
| HIV   | Human Immuno Deficiency Virus                        |
| HMIS  | Health Management Information System                 |
| HQ    | Head quarter   |
| IDM   | Intensified Disease management                       |
| IDSR  | Integrated Disease Surveillance & Response           |
| IPD   | In-patient Department                                |
| KEMRI | Kenya Medical Research Institute                     |
| LEISH | Leishmaniasis  |
| LEP   | Leprosy  |
| LF    | Lymphatic Filariasis                                 |
| MLT   | Medical Laboratory Technician                        |
| MOE   | Ministry of Education                                |
| MoH   | Ministry of Health                                   |
| NGO   | Non-governmental organizations                       |
| NHL   | National Health Laboratory                           |
| NMFA  | National Medicine and Food Administration            |
| OPD   | Out-patient Department                               |
| PCT   | Preventive chemotherapy                              |
| PHC   | Primary Health Care                                  |
| SCH-  | Schistosomiasis                                      |
| SKB   | Semenawi Keih Bahri Zone                             |
| TF-   | Trachomatous Follicular Inflammation                 |
| TRA   | Trachoma   |
| TS    | Trachomatous Conjunctival Scarring                   |
| TT    | Trachomatous Trichiasis                              |
| СО    | Corneal Opacity                                      |
| VHCP  | Village Health Committee Promoters                   |

World Health Organization

WHO

# **List of Figures**

| Figure 1: Administrative map of Eritrea                                | 12 |
|--|----|
| Figure 2: Eritrea population pyramid by age and sex                    | 15 |
| Figure 3: Peoples of Eritrea   | 15 |
| Figure 4: Geographic map of Eritrea                                    | 16 |
| Figure 5: Levels of Service delivery                                   | 19 |
| Figure 6: Distribution of Health Facilities in Eritrea                 | 20 |
| Figure 7: Co-endemicity map for Neglected Tropical Diseases in Eritrea | 67 |

# Forward

Neglected Tropical Diseases (NTD) as the name indicates are a group of diseases that are more or less neglected. The burden of these diseases in endemic countries is high and despite the availability of safe and cost-effective interventions for their prevention and control the resource allocated for NTDs is still inadequate.

The known endemic NTDs in Eritrea are Schistosomiasis, Intestinal Helminthiasis, Trachoma, Lymphatic Filariasis, Leprosy, Dengue Fever and Leishmaniasis and. Exceptionally Eritrea was certified free of Guineaworm disease in 2011. The Neglected Tropical Diseases Programme(NTDP) focuses on an integrated control of the endemic 7 out of the 13 diseases that WHO has classified as common NTDs. Other NTD diseases such as Rabies, Brucellosis and Anthrax which are not on this priority list will be incorporated in the Zonal or sub-zonal activities where they are endemic. NTDP will use cost-effective interventions for prevention, control and elimination of these endemic NTDs.

In order to tackle these diseases, the Eritrea MOH is strengthening with human resources the recently established NTDP under the Communicable Disease Control Division (CDCD). The aim of NTD programme is to increase access to effective drugs for the affected communities. This is supported by other interventions for vector control as well as health education and promotion, environmental management and safe drinking water. An integrated approach to the control of NTDs will save costs and, strengthen the health system for greater impact. The PHASE approach which is preventive chemotherapy, health education, access to clean water, sanitation improvement and environmental manipulation will be the priority activities.

The main objective of this revised Master Plan is to meet the 2020 NTD elimination targets and goals as defined in WHA resolution 66.12 and in the Regional Committee Resolutions. It will provide a tool that clearly articulates the strategies for joint planning, budgeting and resource mobilization for NTDs control and elimination through sustainable integrated interventions.in line with WHO guidelines. It addresses the gaps and challenges from the experiences and lessons learned from the programme implementation in the past years.

The MOH with the collaboration of its stakeholders and partners, including local communities, will achieve the goals set in this Master Plan. The NTD Master Plan 2015-2020 is therefore, an expression of government's commitment and determination to confront NTDS and deliver the best possible response, at all levels, to the people of Eritrea.

Amina Nurhussein Minister for Health Eritrea

## Acknowledgment

The MoH would like to express its deepest gratitude to the NTD-Technical Working Group for their tremendous effort and commitment in updating the existing master plan for NTDs in a very short time.

Our thanks also go to WHO/AFRO and WHO/Eritrea for supporting and facilitating the development of this mater plan. The Ministry greatly appreciates WHO consultants Dr. Ngozi Njepuome and Dr. Nicholas Tendongfor for facilitating and leading the work in finalizing the 2015-2020 NTD Master Plan.

We also thank the Eritrean Mapping and Information Center for providing valuable geographic information of the country.

Dr. Andeberhan Tesfazion A/Director General, Dept. of Public Health, MOH

# List of contributors:

| Dr. Araia Berhane       | Communicable Diseases Control Division, MoH   |
|-------------------------|---|
| Mehreteab Abraha        | NTD Unit                                      |
| Yosief Redie Asgodom    | NTD Unit                                      |
| Goitom Habtemariam      | NTD Unit                                      |
| Nahom Fessehaye         | Asmara College of Health Sciences             |
| Michael Goitom          | National Health Information Management System |
| Dr. Rahwa Tekle         | National TB & Leprosy Control Unit            |
| Nahom Kaleab            | National Health Laboratory                    |
| Yacob Tesfamichael      | Asmara College of Health Sciences             |
| Abraham Milash          | Environmental Health Division                 |
| Daniel Berhane          | National Malaria Control Unit                 |
| Solomon Zewengiel       | National Blindness Prevention Program         |
| Dr. Yohannes Ghebrat    | WHO DPC Officer                               |
| Dr. Tendongfor Nicholas | WHO Advisor                                   |
| Dr. Ngozi Njepuome      | WHO Advisor                                   |

#### **INTRODUCTION**

This document, the NTD Master Plan, is a comprehensive multi-year plan for the control of NTDs in Eritrea. It is a tool for effective planning and implementation of sustainable NTD programmes in the country. It articulates the programme goals, objectives and activities based on extensive situation analysis and address all components of the NTD programmes relevant to the country. It enhances synergies among various NTDs and provides the basis for integrated NTD project plans. It includes costing and financing requirements for effective NTD programme performance. The Ministry of Health in collaboration with WHO and other stakeholders has updated the former strategic plan to this new document which runs from 2017- 2021. This revised document incorporates the lessons learnt from the NTD implementation as articulated in the previous Master Plan and what needs to be done to achieve the 2020 NTD goals. It is the basis for annual NTD work plans and it identifies and integrates activities with relevant health units and Ministries to address cross-cutting problems.

As elsewhere in the developing world, Eritrean communities living in rural and urban areas are more affected by communicable diseases that are mostly preventable and curable. One such group of diseases is Neglected Tropical Diseases (NTDs) which for many reasons have been neglected in detecting, preventing and controlling them. This is despite the fact that the country's facility based health information system is capturing the incidence of the diseases and that they are preventable. NTDs posing public health concerns in Eritrea include Schistosomiasis (SCH), Lymphatic filariasis (LF), Soil Transmitted Helminthiasis, Trachoma (TRA), Dengue Fever (DF), Leishmaniasis (LEISH) Anthrax, Rabies, Brucellosis and Leprosy (LEP). In order to better address these diseases, the Ministry of Health has established NTDs unit under the communicable disease control division (CDCD) following the restructuring of the ministry. The CDCD has championed the review and update of this strategic plan in line with the regional strategy on NTDs in the WHO African Region.

The goal of the NTDP is to improve the health and socio-economic status of Eritreans by reducing significantly the morbidity, disability and mortality caused by the Neglected Tropical Diseases through an integrated delivery of interventions, at a cost-effective approach, to control and eliminate all targeted NTDs"

Based on the mapping exercise conducted in 2014 and 2015, distribution of PCT NTDs in Eritrea is well established. The incidence and prevalence of NTDs can be minimized with safe and effective prevention and treatment strategies such as preventive chemotherapy and integrated vector control. Eritrea has taken considerable action in the past few years in controlling some of the above mentioned neglected diseases. Mass drug administration has been given to school children against schistosomiasis and Soil Transmitted Helminths in selected high burden subzones. Trachoma prevalence in Eritrea has declined owing to mass drug administration, promotion of personal/facial hygiene activities, and the complications were addressed by scaling up successful surgeries. Furthermore, Integrated Vector Management designed to tackle malaria vectors has played a great role in fighting LF and Dengue transmission.

Taking into consideration endemicity–overlaps and similarities of some NTDs, an integrated approach in controlling the diseases must be pursued wherever feasible in order to best achieve the set goals. The following strategies are planned to aid the NTD program attain its ambitions:

- Mass Drug Administration (MDA) for PCT –NTDs.
- Strengthening case detection and management of IDM-NTDs.
- Transmission control through effective and comprehensive vector control, improved safe water supply and sanitation by prioritizing endemic communities in collaboration with relevant agencies.
- Intensive health education and promotion activities to improve including improved environmental and personal hygiene.

The activities will focus primarily on preventive chemotherapy, health education, and access to clean water, sanitation improvement and environmental manipulation (PHASE).

The new NTD Master Plan has enjoyed the commitment and acknowledgement of NTD stakeholders and partners whose inputs were incorporated in finalizing the document. It will henceforth be the TOOL for joint planning, implementation and monitoring of the achievements of the NTD programme in Eritrea.

By provision of adequate funding and following a comprehensive monitoring and evaluation plan the current strategic plan can be implemented successfully thereby contributing to the health and socio-economic well-being of the Eritrean people.

## **PART 1: SITUATION ANALYSIS**

This section describes the country profile, the health system milieu and the programme environment within which the NTDs programme will be developed and implemented.

## **1.1 Country Profile**

This section provides information on factors relating to:

- i) The administrative, demographic and community structures.
- ii) Geographical characteristics
- iii) Socio-economic situation and indicators
- iv) Transportation, communications and technology.

These national environmental and contextual factors are important understanding the distribution of NTDs and their control/elimination.

#### 1.1.1 Administrative, demographic and community structures

Administratively the country is divided into six administrative zones (see figure1) known as Zobas, namely; GashBarka (GB), Anseba, Debub, Debubawi Keyh Bahri (DKB), Maakel (Ma) and Semenawi Keyih Bahri (SKB). The zones are further divided into 58 sub-zones, known as sub-Zobas, 699 administrative areas (called *Memhdar Kebabi*) and 2,564 villages.

Figure 1: Administrative map of Eritrea



Although, no population census has been carried out to date, the estimated population of the country at the end of 2012 was 3,952,788. The majority of the population (65%) resides in rural areas (EPHS, 2010). The population growth rate is 3.0% and total fertility rate was 4.8 children per woman in 2010 (EPHS 2010). Life expectancy at birth is 61 years for both sexes (World Bank, 2010). There are 340 health facilities and 75% of the population have access to health services at a radius of 10Kms (HMIS 2012). There are 870 Primary/elementary schools in Eritrea, distributed 6-30 per sub-Zoba and enrolment in 2011-2012 was 482,609 (Ministry of Education 2012).

| Zone          | Sub-Zone         | No. of<br>villages | Total<br>population | Under-fives (13.7) | 5-14 years (29.2%) | No. of<br>primary | No. of facilities | health |     |
|---------------|------------------|--------------------|---------------------|--------------------|--------------------|-------------------|-------------------|--------|-----|
|               |                  |                    |                     |                    |                    | schools           | Hospitals         | H.C    | H.S |
| Anseba        | Elabered         | 55                 | 63963               | 10,217             | 20,435             | 22                |                   | 1      | 3   |
| Timbeeu       | Geleb            | 39                 | 42922               | 7,262              | 14,525             | 10                |                   | -      | 2   |
|               | Keren            | 52                 | 106,602             | 15,990             | 31,980             | 30                | 1                 | 1      | 5   |
|               | Hagaz            | 81                 | 90,342              | 13,551             | 27,102             | 18                |                   | 1      | 5   |
|               | Halhal           | 29                 | 71,441              | 10,716             | 21,432             | 9                 |                   | 1      | 2   |
|               | Habero           | 36                 | 65,328              | 9,799.             | 19,598             | 10                |                   | 1      | 3   |
|               | Asmat            | 27                 | 49,130              | 7,369              | 14,739             | 8                 |                   | 1      | 2   |
|               | Kerkebet         | 55                 | 40,147              | 6,022              | 12,044             | 9                 |                   | 1      | 3   |
|               | Sela             | 22                 | 13,742              | 2,061              | 4,122              | 7                 |                   |        | 1   |
|               | Adi Tekelizan    | 37                 | 45,655              | 6,848              | 13,696             | 9                 |                   | 1      |     |
|               | Hamelmalo        | 41                 | 37,738              | 5,660              | 11,321             | 11                |                   | 2      | 1   |
|               |                  |                    | 636,661             | 95,499             |                    |                   |                   |        |     |
|               | Zonal population | 474                |                     |                    | 190.998            | 143               | 1                 | 10     | 27  |
| Debub         | Debarwa          | 81                 | 124,667             | 18,701             | 37,402             | 25                |                   | 1      | 6   |
|               | Areza            | 104                | 114,635             | 17,195             | 34,390             | 25                |                   | 2      | 6   |
|               | Mendefera        | 68                 | 80,041              | 12,006             | 24,012             | 16                | 1                 | 1      | 2   |
|               | Dekemhare        | 46                 | 70,312              | 12,882             | 25,765             | 26                | 1                 |        | 5   |
|               | Segeneiti        | 39                 | 69 <i>,</i> 454     | 10,546             | 21,09              | 21                |                   | 3      | 3   |
|               | Adi Keyih        | 99                 | 112,111             | 10,418             | 20,836             | 21                | 1                 |        | 5   |
|               | Senafe           | 120                | 51,845              | 16,816             | 33,633             | 27                | 1                 |        | 7   |
|               | Tsorona          | 88                 | 116,724             | 7,776              | 15 <i>,</i> 553    | 13                |                   | 1      | 6   |
|               | Adiquala         | 109                | 81,245              | 17,508             | 35,017             | 20                | 1                 | 1      | 2   |
|               | Emni-Haili       | 100                | 81245               | 12,186             | 24,373             | 22                |                   | 1      | 2   |
|               | Mai-Aynee        | 59                 | 54156               | 13,661             | 27,322             | 12                |                   | 2      | 1   |
|               | Mai-Mine         | 73                 | 91074               | 8,123.40           | 16,246             | 14                |                   | 2      | 1   |
|               |                  |                    | 1,047,509           | 157.823            |                    |                   |                   |        |     |
|               | Zonal population | 986                |                     |                    | 315,647            | 242               | 5                 | 14     | 46  |
| DKB           | Areta            | 48                 | 27,434              | 4,115              | 8,230              | 8                 | 1                 |        | 3   |
|               | Maekel Denkalia  | 21                 | 19,152              | 2,872              | 5,745              | 3                 | 1                 |        | 2   |
|               | Debub Denkalia   | 34                 | 16,209              | 2,431              | 4,862              | 6                 |                   |        | 5   |
|               | Asseb            | 6                  | 29,600              | 4,440              | 8,880              | 5                 | 1                 |        | 1   |
| -             | Zonal population | 109                | 92,395              | 13.859             | 27.718             | 22                | 3                 |        | 11  |
| Gash<br>Barka | Agurdet          | 103                | 43,326              | 6,498              | 12,997             | 15                | 1                 | 1      | 4   |
|               | Barentu          | 39                 | 29,018              | 4,352              | 8,705              | 16                | 1                 | 1      | 5   |
|               | Dighe            | 88                 | 57,239              | 8,585              | 17,171             | 11                |                   | 1      | 5   |

**Table 1:** National population data, schools, and health facilities at sub-zonal level

|        | Forto                | 84   | 59,816    | 8,972         | 17,944  | 14  |    | 2  | 3   |
|--------|----------------------|------|-----------|---------------|---------|-----|----|----|-----|
|        | Gogne                | 54   | 59,269    | 8,890.35      | 17,78   | 13  |    | 1  | 1   |
|        | Haycota              | 91   | 62,883    | 9,432.45      | 18,864  | 13  |    | 1  | 3   |
|        | Logo Anseba          | 22   | 53,055    | 7,958.25      | 15,916  | 16  |    | 1  | 4   |
|        | Mensura              | 26   | 80,143    | 12,021.45     | 24,042  | 16  |    | 1  | 4   |
|        | Mogolo               | 21   | 31,457    | 4,718.55      | 9,437   | 11  |    | 1  | 2   |
|        | Gulug                | 48   | 76,673    | 11,500.95     | 23,001  | 20  |    | 2  | 7   |
|        | Shambuko             | 38   | 47,655    | 7,148.25      | 14,296  | 19  |    | 1  | 3   |
|        | Mulki                | 61   | 49,517    | 7,427.55      | 14,855  | 13  |    | 1  | 4   |
|        | Teseney              | 62   | 59,665    | 8,949.75      | 17,899  | 18  | 1  | 1  | 4   |
|        | Laalay Gash          | 89   | 76,673    | 11,500.95     | 23,00   | 24  |    | 1  | 5   |
|        | Zonal population     | 826  | 786,389   | 11.795.835    | 23.591  | 219 | 3  | 16 | 54  |
| Maakel | Serejeka             | 28   | 77,028    | 11,554.20     | 23,10   | 17  |    | 1  | 7   |
|        | Berikh               | 22   | 62,331    | 9,349.65      | 18,699  | 16  |    | 1  | 2   |
|        | Ghalanefhi           | 32   | 66,537    | 9,980.55      | 19,961  | 23  |    | 1  | 4   |
|        | North east Asmara    | 4    | 159,896   | 23,984.40     | 47,968  | 13  | 1  | 1  | 2   |
|        | North west<br>Asmara | 3    | 156,395   | 23,459.25     | 46,918  | 14  | 1  | 1  | 2   |
|        | South west           | 3    | 117,217   | 17,582.55     | 35,165  | 8   | 2  | 0  | 4   |
|        | South East           | 3    | 111,016   | 16,652.40     | 33,304  | 18  |    | 1  | 1   |
|        | 7 tomara             | 5    | 750,420   | 112.56        |         | 10  |    | 1  | -   |
|        | Zonal population     | 93   | ,         |               | 225,126 | 109 | 4  | 9  | 22  |
| SKB    | Ghelealo             | 46   | 34,790    | 5,218.50      | 10,437  | 18  |    | 2  | 3   |
|        | Foro                 | 58   | 66792     | 10,018.80     | 20,037  | 12  |    | 1  | 2   |
|        | Dahlak               | 12   | 4,254     | 638.10        | 1,276   | 6   | 0  | 1  | 2   |
|        | Massawa              | 15   | 49,608    | 7,441.20      | 14,882  | 11  | 1  | 1  | 7   |
|        | Ghindae              | 25   | 89,433    | 13,414.95     | 26,829  | 19  | 1  | 2  | 8   |
|        | Shieb                | 10   | 76,520    | 11,478.00     | 22,956  | 8   | 0  | 1  | 1   |
|        | Afabet               | 49   | 145,644   | 21,846.60     | 43,693  | 14  | 1  | 1  | 2   |
|        | Nakfa                | 33   | 76,872    | 11,530.80     | 23,061  | 11  | 1  | 0  | 3   |
|        | Adobha               | 18   | 33,645    | 5,046.75      | 10,093  | 3   |    | 1  | 0   |
|        | Karora               | 22   | 61,856    | 9,278.40      | 18,556  | 8   |    | 1  | 1   |
|        |                      |      | 639,414   | 95.912.10     |         |     |    |    |     |
|        | Zonal population     | 288  |           |               | 191.824 | 108 | 4  | 11 | 21  |
|        | National             |      | 3,952,788 |               |         |     |    |    |     |
|        | population           | 2776 |           | 48,111,526.00 |         | 843 | 20 | 60 | 181 |

Source: HMIS/MOH, MOE



Figure 2: Eritrea population pyramid by age and sex

Settlement patterns in Eritrea are in small community villages (Adi) led by a community leader (Memhdar Adi) organized into Memhdar Kebabi. A Memhdar Kebabi consists of 3-4 villages on average. The people normally live in stable communities although there are a few nomadic populations in some ethnic groups whom the government is in the process of settling. There are 9 major ethnic groups namely, the Afar, Bilen, Hiedareb, Kunama, Nara, Rashaida, Saho, Tigre and Tigrigna (Figure 3).

Most of the population relies on agriculture for living although there are people involved in fishing and trading.



#### Figure 3: Peoples of Eritrea

Source: Malaria Indicator Survey, MOH, 2012

#### **1.1.2 Geographic characteristics**

Eritrea is located in the Horn of Africa, between latitudes 12 degrees 42'N and 18 degrees 2'N and longitudes 36 degrees 30'E to 43 degrees 20'E. It is bounded by the Sudan to the North and West, the Red Sea to the East, Ethiopia to the South and the Republic of Djibouti to the Southeast. The country has a surface area of about 124,320 square kilometres with four distinct topographic regions: central highlands (2000 meters above sea-level), western lowlands (1000 meters above sea level), eastern lowlands (500 meters above sea level) and coastal lands (500 meters above sea level). The altitude in the western low land and coastal land favour the existence of lymphatic filariasis.

The highlands of Eritrea have ameliorating climate conditions with vegetative cover and fertile soils which are suitable for agricultural purposes.

In general, rivers in Eritrea are classified in line to where they drain. Thus, there are 3 groups, those that drain into Sudan, (Barka, Mereb/Gash, Anseba and Tekeze rivers), those that drain into the Red Sea (Hadas River), and those that drain into the Afar Depression. Most of these rivers are not perennial. Eritrea has many dams but the major ones include: Gerset, Fanko, Mai Nefhi, Mai Surwa, Badmait, Kerkebet and Tokor.

The rainy season extends from June to September in the western and southern low lands and from October to March in the coastal plains. In general, rains are scarce and the country is prone to recurrent droughts. In addition in the former area receives little rains called "Azmera rains" in the months of April and May. Eritrea has a variety of climatic conditions. Asmara located at 2,350 meters above sea level has a pleasant climate all year (average temperature of 16° Celsius) and receives 508 mm of rainfall annually.

#### Figure 4: Geographic map of Eritrea



In the highlands, further inland, with an elevation between 1,800 and 2,100 meters the hottest month is usually May (around  $30^{\circ}$ C) and in the winter (December to February) temperatures are near freezing point at night. The highest Point is Amba Soira (3018 meters above sea level). At sea level along the coast (Massawa, Assab), the period from June to September is very hot (40-50^{\circ}C).

In the period of December to February (rainy season) the temperature varies from 20 to  $35^{\circ}$ C. Massawa at sea level has an average annual temperature of  $30^{\circ}$  C and an annual precipitation of 205 mm (80 inches).In the western lowlands (Agordat, Barentu), the temperatures are comparable to those in the coast.

The presence of dams predisposes the country to schistosomiasis, while Lymphatic Filariasis is mainly found in areas bordering neighbouring countries (Sudan and Ethiopia).

#### 1.1.3 Socio-economic status and indicators

Eritrea is poor country. Agriculture and pastoralism are the main sources of livelihood. Other natural resources such as marine resources, energy resources (oil and gas) and minerals are relatively unexploited. Agriculture is the mainstay of the economy, accounting for 20% of Gross Domestic Product (GDP).

The Population health Survey (2010) findings indicate that infant mortality rate (IMR) was 42 per 1000 live births; under-5 mortality rate 63 per 1000 live births and maternal mortality rate (MMR) at 480 per 100,000 making Eritrea one of the countries in Africa that are on track to reach MDG goal 4.

In Eritrea nearly 72.9% in urban areas and 50% in rural areas have access to an improved source of drinking water. The most common source of improved drinking water is pipedwater with 47.7% of households in rural area have direct access to piped water (EPHS 2010). With the establishment of dams, many farmers are increasingly using irrigation for farming, which has the potential to increase the exposure risk to many NTDs. In rural areas, where about 90.3% of the households have no toilet facilities compared to 35.3% of the households in the urban area (EPHS 2010).Poor sanitation and inadequate access to clean water are predisposing factor to most of the NTDs.

#### **1.1.4Transportation and communication**

In general, Eritrea has improved significantly its transportation infrastructure connecting all the major Zones with Asphalt. The construction of this infrastructure goes down to the sub-zones making easy access through motor vehicles (see Annex 1.2 for distances from major cities). Moreover, Eritrea has renovated its railway stations that goes from Asmara to Massawa and has built a highway that goes around 500 kms connecting the ports of Massawa to Assab. Post war reconstruction program is on-going to address asphalting of new roads, improving the ports, and repairing war-damaged roads and bridges. Transport Network e.g. accessibility to peripheral areas has shown marked improvements in the last years. There are also two international airports in Asmara and Massawa and 2 local ones in Assab and Gash Barka. Sea Transportation plays a good role in connecting the remote islands with the main land.

Remarkable effort has been undertaken by the government telephone services, Eritrean Telecommunication Services Corporation (EriTel) to connect all the Zones through mobile phones. In early 2012 penetration was 7% for mobile phones, 1% for fixed lines and 11% for internet access. However, growth in the mobile and internet sector is now accelerating due to roll out of a third generation (3G) mobile network by the ErTel. Postal, radio, and television are common means of communication provided by the government which cover the entire country.

There are still some limitations in the existing transportation and communication systems in relation to the NTD program management and improvements are required to make this system reliable for disease surveillance and control/elimination activities.

#### **1.2 Health System Situation Analysis**

#### 1.2.1 Health System Goals & Priorities

Health systems goals and priorities provide indicators that are used to evaluate progress over time within a country and relative performance across countries and regions. The vision of the Eritrean health policy is to improve health status, wellbeing, productivity and quality of life of the Eritrean people with an enabling and empowering environment for the provision of sustainable quality health care that is effective, efficient acceptable, affordable and accessible to all citizens. The mission is "to promote and provide high quality promotive, preventive, curative and rehabilitative health care services to the Eritrean people". The disease burden in Eritrea as in any other developing country is attributed to infectious diseases, malnutrition and maternal related health problems. These health problems have negative correlation with the socio-economic status of the people. Thus, in societies with better socio-economic status, these health problems have very low occurrences compared to the poor countries.

This variation is also evident in urban and rural societies even within the poor countries. Urban dwellers have relatively better access to basic social services than rural dwellers. Thus higher risk of infectious diseases and malnutrition is evident in rural areas.

Acute respiratory infections (mainly pneumonia), diarrhea, anemia, malnutrition, skin and eye infections, malaria and HIV/AIDS are among the 10 leading causes of morbidity and mortality in the country.

The non-communicable diseases such as hypertension, diabetes, ophthalmic problem, psychiatric problems, and injuries are also emerging health problems in Eritrea.

In 2013 about 63% of the total outpatient morbidity and 43% of total inpatient morbidity was attributed to the top 10 diseases. Similarly over 66 % of inpatient and outpatient mortality among those five and above was attributed to the top ten leading diseases. This means that, reducing the morbidity and mortality of the ten leading causes of illness can decrease the total outpatient and inpatient morbidity and mortality significantly. By preventing only pneumonia and diarrhea, it is possible to reduce child morbidity by above 26%.

In 2013, diarrhea, ARI mainly pneumonia, skin, eye and ear infections, malnutrition, injury of all types and urinary tract infections were the top ten leading causes of outpatient and inpatient morbidity in under-five years of age. Among infants a large portion of the deaths were related to neonatal problems. Congenital malformations were also among the top ten leading causes of deaths in this age group.

#### 1.2.2 Analysis of the overall Health System

#### **Service Delivery**

Health services in Eritrea have been provided through a three tier system, which include primary, secondary and tertiary levels of service (figure 5). Primary level of service consists of (i) Community-based health services with coverage of an estimated 2,000 to 3,000 population. This level provides BHCP based services by empowering communities, mobilizing and maximizing resources. The key delivery agent is the Community Health Worker under the leadership of the Village Health Committee. (ii) Health Stations offer facility-based primary health care services to a catchment population of approximately 5,000-10,000. (iii) Community Hospital is the referral facility for the primary health care level of service delivery serving a community of approximately 50,000-100,000 people. Community hospitals provide all services at the lower level facilities and additionally obstetric and general surgical services with the aim of providing vital lifesaving surgical intervention closest to the people.

Secondary level of services is provided by the regional (Zonal) referral hospitals and 2nd contact hospitals. They serve as referral facilities for the lower level facilities as well as teaching/training institutions for middle and operational level professionals and provide facilities for operational/applied research.

Tertiary level of service is provided by the national referral hospitals which are situated in the capital city-Asmara. They not only serve as national referral facilities but as centers of excellence for specialized training/education and research.

In December 2013, 340 health facilities reported to NHMIS including government and nongovernment health facilities except the Military Health Facilities. The MOH owns 258 (75.9%), Eritrean Catholic Secretariat 30(8.9%), Evangelical Church3(0.9%), private 8(2.4%), Industry 31(9.2%) and the remaining others 9 (2.8%).

Laboratory Services: Eritrea has three levels of laboratory services located at health centers, hospitals and the central health laboratory. A total of 502,679 laboratory tests were performed in all health facilities in 2013 excluding NHL. Haematology, urinalysis and stool analysis were the most common laboratory tests performed in most health facilities. The NHL performs more complicated tests and serves as a referral laboratories for all health facilities in the country. It has six departments, namely microbiology, haematology, immune-serologylogy, clinical chemistry, histopatology and food and drink department.

Figure 5: Levels of Service delivery



Figure 6: Distribution of Health Facilities in Eritrea



#### **Health Work Force**

The total number of clinicians in the country as of December 2013 was: 172 doctors, 1253 nurses, 2727 associate nurses and 397 laboratory technicians (HMIS 2013). The doctors, nurse and associate nurses population ratio in 2013 was 1:23256, 1:3192, 1:1467 respectively indicating that there were 0.43 doctors per 10,000 people, 3.1 nurses and 6.9 associate nurses per 10,000 people. These were staff of the MoH. Considering the WHO minimum health worker requirement per 10,000 people, it will not be long before Eritrea exceeds the

recommended minimum ratio for doctors. Moreover, an average of 30 doctors has graduated every year beginning from 2009. This will significantly reduce the ratio. The minimum requirement for nurses and associate nurses is already achieved. The WHO recommended target for developing countries in the doctor population and nurse population ratio is 1:10,000 and 1:5,000 respectively. In addition to this other paramedical health professional population ratio shows radiology technicians 1:48,750, pharmacist and pharmacy technicians 1:13,514, sanitarians 1:164785, laboratory scientists (MLT+CLS) 1:10,076, public health technologist 1:48,684, and other health professionals (oph. Tech + dental + physio.) 1:33,945. Among those actively working in the health facilities, 2191 (59.7%) were working in hospitals, 666 (18.2%) in health centers, 593 (16.2%) in health stations, 541(5%) in Mother and Child Health Clinics and 166(4.5%) in other clinics, indicating that only one third of the health workers work in primary health facility settings. However, it is also absolutely important to focus attention to primary level care in health center and health stations as most of the health problems in Eritrea are easily preventable and could be handled in those health facilities. These facilities are also found within short distance from the villages compared to the hospitals as a result they are the first entry point to health services. The proportion of health workers deployed to Zobas usually depends on the number of health facilities in the Zoba which also depend on the number of residents in the Zoba. Access to basic health services within 5 km radius is 60% (HHSDP, 2012-2016). The challenges faced by the NTD program include shortage of budget, man power, and poor awareness among the people. There is no NTD policy.

#### **Health Information**

The Ministry of Health developed the Health Management Information System (HMIS) in 1997 and selected disease and health service indicators through the participation of health workers and concerned partners and stakeholders. A total of 320 HF are reporting on a monthly basis data from 22 program activities. Data collection manual was developed and health workers were trained on the use of the data collection and reporting tools. At the initial establishment of the HMIS, the computerized system was developed on Dos-based access operating system and the data entry at Zoba level started in February 1998. The reported data can be disaggregated by Zoba, Sub-Zoba and facility levels. The outpatient and inpatient morbidity and mortality report used to be disaggregated by two age categories (under 5 (U5) and above 5) until the third category (<1) was included in 2004. The reports from Zobas to the national HMIS office are sent in flashes and CDs. Close monitoring of the timely reception of the data is conducted at central level and all data is received within 20 days of the following month. The system is working with high efficacy, timeliness and in an integrated approach. The implementation of the disease surveillance and response (IDSR), which has integrated reporting of 19 priority communicable diseases in the country, was done in 2002.

#### **Medical products**

The National Medicine and Food Administration (NMFA) is the primary regulatory body in charge of control of drug quality and standards in Eritrea. As a regulatory and administrative body, of the Ministry of Health, for drugs and other medical supplies, NMFA regulates the quality of pharmaceuticals and medical supplies that are imported, and those that are produced in the country. This is to ensure that pharmaceutical products conform to acceptable standards of quality, safety, and efficacy before they are registered.

There is a centralised procurement, supply storage, and distribution system in place for medical products in the country which ensure standardization. The sector has also aimed at developing a harmonized, sustainable and efficient procurement and supplies management system through the establishment of PHARMECOR - Eritrea. Pharmaceutical sub-sector

management is guided by the National Medicines Policy under the stewardship role of the division of medicines and medical supplies of MOH.

PHARMECOR plans and procures once a year for supplies funded by government and items that are included in the "Essential medical list" which is regularly revised, and approximately 3 times a year for externally funded supplies to respond to program specific requirements including that for NTDs using appropriate internationally acceptable tendering procedures.

The NMFA ensures a patient-focused service by introducing a functional pharmaceutical care at all levels of service by establishing standard formulary and procedures for use in all hospitals and primary level health facilities, regulate and control advertisement of drugs, medical supplies and health services in the mass media.

Each zone has adequately equipped medical store with staff that include a chief pharmacist. Zonal and hospitals stores requisition quantified supplies on a "pull-basis" determined by facility/zonal budgetary ceiling. The orders are filled by PHARMECOR and collected by zonal stores for health stations and health centers and separately by hospitals. Zones pay directly for received items to PHARMECOR, and when a justified need arises to requisition beyond the set budgetary ceiling, MOH absorbs the difference in expenditure.

Each unit in the MOH is responsible for tracking the ADRs that occur within its mandate. Similarly, pharmacovigilance for NTD related adverse drug reactions (ADR) will be the role of the NTD Program (CDC division) of the MOH in collaboration with the NMFA. Forms will be adapted from WHO for tracking and reporting ADRs related to NTD drugs.

#### **Health Financing**

In early 2002, MOH updated the financial policy, the roles and likely levels of financing from the government, donors and the people. The new policy proposed that health facilities retain a fraction of the revenues collected for maintenance purposes. Government expenditures on health as a percentage of total government expenditures was 4.5% for the period 1995-2000. The share of external resources to total health expenditures in the country grew appreciably between 1995 (33%) and 2000 (61%). The per capita total expenditure on health grew from US\$ 6 in 1995 to US\$ 9 in the year 2000. Information on the government expenditure pattern for MOH in 2002 revealed that around 50% of the total budget was allocated to hospitals and only 16% for PHC activities, an issue which needs to be addressed in the health sector reform programme (MOH 2003).

The government will be responsible for the implementation of the NTDs. Moreover, with the completion of the master plan extensive resource mobilization will be conducted and partner interest in funding the NTDs is expected to grow in the coming years.

#### Leadership and Governance

The Government of Eritrea accords health a prominent place in its priorities and it is committed to the attainment of health goals. In particular, the Government fully appreciates and continuously emphasizes the decisive role of the people in the development and self-reliance. The Government is, therefore, determined to create the requisite social and political conditions conductive to their realization. The ministry is highly committed in the control of communicable disease and to that extent has developed the 5 year health sector strategic development plan with communicable diseases being priorities in the coming years.

Recent restructuring in the health system have involved the inclusion of a Neglected Tropical Diseases Unit within the Division of Communicable Diseases (CDC) within the Department of Public Health. (See Annex 1.3, Ministry of Health Organogram). Even though NTDs do not feature among the top 10 priority diseases, existing conditions within the current health

system are supportive of plans to scale up PCT and CM-IDM in the country (Figure 7). An NTD structure has also been established.





A multi-sectoral approach is maintained especially with the Ministry of Education, Ministry of water and land, Ministry of Local Government, Ministry of Agriculture (where Department of Veterinary Services is embedded) and Local NGOs. Within this framework, inclusion of NTD control in the primary school curriculum will be established, as well as activities relating to zoonotic diseases of public health importance in the country e.g. Rabies.

#### **1.3 NTD Situation Analysis**

The World Health Organization (WHO) estimated that in 2007 at least 1 billion people – one sixth of the world's population, or 1 person in 6 \_- suffer from one or more of the Neglected Tropical Diseases (NTDs) such as Schistosomiasis, Soil transmitted Helminths,Lymphatic filariasis,Trachoma, trypanosomiasis, cystecercosis, onchorcerciasis, Buruli ulcer, dracunculiasis (guinea-worm disease) foodborne trematode infections (such as fascioliasis) hydatidosis, and leshmaniasis. Several of these diseases, and others such as dengue, are vector-borne. These diseases are referred to as Neglected Tropical Diseases, as their burden in endemic countries is high but disproportionate to the resources allocated for their control, they also almost exclusively affect almost poor and under-served communities. Although safe and cost-effective interventions for prevention and control are available, these diseases have continued to cause immense suffering and often life-long disabilities for the rural poor due to neglect.

The Neglected tropical diseases, all of them communicable, are therefore not receiving as much attention as the high profile diseases such as malaria, HIV/AIDS and TB (WHO, 2006). The major known NTDs are:

- A group of about 13 infectious diseases which affect about 1 billion people worldwide and most of whom live in extreme poverty
- Burdened humanity for centuries
- Severely debilitating and disabling
- Associated with poverty and intense stigma and
- Promote the cycle of poverty

The known types of NTDs in Eritrea are:

#### 1. Preventive chemotherapy NTDS (PCT-NTDs)

- 1. Schistosomiasis (SCH)
- 2. Soil transmitted Helminthiasis (STH)
- 3. Trachoma (TRA)
- 4. Lymphatic Filariasis (LF)

#### 2. Intensified Disease management NTDs (IDM-NTDs)

- 1. Leprosy (LEP)
- 2. Leishmaniasis (LEISH)
- 3. Dengue Fever(DF)
- 4. Rabies
- 5. Brucellosis
- 6. Anthrax

#### 1.3.1 Epidemiology and burden of disease

The main health care packages fall under the Department of Public Health and include the following:

- a) Communicable Disease Control Division which embraces of Malaria control, HIV/AIDS/STI Control, TB Control, NTD Control and Integrated Disease Surveillance and Response programs,
- b) Family and Community Health Division: embraces of Family and Reproductive Health, Child and Adolescent Health, EPI, Nutrition,
- c) Non-Communicable Disease Control Division: embraces Blindness prevention, Ear and Orodontal diseases control among others
- d) Environmental Health Division

The top ten leading causes of outpatient and inpatient morbidity alone constitutes to about 90% of the total causes of morbidity and 88 -90% of all causes of mortality in children under five. Similarly, about 60% of the total outpatient morbidity, 40 % of the total inpatient morbidity and 60 % of inpatient mortality in five and above age group.

In 2013, diarrhea, ARI mainly pneumonia, skin, eye and ear infections, malnutrition, injury all types, soft tissue injury and other urinary tract infection are the top ten leading causes of outpatient and inpatient morbidity in under-five years of age. In five and above age group, ARI, ORO-dental infection, gastritis/ulcer, urinary tract infection and Injury all types were the top five causes of morbidity in OPD. (Source: MOH, HMIS, 2013).



The status of NTD endemicity is discussed below Figure 7: Prevalence of S. mansoni in Eritrea by Zoba, 2015

Figure 8: Predicted Map of S. mansoni infection



Out of the total 58 sub zobas in the country, schistosomiaiswas found only in 28 sub zobas. In the sub zobas *with S. mansoni* infection, prevalence ranged from 0.17% in Goluj to 15.35% in Dekemhare subzoba. *S. mansoni* infection was found in all the sub zobas of Debub.Top six sub zobas with the highest prevalence were Dekemhare (15.35%), Maiaini (15.22%), Adi-Tekelezan (15.21%), Adiquala (12.1%), Molqi (10.25%) and Dbarwa (9.48%) with four of them from Debub zoba. Segeneiti, Mendefera, Emnihaili, Ghindae, Halhal, Senafe and Adikeih follow with rates of 8.02%, 7.25%, 5.35%, 4.9%, 4.63%, 4.4% and 4.39% respectively [See

Table 2, Figure 9 and Table 3].

|    | Sub zoba        | Zoba       | Prevalence of S.<br>mansoni | Number of Students |
|----|-----------------|------------|-----------------------------|--------------------|
| 1  | Dekemhare       | Debub      | 15.35                       | 480                |
| 2  | Maiaini         | Debub      | 15.22                       | 260                |
| 3  | Adi-Tekelezan   | Anseba     | 15.21                       | 283                |
| 4  | Adiquala        | Debub      | 12.10                       | 251                |
| 5  | Molqui          | Gash Barka | 10.25                       | 335                |
| 6  | Dbarwa          | Debub      | 9.48                        | 454                |
| 7  | Segeniti        | Debub      | 8.02                        | 197                |
| 8  | Mendefera       | Debub      | 7.25                        | 402                |
| 9  | Imnihaili       | Debub      | 5.35                        | 352                |
| 10 | Ghindae         | SKB        | 4.90                        | 507                |
| 11 | Halhal          | Anseba     | 4.63                        | 279                |
| 12 | Senafe          | Debub      | 4.40                        | 403                |
| 13 | Adikeih         | Debub      | 4.39                        | 483                |
| 14 | Maimine         | Debub      | 1.72                        | 352                |
| 15 | Tsorona         | Debub      | 1.51                        | 370                |
| 16 | Areza           | Debub      | 1.47                        | 501                |
| 17 | Serejeka        | Maakel     | 1.26                        | 273                |
| 18 | Gaa-Nefhi       | Maakel     | 1.18                        | 253                |
| 19 | Massawa         | SKB        | 1.04                        | 450                |
| 20 | Berik           | Maakel     | 1.04                        | 255                |
| 21 | Semenawi-me'rab | Maakel     | 0.86                        | 226                |
| 22 | Foro            | Gash Barka | 0.74                        | 250                |
| 23 | Logo-Anseba     | Gash Barka | 0.71                        | 448                |

#### Table 2: Distribution of S. mansoni infection by subzoba

| 24 | Sheib          | SKB        | 0.67 | 324 |
|----|----------------|------------|------|-----|
| 25 | Haykota        | Gash Barka | 0.20 | 210 |
| 26 | Forto          | Gash Barka | 0.19 | 218 |
| 27 | Debubawi Mbrak | Maakel     | 0.18 | 275 |
| 28 | Goluj          | Gash Barka | 0.17 | 279 |

#### Figure 9: Prevalence map S mansoni by Sub zoba



| S. No | Sub zoba/Zoba  | Prevalence of S. mansoni | Number of Students |
|-------|----------------|--------------------------|--------------------|
|       | Anseba         |                          |                    |
| 1     | Hagaz          | 0.00                     | 279                |
| 2     | Asmat          | 0.00                     | 280                |
| 3     | Elaberd        | 0.00                     | 239                |
| 4     | Geleb          | 0.00                     | 285                |
| 5     | Habero         | 0.00                     | 263                |
| 6     | Hamelmalo      | 0.00                     | 275                |
| 7     | Keren          | 0.00                     | 281                |
| 8     | Kerkebet       | 0.00                     | 196                |
| 9     | Selea          | 0.00                     | 199                |
|       | DKB            |                          |                    |
| 10    | Areata         | 0.00                     | 188                |
| 11    | Assab          | 0.00                     | 262                |
| 12    | Debub denkalya | 0.00                     | 238                |
| 13    | Maakel denkel  | 0.00                     | 254                |
|       | Gash Barka     |                          |                    |
| 14    | Aquordet       | 0.00                     | 491                |
| 15    | Barentu        | 0.00                     | 540                |
| 16    | Dighe          | 0.00                     | 254                |
| 17    | Gogne          | 0.00                     | 421                |
| 18    | Laelay Gash    | 0.00                     | 265                |
| 19    | Mensura        | 0.00                     | 384                |
| 20    | Mogolo         | 0.00                     | 255                |
| 21    | Shambuko       | 0.00                     | 523                |
| 22    | Tessenei       | 0.00                     | 555                |

Table 3: Sub zobas without S. mansoni infection

|    | Maakel          |      |     |
|----|-----------------|------|-----|
| 23 | Debubawi-me'rab | 0.00 | 260 |
| 24 | Semenawi-mibrak | 0.00 | 251 |
|    | SKB             |      |     |
| 25 | Adobha          | 0.00 | 104 |
| 26 | Afabet          | 0.00 | 260 |
| 27 | Gel'alo         | 0.00 | 211 |
| 28 | Karura          | 0.00 | 281 |
| 29 | Nakfa           | 0.00 | 277 |
| 30 | Dahlak          | 0.00 | 134 |

#### 4.2.2 Prevalence of *S. mansoni* by age and sex

Schistosomiasis prevalence increased with an increasing age ranging from 1.90% [1.5%, 4.8%] among those who are 10 years of age to 6.99% [4.9%, 22.3%] among the 14 year olds. The proportion of children infected was higher among the males 4.28% [3.8%, 10.3%] than their females counterparts 1.24% [1.2%, 4.1%] and the difference was statistically significant ( $\chi$  2 =90.063, p=0.000 <0.001) [Table 4].

Table 4: Percentage of children age 10-14 infected with S. mansoni by age and sex

| Age and sex | %    | Number of Children |
|-------------|------|--------------------|
|             |      |                    |
| Age         |      |                    |
| 10          | 1.90 | 5567               |
| 11          | 2.35 | 4057               |
| 12          | 2.73 | 4048               |
| 13          | 2.68 | 2588               |
| 14          | 6.99 | 1815               |
| Sex         |      |                    |
| Male        | 4.28 | 9373               |
| Female      | 1.24 | 8702               |
| Total       | 2.82 | 18075              |

#### 4.2.3 Prevalence of *S. mansoni* by schools

Ninety one out of the 344 schools selected for the survey have at least one school child infected with *S. mansoni*. Of these, the highest infection rate (43.76%) was recorded in Halibo Elementary School in sub-zoba Dekemhare. This was followed by Meadin Elementary &Junior,Kinafina Elementary and Warsay junior with prevalence of 34.92%, 31.56% & 31.56%, respectively. The lowest prevalence (1.24%) was in Adi Nebri elementary and junior school of sub-zoba Maiani.

According to the WHO risk level classification, based on prevalence of infection, 20 of the investigated schools were located in medium-risk areas of S. mansoni infection with prevalence ranging between 10% and 50% [Table 5]. Sixty eight schools were located in low-risk areas with prevalence between 1% and 10%). In the remaining schools none of the children were infected with S. mansoni. See Error! Reference source not found. for details.

| Name of School                    | %     | Number of<br>Students |
|-----------------------------------|-------|-----------------------|
| Halibo Elementary                 | 43.76 | 52                    |
| Meadin Elementary & Junior        | 34.92 | 55                    |
| Warsay Junior                     | 31.56 | 56                    |
| Kinafina Elementary               | 31.56 | 54                    |
| Quaetit Elementary                | 27.86 | 53                    |
| Mihiram Geido Elementary          | 26.98 | 50                    |
| Embakakat Elementary & Junior     | 22.92 | 52                    |
| M.Tsion Hebo Elementary &Junior   | 21.73 | 37                    |
| Bana Harnet Elementary            | 19.59 | 57                    |
| Kudo Felasi Elementary            | 19.50 | 51                    |
| Mai Gume Elementary &Junior       | 18.26 | 50                    |
| Tsinat Elementary &Junior         | 16.01 | 57                    |
| Ibrahim Afa Ele & Junior          | 15.54 | 56                    |
| Shekawedibsrat Elementary &Junior | 14.00 | 50                    |
| Kidanemhret Elementary            | 13.76 | 56                    |
| Shketi Elementary &Junior         | 12.91 | 53                    |
| Adi-Wisk Elementary               | 12.60 | 56                    |
| Petros Paulos A Elementary        | 12.43 | 52                    |
| Mendefera Junior                  | 11.50 | 50                    |
| Zara Junior                       | 10.17 | 51                    |
|                                   |       |                       |

#### Table 5: Schools in medium-risk areas of S. mansoni infection

#### 4.3 Prevalence of *S. Haematobium*

*S. haematobium* was found in only two school boys aged 12 & 13 years out of 257 tested making the overall prevalence of *Schistosoma hematobium* infection in the Goluj subzone of 0.78%. The two students are from the same school and they had also high intensity of infection.

## Prevalence of Soil-transmitted helminth

4.4.1 Prevalence of Soil-transmitted helminth by zoba and sub-zoba

In this survey, the overall prevalence of any STH in children age 10-14 years was 0.17.Relatively high prevalence (0.29%) was recorded in Anseba followed by SKB (0.25%) and Gash Barka (0.21%). This study also revealed that none of the children examined were positive for any STH in DKB.Hook worm infection was also absent in Gash Barka & Maakel. T. Truchria was not found in Debub and SKB [Figure 10].



Figure 10: Distribution & type of STH Infection by Zoba

The findings showed STH to be prevalent in 20 out of the 58 sub zobas with Sub zobal comparison showeing Halhal to have the highest prevalence (1.57%) followed by Aqordat (1.2%) and Ghindae (1%). The remaining 17 sub zobas had prevalence rates ranging in between 0.87% and 0.06%. Hook Worm occurred in six sub zobas namely Halhal, Ghindae, Massawa, Shieb and Senafe while Ascariasis and Trichiriasis occurred in nine and eight sub zobas respectively [see **Table 6** and **Figure 11**]. Three sub zobas, namely Hagaz, Logo-Anseba and Adikeih had two types of STH namely Ascariasis and Trichiriasis, while Dbarwa had Hook Worm and Ascariasis. For list of sub zobas without any STH, please refer **Error! Reference source not found.** 

| S. No. | Sub zobas | Hook Worm | Ascariasis | Trichuriasis | STH  | Number of<br>Students |
|--------|-----------|-----------|------------|--------------|------|-----------------------|
| 1      | Halhal    | 1.57      | 0.00       | 0.00         | 1.57 | 279                   |
| 2      | Aquordet  | 0.00      | 0.00       | 1.20         | 1.20 | 491                   |

#### Table 6: Distribution of Soil-transmitted helminth by type, according to sub-zoba

| 3  | Ghindae        | 1.00 | 0.00 | 0.00 | 1.00 | 507 |
|----|----------------|------|------|------|------|-----|
| 4  | Hagaz          | 0.00 | 0.47 | 0.40 | 0.87 | 279 |
| 5  | Mensura        | 0.00 | 0.00 | 0.66 | 0.66 | 384 |
| 6  | Logo-Anseba    | 0.00 | 0.32 | 0.32 | 0.64 | 448 |
| 7  | Adikeih        | 0.00 | 0.48 | 0.00 | 0.48 | 483 |
| 8  | Gogne          | 0.00 | 0.00 | 0.48 | 0.48 | 421 |
| 9  | Debubawi Mbrak | 0.00 | 0.00 | 0.46 | 0.46 | 275 |
| 10 | Habero         | 0.00 | 0.44 | 0.00 | 0.44 | 263 |
| 11 | Selea          | 0.00 | 0.34 | 0.00 | 0.34 | 199 |
| 12 | Berik          | 0.00 | 0.34 | 0.00 | 0.34 | 255 |
| 13 | Massawa        | 0.30 | 0.00 | 0.00 | 0.30 | 450 |
| 14 | Sheib          | 0.25 | 0.00 | 0.00 | 0.25 | 324 |
| 15 | Adi-Tekelezan  | 0.00 | 0.23 | 0.00 | 0.23 | 283 |
| 16 | Senafe         | 0.23 | 0.00 | 0.00 | 0.23 | 403 |
| 17 | Keren          | 0.00 | 0.11 | 0.09 | 0.21 | 281 |
| 18 | Goluj          | 0.00 | 0.17 | 0.00 | 0.17 | 279 |
| 19 | Molqui         | 0.00 | 0.00 | 0.15 | 0.15 | 335 |
| 20 | Dbarwa         | 0.04 | 0.02 | 0.00 | 0.06 | 454 |

#### Figure 11: Prevalence map STH by Sub zoba



#### 4.4.2 Prevalence of Soil-transmitted helminth by age and sex

As indicated in Table 7, there is no significant variation in the prevalence of any STH between boys and girls ( $\chi^2 = 0.037$ , p=0.847>0.05). The proportion of children infected with any STH species generally tends to increase with an increasing age, but the difference was not statistically significant ( $\chi^2 = 22.52$ , p=0.274>0.05). The overall age and sex pattern of the prevalence of infection with any STH also holds true for the different species of STH.

| Age and Sex | Hook Worm | Ascaris<br>Lumbricoides | Trichuris<br>Trichiura | Any Soil<br>Transmitted<br>helminth (STH) | Number of<br>Students |
|-------------|-----------|-------------------------|------------------------|---|-----------------------|
| Age         |           |                         |                        |   |                       |
| 10          | .02       | .09                     | .02                    | .13                                       | 5567                  |
| 11          | .09       | .03                     | .07                    | .19                                       | 4057                  |
| 12          | .02       | .04                     | .03                    | .09                                       | 4048                  |
| 13          | .03       | .09                     | .12                    | .24                                       | 2588                  |
| 14          | .03       | .04                     | .25                    | .32                                       | 1815                  |
| Sex         |           |                         |                        |   |                       |
| Male        | .06       | .05                     | .12                    | .23                                       | 9373                  |
| Female      | .02       | .06                     | .02                    | .10                                       | 8702                  |
| Total       | 0.04      | 0.06                    | 0.07                   | 0.17                                      | 18075                 |

## 4.4.3 Prevalence of Soil-transmitted helminth by schools

STH was prevalent in 31 schools out of 345 surveyed schools. Abdella Degol Elementary, Alnejah Elementary & Junior, Gerger Elementary & Junior, Erdi Elementary & Junior and Alnahda Elementaryschools had the highest prevalence rates of 10.03%, 9.37%, 6.73%, 5.26% and 5.12%, respectively. The remaining 21 schools have prevalence in the range of 4.13% and 0.22%. Hook Worm was prevalent in 10 schools, Ascariasis in 11 schools and Trichiriasis in 10 schools [

Table 8: Prevalence of STH by schools].

According to the WHO standard classification<sup>1</sup> on the risk level of infection, based on the prevalence of infection with any STH, none of the schools were located in low or high risk areas. The presence of STH in scattered places indicates that STH infection is almost insignificant as a public health problem in Eritrea. See **Error! Reference source not found.** 

<sup>&</sup>lt;sup>1</sup>WHO standard classification of risk level of infection with any STH: Schools in high-risk areas (Prevalence  $\geq$  50%); Schools in low-risk areas (Prevalence  $\geq$  20% and >50%).
#### Table 8: Prevalence of STH by schools

| S. No. | Name of school                       | Hoowk<br>Worm | Ascariasis | Trichiriasis | STH   | Number of<br>Students |
|--------|--------------------------------------|---------------|------------|--------------|-------|-----------------------|
| 1      | Abdella Degol Flementary             | 10.03         | 0.00       | 0.00         | 10.03 | 56                    |
| 1      | Abdella Degol Liementary             | 10.05         | 0.00       | 0.00         | 10.03 | 50                    |
| 2      | Alnejah Elementary&Junior            | 0.00          | 0.00       | 9.37         | 9.37  | 49                    |
| 3      | Gerger Elementary&Junior             | 0.00          | 0.00       | 6.73         | 6.73  | 50                    |
| 4      | Erdi Elementary & Junior             | 0.00          | 0.00       | 5.26         | 5.26  | 49                    |
| 5      | Alnahda Elementary                   | 0.00          | 0.00       | 5.12         | 5.12  | 56                    |
| 6      | ferdigi Elementary&Junior            | 0.00          | 0.00       | 4.13         | 4.13  | 56                    |
| 7      | Seid Ferej Elementary                | 4.03          | 0.00       | 0.00         | 4.03  | 54                    |
| 8      | ahune elementary school              | 0.00          | 3.56       | 0.00         | 3.56  | 56                    |
| 9      | Takawda Elementary                   | 0.00          | 0.00       | 2.92         | 2.92  | 56                    |
| 10     | Dongolo Tahtay Elementary<br>&Junior | 2.53          | 0.00       | 0.00         | 2.53  | 44                    |
| 11     | Senafe Elementary                    | 2.50          | 0.00       | 0.00         | 2.50  | 56                    |
| 12     | Hirkuk Elementary & Junior           | 0.00          | 0.00       | 2.40         | 2.40  | 95                    |
| 13     | Shid M/Seid Shemsi Elementary        | 2.23          | 0.00       | 0.00         | 2.23  | 50                    |
| 14     | Fre Selam Elementary&Junior          | 0.00          | 0.00       | 2.02         | 2.02  | 50                    |
| 15     | Faith mission Elementary&Junior      | 0.00          | 0.00       | 1.98         | 1.98  | 52                    |
| 16     | Lemlem Seti Elementary               | 0.00          | 1.97       | 0.00         | 1.97  | 100                   |
| 17     | Rekeb Elementary&Junior              | 0.00          | 1.88       | 0.00         | 1.88  | 56                    |
| 18     | Felega elementary                    | 0.00          | 1.85       | 0.00         | 1.85  | 50                    |
| 19     | Mai Habar Elementary& Junior         | 1.83          | 0.00       | 0.00         | 1.83  | 56                    |
| 20     | Tala Elementary                      | 1.83          | 0.00       | 0.00         | 1.83  | 50                    |
| 21     | Torat Elementary                     | 0.00          | 1.81       | 0.00         | 1.81  | 50                    |
| 22     | Mohammed Idrsi<br>Elementary&Junior  | 0.00          | 1.74       | 0.00         | 1.74  | 56                    |
| 23     | Aditekelezan Elementary&Junior       | 0.00          | 1.67       | 0.00         | 1.67  | 56                    |
| 24     | Anseba Islamic                       | 0.00          | 1.60       | 0.00         | 1.60  | 57                    |

|    | Elementary&Junior                    |      |      |      |      |     |
|----|--------------------------------------|------|------|------|------|-----|
| 25 | Embakakat Elementary&Junior          | 0.00 | 1.58 | 0.00 | 1.58 | 52  |
| 26 | Salih Meki Elementary& Junior        | 1.56 | 0.00 | 0.00 | 1.56 | 56  |
| 27 | kidane Mihret H<br>Elementary&Junior | 0.00 | 1.34 | 0.00 | 1.34 | 56  |
| 28 | Jehan Elementary&Junior              | 0.00 | 0.00 | 1.15 | 1.15 | 56  |
| 29 | Emberami Elementary &Junior          | 1.12 | 0.00 | 0.00 | 1.12 | 100 |
| 30 | Ibrahim Afa Elementary& Junior       | 0.86 | 0.00 | 0.00 | 0.86 | 56  |
| 31 | Darelneem Elementary                 | 0.00 | 0.22 | 0.00 | 0.22 | 56  |

# 4.5 Co-infection of *S. mansoni* and any Soil-transmitted helminth

Co-infection of S. mansoni and any Soil-transmitted helminth was not common among the school children. Only 11 of the children participated in the parasitological survey were found to be infected with both *S. mansoni* and any Soil-transmitted helminth. Ten of these students were residents of zoba Debub and the 1 was from Zoba Anseba.

# 4.6 Intensity of Infection of *S. mansoni*

The survey also estimated the intensity of infection with the parasites for each child based on the count of eggs per gram of faeces (epg). WHO standard classification [

Table 9: Classification of intensity of infection for soil-transmitted helminths and schistosomiasis] is used to identify the level of intensity of infection of each child. Classification of the results into the classes of intensity allows an immediate assessment of the proportion of individuals suffering from the severe consequences of the infection and therefore, of the public health relevance of the infections in the community. Following the recommendation by WHO, proportion of children falling in each classe is taken to measure and present the intensity of infection. Table 9: Classification of intensity of infection for soil-transmitted helminths and schistosomiasis

| Parasite        | Light-intensity<br>Infections** | Moderate-<br>intensity of<br>infections** | Heavy-intensity of infections                       |
|-----------------|---------------------------------|---|---|
| A. lumbricoides | 1-4,999 epg                     | 5,000-49,999 epg                          | ≥50,000 epg   |
| T. trichiura    | 1-9,99 epg                      | 1,000-9,999 epg                           | ≥10,000 epg   |
| Hookworms       | 1-1,999 epg                     | 2,000-3,999 epg                           | ≥4,000 epg  |
| S.mansoni       | 1-99 epg                        | 100-399 epg                               | ≥400 epg  |
| S. haematobium  | 1-50 eggs/10ml of urin          | e   | >50 epgs/10ml of<br>urine (or visible<br>haematuria |

\*WHO 2002

\*\*epg=eggs per gram of faeces

4.6.1 Intensity of Infection of *S. mansoni* by zoba and sub-zoba

As indicated above, the overall prevalence of S. mansoni in children 10-14years age in the country is 2.82% [1.8%, 4.5%]. Majority of these children have light intensity infection 1.28% [0.9%, 1.9%]. The rate of moderate and heavy intensity of infections in these children is 0.8% [0.4%, 1.6%] and 0.74% [0.3%, 2.0%], respectively [Table 10].

The intensity of infections for *S. mansoni* is much higher in Zoba Debub compared to the other four zobas. The presence of heavy intensity *S.mansoni* infection is 2.69% [1.1%, 6.4%] among children in Zoba Debub, compared with only below 0.2% among those in zobas SKB(0.18%), Anseba (0.04%), Gash Barka (0.01%), and Maekel (0%)). The variation in the intensity of infection between zobas is stronglysignificant ( $\chi$  2 =834.248, p=0.000<0.001).

Table 10: Percentage of children by intensity of infection of SCH, according to zoba and sub-zoba

| Zoba and sub-zoba | No infection | Light<br>infection | Moderate<br>Infection | Heavy Infection | Total  | No. of students |
|-------------------|--------------|--------------------|-----------------------|-----------------|--------|-----------------|
| Hagaz             | 100.00       | 0.00               | 0.00                  | 0.00            | 100.00 | 279             |
| Adi-Tekelezan     | 84.79        | 12.27              | 2.94                  | 0.00            | 100.00 | 283             |
| Asmat             | 100.00       | 0.00               | 0.00                  | 0.00            | 100.00 | 280             |
| Elaberd           | 100.00       | 0.00               | 0.00                  | 0.00            | 100.00 | 239             |
| Geleb             | 100.00       | 0.00               | 0.00                  | 0.00            | 100.00 | 285             |
| Habero            | 100.00       | 0.00               | 0.00                  | 0.00            | 100.00 | 263             |
| Halhal            | 95.37        | 2.48               | .89                   | 1.26            | 100.00 | 279             |
| Hamelmalo         | 100.00       | 0.00               | 0.00                  | 0.00            | 100.00 | 275             |
| Keren             | 100.00       | 0.00               | 0.00                  | 0.00            | 100.00 | 281             |
| Kerkebet          | 100.00       | 0.00               | 0.00                  | 0.00            | 100.00 | 196             |
| Selea             | 100.00       | 0.00               | 0.00                  | 0.00            | 100.00 | 199             |
| Anseba            | 98.83        | .90                | .23                   | .04             | 100.00 | 2859            |
|                   |              |                    |                       |                 |        |                 |
| Adequala          | 87.90        | .84                | .42                   | 10.83           | 100.00 | 251             |
| Adikeih           | 95.61        | 2.33               | 1.53                  | .53             | 100.00 | 483             |
| Areza             | 98.53        | 1.27               | .20                   | 0.00            | 100.00 | 501             |
| Dbarwa            | 90.52        | 5.16               | 1.96                  | 2.36            | 100.00 | 454             |
| Dekemhare         | 84.65        | 4.57               | 7.55                  | 3.23            | 100.00 | 480             |
| Imnihaili         | 94.65        | 3.68               | 1.49                  | .19             | 100.00 | 352             |
| Maiaini           | 84.78        | 7.09               | 6.92                  | 1.21            | 100.00 | 260             |
| Maimine           | 98.28        | .71                | 0.00                  | 1.01            | 100.00 | 352             |
| Mendefera         | 92.75        | 4.64               | 1.30                  | 1.31            | 100.00 | 402             |
| Segeniti          | 91.98        | 4.15               | 3.77                  | .10             | 100.00 | 197             |
| Senafe            | 95.60        | 2.69               | .26                   | 1.45            | 100.00 | 403             |
| Tsorona           | 98.49        | .82                | .69                   | 0.00            | 100.00 | 370             |
| Debub             | 91.32        | 3.42               | 2.58                  | 2.69            | 100.00 | 4505            |
|                   |              |                    |                       |                 |        |                 |
| Areata            | 100.00       | 0.00               | 0.00                  | 0.00            | 100.00 | 188             |

| Assab           | 100.00 | 0.00 | 0.00 | 0.00 | 100.00 | 262  |
|-----------------|--------|------|------|------|--------|------|
| Debub denkalya  | 100.00 | 0.00 | 0.00 | 0.00 | 100.00 | 238  |
| Maakel denkel   | 100.00 | 0.00 | 0.00 | 0.00 | 100.00 | 254  |
| DKB             | 100.00 | 0.00 | 0.00 | 0.00 | 100.00 | 942  |
|                 |        |      |      |      |        |      |
| Aquordet        | 100.00 | 0.00 | 0.00 | 0.00 | 100.00 | 491  |
| Barentu         | 100.00 | 0.00 | 0.00 | 0.00 | 100.00 | 540  |
| Dighe           | 100.00 | 0.00 | 0.00 | 0.00 | 100.00 | 254  |
| Forto           | 99.81  | 0.00 | 0.00 | .19  | 100.00 | 218  |
| Gogne           | 100.00 | 0.00 | 0.00 | 0.00 | 100.00 | 421  |
| Goluj           | 99.83  | .17  | 0.00 | 0.00 | 100.00 | 279  |
| Haykota         | 99.80  | 0.00 | 0.00 | .20  | 100.00 | 210  |
| Laelay Gash     | 100.00 | 0.00 | 0.00 | 0.00 | 100.00 | 265  |
| Logo-Anseba     | 99.29  | .71  | 0.00 | 0.00 | 100.00 | 448  |
| Mensura         | 100.00 | 0.00 | 0.00 | 0.00 | 100.00 | 384  |
| Mogolo          | 100.00 | 0.00 | 0.00 | 0.00 | 100.00 | 255  |
| Molqui          | 89.75  | 6.89 | 3.36 | 0.00 | 100.00 | 335  |
| Shambuko        | 100.00 | 0.00 | 0.00 | 0.00 | 100.00 | 523  |
| Tessenei        | 100.00 | 0.00 | 0.00 | 0.00 | 100.00 | 555  |
| Gash-Barka      | 99.62  | 0.28 | 0.09 | 0.01 | 100.00 | 5178 |
| Porik           | 08.06  | 64   | 20   | 0.00 | 100.00 | 255  |
| Dehukeuri Mkrek | 90.90  | .04  |      | 0.00 | 100.00 | 200  |
|                 | 99.82  | .18  | 0.00 | 0.00 | 100.00 | 275  |
| Debubawi-me'rab | 100.00 | 0.00 | 0.00 | 0.00 | 100.00 | 260  |
| Gaa-Nethi       | 98.82  | 1.18 | 0.00 | 0.00 | 100.00 | 253  |
| Semenawi-me'rab | 99.14  | .86  | 0.00 | 0.00 | 100.00 | 226  |
| Semenawi-mibrak | 100.00 | 0.00 | 0.00 | 0.00 | 100.00 | 251  |
| Serejeka        | 98.74  | .80  | .46  | 0.00 | 100.00 | 273  |
| Maekel          | 99.35  | 0.58 | 0.08 | 0.00 | 100.00 | 1793 |
| Adobha          | 100.00 | 0.00 | 0.00 | 0.00 | 100.00 | 104  |
|                 | 100.00 | 0.00 | 0.00 | 0.00 | 100.00 | 10-1 |

| Afabet  | 100.00 | 0.00 | 0.00 | 0.00 | 100.00 | 260   |
|---------|--------|------|------|------|--------|-------|
| Foro    | 99.26  | .74  | 0.00 | 0.00 | 100.00 | 250   |
| Gel'alo | 100.00 | 0.00 | 0.00 | 0.00 | 100.00 | 211   |
| Ghindae | 95.10  | 2.32 | 1.62 | .97  | 100.00 | 507   |
| Karura  | 100.00 | 0.00 | 0.00 | 0.00 | 100.00 | 281   |
| Massawa | 98.96  | .56  | .48  | 0.00 | 100.00 | 450   |
| Nakfa   | 100.00 | 0.00 | 0.00 | 0.00 | 100.00 | 277   |
| Sheib   | 99.33  | .59  | .08  | 0.00 | 100.00 | 324   |
| Dahlak  | 100.00 | 0.00 | 0.00 | 0.00 | 100.00 | 134   |
| SKB     | 98.81  | 0.65 | 0.37 | 0.18 | 100.00 | 2798  |
|         |        |      |      |      |        |       |
| Total   | 97.18  | 1.28 | .80  | .74  | 100.00 | 18075 |

In the majority of the infected students, the intensity of infection of *S. mansoni* was light in all sub-zobas. Since the first objective of any control programme is to reduce the proportion of heavily infected individuals, the proportion of children with heavy intensity of infection of SCH is extremely important for monitoring the progress of the programme. With the exception of sub-zobas Areza and Tsorona, all of the sub-zobas in Zoba Debub had at least one child with heavy intensity *S. mansoni* infection. The subzobas with high intensity of infection, Adequala, Dekemhare, Dbarwa, Senafe and Mendefera were located in Zoba Debub. In sub-zoba Adequala, the overwhelming majority of the infected children have heavy intensity of infection with prevalence of 10.83% [4.7%, 23.1%]. Sub-zobas Dekemhare, Dbarwa and Senafe also have higher proportion of children with heavy intensity infections of SCH]. Sub-zoba Dekemhare and Maini have higher proportion of children with moderate intensity of infection with 7.55% and 6.92%, respectively. There is significant relationship between sub-zobas and intensity of infections of schistosomiasis ( $\chi 2 = 1346.467$ , p=0.000<0.001). See **Error! Reference source not found.** for details.

Figure 12: Sub zobas with high intensity infections of SCH



## 4.6.2 Intensity of Infection of *S. mansoni* by age and sex

Generally, older children are more likely to have moderate and heavy intensity of infection compared to younger children. Whereas 2.46%, 2.26% and 2.27% of children who are 14 years of age have light, moderate and heavy intensity of infections respectively, the corresponding figures for 10 years old children are only 1.42%, 0.27% and 0.20% respectively. Age is found to have significant relationship with the intensity of infection ( $\chi$  2 =141.030, p=0.000<0.001).

The intensity of infection of *S. mansoni* is significantly higher among males than females ( $\chi$  2 =152.096, p=0.000<0.001). Proportion of boys with light, moderate and heavy intensity of infections are estimated at 1.93%, 1.28% and 1.07%, respectively, compared with 0.58%, 0.27% and 0.40% among girls [Table 11].

| Age and sex | No<br>infection | Light<br>infection | Moderate<br>Infection | Heavy<br>Infection | Total  | Number of<br>Children |
|-------------|-----------------|--------------------|-----------------------|--------------------|--------|-----------------------|
| Age         |                 |                    |                       |                    |        |                       |
| 10          | 98.10           | 1.42               | .27                   | .20                | 100.00 | 5567                  |
| 11          | 97.65           | 1.02               | .68                   | .65                | 100.00 | 4057                  |
| 12          | 97.27           | 1.17               | .59                   | .97                | 100.00 | 4048                  |
| 13          | 97.32           | .63                | 1.42                  | .63                | 100.00 | 2588                  |
| 14          | 93.01           | 2.46               | 2.26                  | 2.27               | 100.00 | 1815                  |
| Sex         |                 |                    |                       |                    |        |                       |
| Male        | 95.72           | 1.93               | 1.28                  | 1.07               | 100.00 | 9373                  |
| Female      | 98.76           | .58                | .27                   | .40                | 100.00 | 8702                  |
| Total       | 97.18           | 1.28               | .80                   | .74                | 100.00 | 18075                 |

Table 11 : Percentage of children by intensity of infection of S. mansoni, according to age and sex

# 4.6.3 Intensity of Infection of *S. mansoni* by schools

Two hundred and fifty four (73.62%) of the surveyed 345 schools have children with no infections, 35 (10.1%) schools have children with only light intensity of infections and 7.69% and 8.79% of the schools have moderate and heavy intensity of infections, respectively[Figure 13]. The remaining schools have children with different intensity of infections; 56(16.23%) of the surveyed schools have at least one child with moderate or heavy intensity of infection and 27 (7.82%) have at least one child with heavy intensity of infections.

Figure 13: Distribution of schools by S. mansoniintensity of infection



In the majority of schools the intensity of infection was light. The majority of schools with higher proportion of children heavily infected with S. mansoni were located in Zoba Debub. Schools with heavy intensity infections include: Mai Gume Elementary and Junior school (18.26%) followed by Rahwa Junior School (9.97%), Halibo Elementary school (7.93%), Warsay junior school (7.59%), Mendefera junior (6.9%) and Mihiram Geido Elementary school (6.25%). See Error! Reference source not found., Error! Reference source not found., Error! Reference source not found. for the list of schools by intensity of S. mansoni infections.

4.7 Intensity of Infection of any STH

# 4.7.1 Intensity of Infection of Any STH by Zoba and sub-zoba

As indicated above almost all (99.8%) of the surveyed children were free from any STH infections. In all the five zobas where STH was found, no high or moderate intensity of infection was detected. The rate of light intensity infection is as follows: Anseba 0.29%, SKB 0.25%, Gash Barka 0.21% Maekel 0.13% and Debub 0.07% [

Figure 14: Distribution of light Infection from any STH in all zobas].





Out of the 58 sub zobas of the country, 20 sub zobas had light infection of STH. The remaining 38 sub zobas were free of STH infection. The sub zoba with the highest infection is Halhal (1.57%) followed by Aqurdet, Ghindae and Hagaz with percentages of 1.2%, 1% and 0.87% respectively. The remaining six sub zobas, namely Mensura, Logo Anseba, AdiKeih, Gogne, DebubawiMibraq and Habero rank from fifth to tenth with percentages ranging from 0.66% to 0.44%.

# 4.7.2 Intensity of Infection of Any STH by age and sex

Disaggregation of STH infection by age shows that light infections from any STH occurred among students aged 14 years(0.32%) followed by 13 years of age (0.24%). The lowest infection occurred among students' aged12 years (0.09%). Comparison of STH light infection by sex showed that males are more prone to the infection than females (0.23% Vs 0.10%)[

Table 12: Distribution of light Infection from any STH in all zobas]. Results of the study show that there is no significant difference in intensity of infections from any STH between boys and girls.

Table 12: Distribution of light Infection from any STH in all zobas

| Age and sex | No infection<br>from any STH | Light Infection from any<br>STH | Moderate<br>Infection from<br>any STH | Heavy<br>infection from<br>any STH | Total |
|-------------|------------------------------|---------------------------------|---------------------------------------|------------------------------------|-------|
| Age         |                              |                                 |                                       |                                    |       |
| 10          | 99.87                        | 0.13                            | 0.00                                  | 0.00                               | 5567  |
| 11          | 99.81                        | 0.19                            | 0.00                                  | 0.00                               | 4057  |
| 12          | 99.91                        | 0.09                            | 0.00                                  | 0.00                               | 4048  |
| 13          | 99.76                        | 0.24                            | 0.00                                  | 0.00                               | 2588  |
| 14          | 99.68                        | 0.32                            | 0.00                                  | 0.00                               | 1815  |
| Sex         |                              |                                 |                                       |                                    |       |
| Male        | 99.77                        | 0.23                            | .09                                   | .03                                | 9373  |
| Female      | 99.9                         | 0.10                            | .02                                   | .07                                | 8702  |
| Total       | 99.83                        | 0.17                            |                                       |                                    |       |

# 4.7.3 Intensity of Infection of Any STH by schools

The survey showed that in 31 out of the 344 surveyed schools there was light STH infection. Table 13shows that the following five schools had the highest intensity of infections: Abdela Degol (10.03%), Alnejah (9.37%), Gerger (6.73), Erdi (5.26%) and Alnahda (5.12%). See Error! Reference source not found. for detailed list of STH intensity of infection.

Table 13: Schools with at least one child having moderate or heavy intensity of infections from any STH

| Sub-zoba  | School                        | No<br>infection<br>from<br>any STH | Light<br>Infection<br>from<br>any STH | Moderate<br>Infection<br>from any<br>STH | Heavy<br>infection<br>from<br>any STH | Number<br>of<br>Students |
|-----------|-------------------------------|------------------------------------|---------------------------------------|--|---------------------------------------|--------------------------|
| Kerkebet  | Hamush Duba Elementary        | 91.71                              | 0                                     | 0  | 8.29                                  | 58                       |
| Kerkebet  | Aykarie Elementary            | 94.48                              | 3.79                                  | 1.73                                     | 0                                     | 53                       |
| Kerkebet  | Amalayet<br>Elementary&Junior | 79.67                              | 3.39                                  | 10.17                                    | 6.78                                  | 29                       |
| Adequala  | Rahwa Junior                  | 95.33                              | 2.33                                  | 0  | 2.33                                  | 51                       |
| Dbarwa    | Debarwa Elementary            | 88.19                              | 9.7                                   | 2.11                                     | 0                                     | 50                       |
| Dbarwa    | Tala Elementary               | 92                                 | 6.06                                  | 1.94                                     | 0                                     | 50                       |
| Imnihaili | Egri Mekel Elementary         | 93.79                              | 4                                     | 2.21                                     | 0                                     | 50                       |

| Mendefera | Fre Kalsi Elementary           | 92    | 0    | 1.71 | 6.29 | 50 |
|-----------|--------------------------------|-------|------|------|------|----|
| Mendefera | Ma'ahad Elementary             | 94.13 | 1.87 | 1.87 | 2.13 | 50 |
| Berik     | Tsaeda Christian<br>Elementary | 96.16 | 1.92 | 1.92 | 0    | 52 |

4.8 Relationship of infection with selected background characteristics

Chi-square procedure of the SPSS program was used to test the statistical significance of the relationship between infections of SCH and STH with selected background characteristics of the children surveyed. The background characteristics considered were age, sex, and zoba.

4.8.1 Relationship of SCH and any STH infection with age, sex, and zoba

The analysis showed that the relationship between SCH infections and all the background characteristics considered was stronglysignificant [

Table 14: SCH infection status of children age 10-14, according to selected background characteristics]. Girls, younger children, and those residing in Zoba Debub are more likely to be infected with SCH than their counterparts (p=0.000<0.001).

| Background Characteristic | Negative | Positive | Number<br>of<br>Students | Association measu | ıre      |
|---------------------------|----------|----------|--------------------------|-------------------|----------|
|                           |          |          | brudents                 | $\chi^2$          |          |
|                           |          |          |                          | P-value           | Sig.     |
| Sex                       |          |          |                          |                   |          |
| Male                      | 0.96     | 0.04     | 9373                     | 152 096           | 0.000*** |
| Female                    | 0.99     | 0.01     | 8702                     | 102.000           | 0.000    |
| Age                       |          |          |                          |                   |          |
| 10                        | 0.98     | 0.02     | 5729                     |                   |          |
| 11                        | 0.98     | 0.02     | 4127                     |                   |          |
| 12                        | 0.97     | 0.03     | 3886                     | 141.03            | 0.000*** |
| 13                        | 0.97     | 0.03     | 2442                     |                   |          |
| 14                        | 0.93     | 0.07     | 1890                     |                   |          |
| Zoba                      |          |          |                          |                   |          |
| Anseba                    | 0.988    | 0.012    | 2120                     |                   |          |
| Debub                     | 0.913    | 0.087    | 4835                     |                   |          |
| Debubawi Keih Bahri       | 100.000  | 0.000    | 297                      |                   |          |
|                           |          |          |                          | 834.248           | 0.000*** |
| Gash-Barka                | 0.996    | 0.004    | 5810                     |                   |          |
| Maekel                    | 0.993    | 0.007    | 3180                     |                   |          |
| NRS                       | 0.988    | 0.012    | 1833                     |                   |          |

#### Table 14: SCH infection status of children age 10-14, according to selected background characteristics

\*\*\* Significant at 0.001 level of significant

The likelihood of infections from any STH does not vary by sex of children [Table 15] eventhough the difference was statistically significant (P=0.033 < 0.05). Similarly, there is no statistically significant variation in the likelihood of infection from any STH by age of the children (P=0.274 > 0.05) and zoba (P=7.544 > 0.05) where they reside.

| Background Characteristic | Negative | gative Positive |          | Association measure |        |
|---------------------------|----------|-----------------|----------|---------------------|--------|
|                           |          |                 | Students | $\chi^2$            |        |
|                           |          |                 |          | P-value             | Sig.   |
| Sex                       |          |                 |          |                     |        |
| Male                      | 0.998    | 0.002           | 9373     | 4 5 4 2             | 0.022* |
| Female                    | 0.999    | 0.001           | 8702     | 4.040               | 0.033  |
| Age                       |          |                 |          |                     |        |
| 10                        | 0.999    | 0.001           | 5728     |                     |        |
| 11                        | 0.998    | 0.002           | 4127     |                     | 0.274  |
| 12                        | 0.999    | 0.001           | 3887     | 5.137               |        |
| 13                        | 0.998    | 0.002           | 2443     |                     |        |
| 14                        | 0.997    | 0.003           | 1890     |                     |        |
| Zoba                      |          |                 |          |                     |        |
| Anseba                    | 0.997    | 0.003           | 2120     |                     |        |
| Debub                     | 0.999    | 0.001           | 4835     |                     |        |
| Debubawi Keih Bahri       | 100.0    | 0.0             | 297      |                     |        |
| Gash-Barka                | 0.998    | 0.002           | 5810     | 7.54                | 0.183  |
| Maekel                    | 0.999    | 0.001           | 3180     |                     |        |
| NRS                       | 0.997    | 0.003           | 1834     |                     |        |

#### Table 15: Any STH infection status of children age 10-14, according to selected background characteristics

\*\* Significant at 0.01 level of significant

# 4.9 Determinants of Infections of SCH and STH

The earlier bivariate analysis showed that there are differentials between infection from SCH and any STH and selected background characteristics of children (age, sex, and zoba). There is, however, a need to appraise the effect of a single factor when other variables are controlled. Therefore, when evaluating the effects of any factor on intensity of infections, a multivariate analysis is necessary to control for the effects of others. To this end, logistic regression analysis was carried out to quantify the net effects of age, sex, and zoba on the likelihood of infection from SCH and any STH; which will be the dependent variables. In order to use logistic regression model, the dependent variables were transformed (recoded) to dichotomous variables to fit the model, as the logistic regression is used only for the variables that have dichotomous nature.

The output of the regression model included level of significance, coefficients, odds ratio and probabilities of infections from the parasites. The interpretation of the results was based on the references categories. The reference categories were selected on the basis that they have the least likelihood of infections from the parasites.

## Prevalence & Intensity of Infection of *H. nana*

Although the main objective of mapping survey was to identify and determine the prevalence of *S. mansoni* and STH (*A. lumbricoides, T. trichiura* and hookworm), other parasites found during the survey were also documented, tabulated and analysed. One of the parasites that werefound commonly in all the six zobas of the country was H. nana.

## 4.10.1 Prevalence of *H.nana* by Zoba & Subzoba

The study showed that H. nana prevalence in Eritrea is 2.1%. The highest prevalence of H.nana was found in SKB with 4.4% followed by Debub, Anseba and DKB with prevalence of 3.4%, 2.5% and 2.0% respectively [Figure 15].



#### Figure 15: Prevalence of H.nana by Zoba

Out of the 58 subzobas surveyed *H.nana* was found in 47 of them. The highest prevalence of *H.nana* was found in Mendefera sub zoba (11.63%) followed by Kerkebet, Foro and Gelalo (9.60%, 8.73% and 8.24%), respectively.

Table 16: Prevalence of H.nana by Sub Zoba& Zoba

| Zoba/Subzot | Da            | Prevalence | Number of<br>Students |  |
|-------------|---------------|------------|-----------------------|--|
| Anseba      |               |            |                       |  |
| Sub-zoba    | Hagaz         | 0.00       | 279                   |  |
|             | Adi-Tekelezan | 1.39       | 283                   |  |
|             | Asmat         | 0.00       | 280                   |  |
|             | Elaberd       | 0.00       | 239                   |  |
|             | Geleb         | 0.00       | 285                   |  |
|             | Habero        | 4.58       | 263                   |  |
|             | Halhal        | .49        | 279                   |  |
|             | Hamelmalo     | 1.69       | 275                   |  |
|             | Keren         | 4.69       | 281                   |  |
|             | Kerkebet      | 9.60       | 196                   |  |
|             | Selea         | 6.98       | 199                   |  |
|             | Total         | 2.51       | 2859                  |  |
| Debub       |               |            |                       |  |
| Sub-zoba    | Adiquala      | 1.40       | 251                   |  |
|             | Adikeih       | 4.06       | 483                   |  |
|             | Areza         | .66        | 501                   |  |
|             | Dbarwa        | 2.34       | 454                   |  |
|             | Dekemhare     | 3.13       | 480                   |  |
|             | Imnihaili     | 3.07       | 352                   |  |
|             | Maiaini       | 1.98       | 260                   |  |

|            | Maimine        | .40   | 352  |
|------------|----------------|-------|------|
|            | Mendefera      | 11.63 | 402  |
|            | Segeniti       | 2.51  | 197  |
|            | Senafe         | 6.80  | 403  |
|            | Tsorona        | 2.99  | 370  |
|            | Total          | 3.40  | 4505 |
| DKB        |                |       |      |
| Sub-zoba   | Areata         | 0.00  | 188  |
|            | Assab          | 3.18  | 262  |
|            | Debub denkalya | 1.60  | 238  |
|            | Maakel denkel  | 2.02  | 254  |
|            | Total          | 2.18  | 942  |
| Gash-Barka |                |       |      |
| Sub-zoba   | Aquordet       | .31   | 491  |
|            | Barentu        | .31   | 540  |
|            | Dighe          | 1.90  | 254  |
|            | Forto          | 1.23  | 218  |
|            | Gogne          | 0.00  | 421  |
|            | Goluj          | .08   | 279  |
|            | Haykota        | 0.00  | 210  |
|            | Laelay Gash    | 0.00  | 265  |
|            | Logo-Anseba    | .20   | 448  |
|            | Mensura        | 0.00  | 384  |
|            | Mogolo         | 0.00  | 255  |
|            | Molqui         | 0.00  | 335  |

|          | Shambuko        | .54  | 523  |
|----------|-----------------|------|------|
|          | Tessenei        | .92  | 555  |
|          | Total           | .26  | 5178 |
| Maekel   |                 |      |      |
| Sub-zoba | Berik           | 3.42 | 255  |
|          | Debubawi Mbrak  | 1.64 | 275  |
|          | Debubawi-me'rab | 2.87 | 260  |
|          | Gaa-Nefhi       | 1.11 | 253  |
|          | Semenawi-me'rab | 2.14 | 226  |
|          | Semenawi-mibrak | 1.20 | 251  |
|          | Serejeka        | 1.90 | 273  |
|          | Total           | 1.81 | 1793 |
| SKB      |                 |      |      |
| Sub-zoba | Adobha          | 2.31 | 104  |
|          | Afabet          | 3.05 | 260  |
|          | Foro            | 8.73 | 250  |
|          | Gel'alo         | 8.24 | 211  |
|          | Ghindae         | 2.66 | 507  |
|          | Karura          | 4.48 | 281  |
|          | Massawa         | 4.91 | 450  |
|          | Nakfa           | .66  | 277  |
|          | Sheib           | 6.20 | 324  |
|          | Dahlak          | 3.07 | 134  |
|          | Total           | 4.43 | 2798 |

## 4.10.2 Prevalence of *H.nana* by Schools

The highest prevalence of *H.nana* was found in Senafe Elementary school (24.31%), followed by Fithi Junior school in Mendefera sub zoba, Amalayt elementary school in Kerkebet s/zoba and Irafale elementay and junior school in Foro sub zoba (22%,21.21% and18.01%), respectively. The prevalence in the rest of the schools ranged from 0.00-13.82

### Trachoma

Two national surveys on Trachoma were conducted, in 2005 and 2012 to determine the prevalence of trachoma in 3 separate Zobas. The cross sectional survey was conducted in May 2005, in Gash-Barka, Debub and Northern Red Sea Zones, in children 1 - 9 years of age and adults above 15 years of age. Trachoma in children was more prevalent in Debub followed by Northern Red Sea (SKB) and was least prevalent in Gash Barka. Prevalence of TF in children 1 – 9 years was 14.9% in Debub. In SKB it was 5.5% and Gash Barka it was 2.4%. Prevalence of TT was higher in older age groups and in persons with no schooling. The highest prevalence in the country is in Mai mine sub-zoba in Debub with over 69% prevalence of TF in children 1–9 years of age. Other sub-zobas in Debub with high prevalence include Adi Quala with 26.4%. Areza, Dubarwa, Emni Hayli, Senafe and Mendefera have prevalence between 10 and 20%.

In Northern Red Sea, Nakfa has prevalence of 11.1%, while Afabet, Ghindae, Massawa and Shieb have more than 5% but less than 10%. In Gash Barka, only Barentu and Shambuqo have more than 5% but less than 10%.

All Sub-zobas with high prevalence of TF in children also have high prevalence of TT in adults except Massawa, Mendefera and Nakfa. In addition, some sub-Zobas with relatively lower prevalence of TF in Children have higher prevalence of TT in adults. These include Logo Anseba, Molqui and Omhajer in Gash Barka, Dige-Adobha in SKB and Adi Keyh in Debub. Implementation of MDAs for 8 sub-zobas found to be endemic for Trachoma was started in 2011.

| Province or region | Sub zoba or community* | Prevalence<br>(number and rate) | Study method   | Year of<br>survey |
|--------------------|------------------------|---------------------------------|----------------|-------------------|
|                    | Hagaz                  | 8.5                             | ITI guidelines | 2014              |
|                    | Adi-Tekelezan          | 9.8                             | ITI guidelines | 2014              |
|                    | Asmat                  |                                 |                |                   |
|                    | Elaberd                | 9.8                             | ITI guidelines | 2014              |
|                    | Geleb                  | 9.8                             | ITI guidelines | 2014              |
| Anseba             | Habero                 | 9.8                             | ITI guidelines |                   |
|                    | Halhal                 | 8.5                             | ITI guidelines | 2014              |
|                    | Hamelmalo              | 8.5                             | ITI guidelines | 2014              |
|                    | Keren                  | 8.5                             | ITI guidelines | 2014              |
|                    | Kerkebet               |                                 |                |                   |
|                    | Selea                  |                                 |                |                   |
| Dilal              | Adequala               | 26.4                            | ITI guidelines | 2006              |
| Debub              | Adikeih                | 1.8                             | ITI guidelines | 2006              |

|            | Areza               | 10.7 | ITI guidelines   | 2006 |
|------------|---------------------|------|------------------|------|
|            | Dbarwa              | 16.7 | ITI guidelines   | 2006 |
|            | Dekemhare           | 6.6  | ITI guidelines   | 2006 |
|            | Imnihaili           | 16.7 | ITI guidelines   | 2006 |
|            | Maiaini             | 8.6  | ITI guidelines   | 2006 |
|            | Maimine             | 69   | ITI guidelines   | 2006 |
|            | Mendefera           | 20.5 | ITI guidelines   | 2006 |
|            | Segeniti            | 3.3  | ITI guidelines   | 2006 |
|            | Senafe              | 15.6 | ITI guidelines   | 2006 |
|            | Tsorona             | 6.8  | ITI guidelines   | 2006 |
|            | Areta               | 0    | Rapid assessment | 2012 |
| DVD        | Makelay Keyih Bahri | 0    | Rapid assessment | 2012 |
| DKB        | Debub Denkalia      |      |                  |      |
|            | Asseb               | 2.8  | Rapid assessment | 2012 |
|            | Agurdet             | 0.9  | ITI guidelines   | 2006 |
|            | Barentu             | 7.5  | ITI guidelines   | 2006 |
|            | Dighe               | 0    | ITI guidelines   | 2006 |
|            | Forto               | 3.5  | ITI guidelines   | 2006 |
|            | Gogne               | 1.9  | ITI guidelines   | 2006 |
|            | Haycota             | 1.7  | ITI guidelines   | 2006 |
| Gash Barka | Logo Anseba         | 0    | ITI guidelines   | 2006 |
|            | Mensura             | 0    | ITI guidelines   | 2006 |
|            | Mogolo              | 0    | ITI guidelines   | 2006 |
|            | Gulug               | 1    | ITI guidelines   | 2006 |
|            | Shambuko<br>Mulki   | 6.8  | ITI guidelines   | 2006 |
|            | Teseney             | 0    | ITI guidelines   | 2006 |
|            | Laalay Gash         | 4.3  | ITI guidelines   | 2006 |
|            |                     |      |                  |      |
|            | Berik               | 0    | Rapid assessment | 2012 |
|            | Debubawi Mbrak      | 0    | Rapid assessment | 2012 |
| Maakal     | Debubawi-me'rab     | 10   | Rapid assessment | 2012 |
| WIAAKCI    | Gaa-Nefhi           | 5.8  | Rapid assessment | 2012 |
|            | Semenawi-me'rab     | 0    | Rapid assessment | 2012 |
|            | Semenawi-mibrak     | 7.7  | Rapid assessment | 2012 |
|            | Serejeka            |      |                  |      |
|            | Ghelealo            | 1.4  | ITI guidelines   | 2006 |
|            | Foro                | 0    | ITI guidelines   | 2006 |
|            | Dahlak              | 0    | ITI guidelines   | 2006 |
|            | Massawa             | 5.6  | ITI guidelines   | 2006 |
| SVD        | Ghindae             | 5.8  | ITI guidelines   | 2006 |
| SKB        | Shieb               | 5.5  | ITI guidelines   | 2006 |
|            | Afabet              | 7.9  | ITI guidelines   | 2006 |
|            | Nakfa               | 11.7 | ITI guidelines   | 2006 |
|            | Adobha              | 0    | ITI guidelines   | 2006 |
|            | Karora              | 1.4  | ITI guidelines   | 2006 |



Figure 10: Prevalence of TF in Children 1-9 years by sub-Zoba (SKB, Debub and Gash Barka)

The 2012 study was a Trachoma Rapid Assessment in Zobas Anseba, Maakel, and DKB and the results are shown in figure 10.

Figure 11: Trachoma endemicity map



## Lymphatic filariasis

Lymphatic filariasis is caused by *Wuchereria bancrofti*. There are 142 Filariasis cases reported between 1998 -2011 from different health facilities in all the zones of the country (Source, HMIS). LF transmission is optimum in high humidity areas transmitted by mosquito of both Anopheles and Culex spp. In 2014, 57 villages were mapped for LF using ICT cards. Out of these villages, 7 individuals tested positive by ICT card. The positive results were found in two villages, Adibara (Gash Barka) and Tio (DKB). Adibara borders Sudan while Tio is located in the coastal area.

Table 2d: LF distribution in the country

| Zoba       | Location /site | Prevalence<br>(%) | Method used | Year documented<br>(Source) |     |
|------------|----------------|-------------------|-------------|-----------------------------|-----|
| National N | TD Mapping     | - 2014            |             |                             |     |
| Gash-Barka | Forto          | <1% (6/22)        | ICT Cards   | 2014; National Mapping      | NTD |
| DKB        | Arata (Tio)    | <1 (1/100)        | ICT Cards   | 2014; National Mapping      | NTD |

Figure 11: LF endemicity map



## Leprosy

Leprosy control program is one of the oldest program in the country. Leprosy is prevalent all over the country. Cases are treated currently at central level in the Leprosy Hospital in Asmara. In recent times cases are coming mostly from Debub and Southern Red Sea Zoba. In 2012, seven cases were reported by the National Leprosy Hospital.

#### **Dengue fever**

Dengue fever is one of the epidemic prone diseases that is rapidly expanding in many parts of the world. Dengue haemorrhagic fever has been common in the West African countries. In recent years, outbreaks of dengue fever have occurred in the east coast of Africa expanding from Ethiopia to Mozambique as well as in the shores of the small islands of Comoros and Seychelles. Similar cases of dengue haemorrhagic fever like illnesses have also been reported in Saudi Arabia. There are four sero-types of the virus and each one can manifest itself in one of the three forms: as Dengue Fever (DF), Dengue Haemorrhagic Fever (DHF) or Dengue Shock Syndrome (DSS).

There were reports of DF like outbreaks in the Western part of Eritrea, in the Gash-Barka region, in 2005 - 2008 (MOH Reports). In the recent past years, there were continuous incidences of increased dengue like febrile illnesses in the Northern Red Sea, Southern Red Sea and Gash-Barka Zones of the country that was locally nick named as "Welcome" disease. In the years 2006 – 2008, although the trend was low, there was almost a continuous transmission throughout the year. One expects an increase in the incidence of the DF outbreak following the rainy season which is usually between the period November – January, however, the incidence of the suspected DF cases did not look to limit within this period of time alone. This was mainly because of the presence of various water bodies such as open public pipe water that continually leak into their surroundings, open tankers, swamps, disposed tires, open water barrels at homes that served for the free reproduction of the mosquitoes, *Aedes egypti*.

The attack rates of dengue fever in the three Zones during the period 2010 - 2012 are presented below. This data includes only those cases seen at the health centers and hospitals

but not those seen at the health stations, where majority patients are seen. Suspected dengue fever cases seen at health stations are excluded because of possible over diagnosis due to overlap with malaria cases and lack of confirmatory diagnostic tests at this level of health facility. There were no cases of mortality reported in any of the Zones.

|                | 2010  | Population | Attack Rate<br>(per 100,000 | 2011  | Population | Attack Rate<br>(per 100,000 | 2012<br>(10<br>months) | Population | Attack<br>Rate (per<br>100,000 |
|----------------|-------|------------|-----------------------------|-------|------------|-----------------------------|------------------------|------------|--------------------------------|
| SKB            | 6,664 | 607,414    | 1,097                       | 6,879 | 624,422    | 1,102                       | 4,776                  | 641,906    | 744                            |
| DKB            | 366   | 61,103     | 599                         | 1726  | 62,993     | 2,740                       | 845                    | 64,941     | 1,301                          |
| Gash-<br>Barka | 3,414 | 705,675    | 484                         | 5405  | 727,500    | 743                         | 3667                   | 750,000    | 489                            |

Table 2e: Dengue Fever Incidence by Year and Zones in Eritrea

(Source: MOH)

To further verify and document the presence of DF in the region, WHO and the MOH conducted a cross sectional study in Massawa and its surroundings in March 2010. A total of twenty six blood samples were collected and sent to KEMRI, Nairobi, for analysis and sero-typing. The result showed that 23/26 (88%) were positive for Dengue Fever virus sub-type 1. Out of the 26 patients seen only 5 (19%) were Females while the rest (81%) were Males. The age group of the patients ranged from 9 up to 58 years and the majority were above the age 15 years.

DF virus serotypes can manifest in any one of the clinical manifestations. The signs and symptoms that were seen in Eritrea were typical of DF and in most, blood film for malaria was negative. The main clinical manifestations included an acute fever plus: headache, severe muscle pain, arthralgia (back pain), anorexia and fatigue.

The illness affected all sex and age groups though pronounced among the age group 5 years and above. Except for a few health facilities, all health facilities in the region reported DF like illness outbreak.

Overall the trend and severity of the disease has been increasing with time and recently, there were reports of suspected Dengue Haemorrhagic Fever among Chinese working in the Cement Factory in the Northern Red Sea Region of the country. In addition, Dengue fever is reported to be expanding to the other hitherto unaffected villages and towns in the coastal region.

#### Leishmaniasis

Leishmaniasis is reported from health facilities in different corners of the country but mainly from Gash Barka Northern Red Sea , Debub , Anseba and Maekel. The distribution by age is 5% of the cases "LessThanFive" and 95% "FiveAndAbove". The reported data is agregatted from all Leishmaniasis cases (mucocutaneous, cutaneous and visceral leishmaniasis). The usual pattern in Horn of Africa for visceral leishmaniasis is the lowlands (Western and South) and for cutaneous leishmaniasis the highlands (Central and Northern), although population movements should be considered and taken into account for the planification

## **Co-endemicity of NTD's**

Data on the co-endemicity of NTD's in Eritrea is scanty. Table 3 shows sub-Zobas where coendemicity has been confirmed.

|                |                  | Diseases   |           |              |          |                 |                  |         |  |
|----------------|------------------|------------|-----------|--------------|----------|-----------------|------------------|---------|--|
| Zoba           | Sub Zoba         | Preventive | Chemother | apy Diseases |          | Case man        | agement Diseases |         |  |
|                |                  | LF         | Schisto   | STH          | Trachoma | Dengue<br>fever | Leishmaniasis    | Leprosy |  |
| -              | Elabered         | -          | -         | +            | +        | +               | +                |         |  |
| Anseba         | Geleb            | -          |           |              | +        |                 |                  |         |  |
|                | Keren            | -          | -         | +            | +        | +               | +                | +       |  |
|                | Hagaz            | -          | -         | +            | +        | +               |                  |         |  |
|                | Halhal           | -          | +         | +            | +        |                 | +                |         |  |
|                | Habero           | -          | -         | +            | +        | +               |                  |         |  |
|                | Asmat            | -          | -         |              |          |                 |                  |         |  |
|                | Kerkebet         | -          | -         |              |          | +               |                  |         |  |
|                | Sela             | -          | -         |              |          |                 |                  |         |  |
|                | AdiTekelezan     | -          | +         | +            | +        |                 |                  |         |  |
|                | Hamelmalo        | -          | -         | +            | +        | +               |                  |         |  |
|                | Debarwa          | -          | +         | +            | +        |                 |                  | +       |  |
|                | Areza            | -          | +         |              | +        |                 |                  | +       |  |
| Debub          | Mendefera        | -          | +         | +            | +        |                 | +                | +       |  |
|                | Dekemhare        | -          | +         | +            | +        | +               | +                | +       |  |
|                | Segeneiti        | -          | +         | +            | +        |                 | +                | +       |  |
|                | AdiKeyih         | -          | +         | +            | +        | +               | +                | +       |  |
|                | Senafe           | -          | +         | +            | +        | +               | +                | +       |  |
|                | Tsorona          |            | +         | +            | +        |                 |                  | +       |  |
|                | Adiquala         | -          | +         | +            | +        | +               | +                | +       |  |
|                | Emni-Haili       | -          | +         |              | +        |                 |                  | +       |  |
|                | May- aynee       | -          | +         | +            | +        |                 |                  | +       |  |
|                | Mai-Mine         | -          | +         |              | +        | +               |                  | +       |  |
|                | Areta            | -          | -         | +            | +        | +               |                  |         |  |
| DKR            | MakelayKeihbahri | -          | -         |              | +        | +               |                  | +       |  |
| DKB            | DebubDenkalia    | -          | -         |              | +        |                 |                  | +       |  |
|                | Asseb            | -          | -         | +            | +        | +               | +                | +       |  |
| Gash-<br>Barka | Akordat          | -          | -         | +            | +        | +               | +                | +       |  |
|                | Barentu          | -          | -         | +            | +        | +               | +                |         |  |
|                | Dighe            | -          | -         | +            | +        | +               |                  |         |  |

# Table 3: NTD co-endemicity

|        | Forto                | - | - | + | + | + |   |   |
|--------|----------------------|---|---|---|---|---|---|---|
|        | Gogne                | - | - | + | + |   |   |   |
|        | Haycota              | - | + | + | + |   |   |   |
|        | LogoAnsseba          |   | + | + | - | + |   |   |
|        | Tesseney             |   | - |   | - |   |   |   |
|        | Mensura              |   | - | + | - |   | + |   |
|        | Mogolo               |   | - | + | - | + |   |   |
|        | Guluj                |   | + | + | + |   | + | + |
|        | Shambuko             |   | - |   | + |   | + |   |
|        | Mulki                |   | + | + | + |   | + |   |
|        | La'elay Gash         |   |   |   | + |   |   |   |
|        | Omhajor              |   |   |   | + |   |   |   |
|        | Ghelealo             |   |   |   | + |   |   |   |
|        | Foro                 |   |   |   | + |   |   |   |
|        | Dahlak               |   |   |   | - |   |   |   |
|        | Massawa              |   |   |   | + |   |   |   |
| SVD    | Ghindae              |   |   |   | + |   |   |   |
| SKD    | Shieb                |   |   |   | + |   |   |   |
|        | Afabet               |   |   |   | - |   |   |   |
|        | Nakfa                |   |   |   | + |   |   |   |
|        | Adobha               |   |   |   | - |   |   |   |
|        | Karora               |   |   |   | + |   |   |   |
|        | Serejeka             |   |   |   | - |   |   |   |
|        | Berikh               |   |   |   | - |   |   |   |
|        | Ghalanefhi           |   |   |   | + |   |   |   |
| Maakel | North east<br>Asmara |   |   |   | - |   |   |   |
|        | North west<br>Asmara |   |   |   | + |   |   |   |
|        | South west<br>Asmara |   |   |   | - |   |   |   |
|        | South East<br>Asmara |   |   |   | + |   |   |   |



Figure 16: Co-endemicity map for Neglected Tropical Diseases in Eritrea

| Table 4: NTD mapping status |              |                    |                      |              |  |  |  |  |  |  |
|-----------------------------|--------------|--------------------|----------------------|--------------|--|--|--|--|--|--|
| Endemic                     | Total number | Number of Sub      | N umber of sub zones | Number of    |  |  |  |  |  |  |
|                             | of Sub-zones | zones suspected to | mapped or known      | Sub zones to |  |  |  |  |  |  |
|                             |              | be endemic         | endemicity status    | be mapped    |  |  |  |  |  |  |
| Schistosomiasis             | 58           | 31                 | 28                   | 0            |  |  |  |  |  |  |
| STH                         | 58           | 58                 | 21                   | 0            |  |  |  |  |  |  |
| Leishmaniasis               | 58           | 58                 | 0                    | 0            |  |  |  |  |  |  |
| Lymphatic                   | 58           | 24                 | 0                    | 0            |  |  |  |  |  |  |
| Filariasis                  |              |                    |                      |              |  |  |  |  |  |  |
| Trachoma                    | 58           | 58                 | 55                   | 0            |  |  |  |  |  |  |
| Dengue fever                | 58           | 58                 | 0                    | 58           |  |  |  |  |  |  |
| Leprosy                     | 58           | 58                 | 0                    | 58           |  |  |  |  |  |  |
| Brucellosis                 | 58           | 58                 | 0                    | 58           |  |  |  |  |  |  |
| Anthrax                     | 58           | 58                 | 0                    | 58           |  |  |  |  |  |  |
| Rabies                      | 58           | 58                 | 0                    | 58           |  |  |  |  |  |  |

\*Trachoma partially mapped used Trachoma Rapid assessment in 2012

#### **1.3.2 NTD programme implementation**

This section list the past and on-going NTD control programmes for the PCT and CM-NTDs. These interventions are also summarized for PCT and CM-NTDs in tables 5.1 and 5.2 and annexes 1.6 and 1.7 respectively.

#### Past and current NTDs intervention for PCT NTDs.

#### SCH

Past and current interventions: Mass drug administration and associated interventions were done in some places of Zoba Anseba (Adi tekelezan sub-zone in 2011 and 2012)

and Zoba Debub (Adi-Qualla Sub-zone in 2010 and 2012. Mapping has recently been concluded.

After Mapping 2014 and 2015 in two subzones of zoba Debub (Mai Aini and Dekemhare sub zones MDA for SCH and STH is conducted ,as the same time for all students found positive for STH and SCH given praziquantil and albendazole.

## STH

No MDA intervention was implementend. But with this new strategy and having cmpleted the mapping in all Zobas, MDA will not commence because the prevalence is below tresh hold .

## LF

There has been no on-going intervention, however having completed the mapping for this disease, appropriate interventions will follow as reflected in the 2015 annual work plan.

### Trachoma

Trachoma mapping has been completed in 4 Zobas and intervention is on-going in 8 sub-Zobas. Impact assessment was conducted in 2014 in 7 of the 8 sub-Zobas and 6 were declared free of infection.

## Leprosy

The Leprosy control program is joined with the National TB control program and hence most activities are jointly performed. The Hansonian Hospital in the central zone is the only hospital that is designated to initiate treatments and follow some of them. All suspected cases from the sub zones are referred to the central level for confirmation and treatment of the cases. The hospital provides treatment and adjuvant treatment for coexisting conditions. Currently the case finding management has been confined to passive one where patients seek medical attention.

The capacity building particularly in case management of leprosy has been sub-optimal. However packages of trainings have been given together with TB. The program collects data on case notification and treatment outcome every quarter.

The program has also managed to come up with revised guidelines for leprosy in August 2013.

#### Dengue Fever & Leishmaniasis

Other CM-NTDs- Lymphatic filariasis, Leishmaniasis, Degue Fever there are no ongoing national programmes. They are managed at health facilities whenever patients appear in the facilities. These diseases will be addressed as reflected in this document.

| NTD | Date    | Total sub | No.   | Of   | Sub  | Total      | No. (%) | Key        | Key Partners |
|-----|---------|-----------|-------|------|------|------------|---------|------------|--------------|
|     | Program | zones     | zones | cove | ered | population | covered | Strategies |              |
|     | started | targeted  | (geog | raph | ical | in target  |         | used       |              |
|     |         |           | cover | age) |      | Sub zone   |         |            |              |

 Table 5.1: Summary of intervention information on existing PCT programmes

| Tracho<br>ma | 2011 | 8 | 8 | 1364830 |               | SAFE,MD<br>A | Fred Hollows, MOH<br>ITI,UNICEF,CBM,W<br>ASH |
|--------------|------|---|---|---------|---------------|--------------|--|
| SCH          | 2010 | 3 | 3 | 3246    | 3002(92<br>%) | MDA          | WHO,MOH                                      |
| STH*         |      |   |   |         |               |              |  |
| LF*          |      |   |   |         |               |              |  |

\*: Not yet

#### Table 5.2: Summary of intervention information on existing CMDs

| NTD           | Date<br>Program<br>started | Total sub<br>zones<br>targeted | No. Of Sub<br>zones covered<br>(geographical<br>coverage) | Total<br>population<br>in target Sub<br>zone | No. (%)<br>covered | Key Strategies<br>used      | Key<br>Partners |
|---------------|----------------------------|--------------------------------|---|--|--------------------|-----------------------------|-----------------|
| Leprosy       | 1970                       | 6                              | 57  | -  | -                  | Active/Passive case finding | WHO             |
| Leishmaniasis | Not yet                    |                                |   |  |                    |                             |                 |
| Dengue Fever  | Not yet                    |                                |   |  |                    | Active/Passive case finding | WHO             |
| LF            | Not yet                    | 2                              |   |  |                    |                             |                 |
| ТТ            | 2011                       | 8                              | 5   | 422,660                                      | 62%                | Active/Passive case finding | ITI             |

#### **1.3.3 Gaps and Priorities**

The gaps and priorities for the NTD programme in Eritrea as listed below have being used to develop the SWORT analysis and the SWORT counteracting table.

The SWOT analysis table 6.1 implementation of the NTD programme in Eritrea. A further analysis of the SWOT on table 6.2matches the strengths and opportunities which can be used to counter the identified weaknesses and threats to the programme.

#### Table 6.1: SWOT Analysis

| Strengths                               | Weaknesses              | Opportunities                          | Threats   |
|---|-------------------------|--|---|
| Country profile                         |                         |  |   |
| Well organized administrative structure |                         | Growing international interest on NTDs | SAFE activities ongoing in the Ministry of health |
|   |                         | More resource available                |   |
|   |                         | on NTDs                                |   |
|   |                         | More local partners                    |   |
| Good health system                      | Weak Intra and inter    |  |   |
| indicators                              | sectoral collaboration  |  |   |
| Existence of community                  |                         |  | Malaria and TB in the same                        |
| health agent                            | Weak IDM programmes     |  | division as NTD                                   |
| Functional health delivery              |                         |  |   |
| system                                  | Poor electricity supply |  |   |

| Very good road network   |   |  |   |
|--|---|--|---|
| New staff posted to the NTD programme  | Low mobile telephone penetration network  | More local partners for NTDs           | Expensive fuel and higher car rental rate                   |
| SuccessfulexperienceincludingGuineawormeradicationandcertification in 2011   | Weak experiences in<br>majority of the NTDs;<br>Inadequate experienced<br>human workforce | Growing international interest on NTDs | Inadequate funding of<br>NTDs                               |
| Good intersectoral<br>participation in reviewing<br>of master plan.  | Poor advocacy and<br>resource mobilization<br>for NTDs                                    | More resource available<br>on NTDs     | Inadequate safe water<br>supply and lantrines               |
| Good performance of Trachoma and leprocy   | Lack of health policy<br>and guideline on NTDs  | Increasing political commitment        | Poor Cross border collaboration                             |
| The WHO recommended<br>health worker/population<br>ratio   |   | More partners for NTDs                 | Presence of high priority<br>diseases overshadowing<br>NTDs |
| Inadequate national funding  |   |  |   |
| Mapping completed for<br>PCT NTDS, however<br>Maakel and DKB were<br>done by rapid assessment<br>method in a non-<br>representative sample for<br>Trachoma |   |  |   |

 Table 6.2: SWOT counteracting table

| Weaknesses                                       | Strengths counteracting weaknesses                            | Opportunities counteracting weaknesses |
|--|---|--|
| Weak intra and inter sectoral collaboration      | Good intersectoral participation in reviewing of master plan. | Malaria in the same division with NTD. |
| Weak IDM programmes                              | Good performance of Trachoma and leprosy                      |  |
| Poor electricity supply                          | Costed master plan  |  |
| Low mobile telephone penetration network         |   |  |
| Inadequate experienced NTD workforce             | The WHO recommended health worker/population ratio            |  |
|  | New staff posted to the NTD programme                         |  |
| Poor advocacy and resource mobilization for NTDs |   | Growing international interest on NTDs |
|  |   | More resource available on NTDs        |

|   |   | More local partners                 |
|---|---|-------------------------------------|
| Lack of health policy and guideline on NTDs |   |                                     |
| Inadequate national funding                 | Costed master plan                      |                                     |
|   |   |                                     |
| Treads                                      |   |                                     |
| Expensive fuel and higher car rental        | Good road network                       |                                     |
| rate  |   |                                     |
| Inadequate funding of NTDs                  |   | Global availability                 |
| Inadequate safe water supply and            | SAFE activities ongoing in the Ministry |                                     |
| lantrines                                   | of health                               |                                     |
| Poor Cross border collaboration             |   | Collaboration between Eritrea and   |
|   |   | neighboring countries.              |
| Presence of high priority diseases          |   | Malaria and TB in the same division |
| overshadowing NTDs                          |   |                                     |

- a) Assessment of trachoma in two Zobas (Maakel and DKB) was done in 2012 using a rapid assessment method with a sample size that was not representative. Thus, detailed mapping based on WHO guidelines is needed in these Zobas.
- b) Poor advocacy and resource mobilization for NTDs
- c) Insufficient national funding of NTDs
- d) Inadequate experienced human workforce;
- e) Lack of NTD policy and guidline; NTD training manual.
- f) Weak inter-sectoral collaboration and poor joint planning;
- g) Low mobile telephone penetration network
- h) Transportation challenges

Following the above gaps, the main priorities of NTDs in Eritrea are as follows.

**Planning:** An NTD policy will be developed as well the relevant NTD guidelines. Annual work plans will be drawn from these devised work plans.

**Coordination and Management:**A leadership and management trainings will be organized at national and zonal levels. Collaboration between the MoH and other ministries such as Education, water and environment will be intensified. Morever the engagement of partners and will be an inclusive and participatory approach.

**Partnerships:** A network of partners interested in some particular NTDs such as Trachoma exists within the country. Opportunities are there to bring other partners on board to support other NTDs.

**Implementation of Interventions:**There are ongoing NTD interventions strengthen further by the development of master plan. Activities that will be given priority will
include development of policies and guidelines, national training curriculum and tools, IEC materials and advocacy at all levels. PHASE approach will be prioritized and access to intervention scaled up across all endemic sub-Zobas. The health system administrative structure and the community structure will collaborate to insure successful implementation of interventions. Opportunities of NTD drug donations will greatly reduce the cost of implementation of interventions.

**Surveillance, Monitoring and Evaluation**: NTDs will be incorporated and monitored alongside other conditions through the existing HMIS system in the MoH and monitored alongside other health interventions. The NTD programme will also supervise closely all intervention as the country moves from control to elimination of most NTDs. monitor progress of implementation. M&E tools will therefore be developed and annual reviews of programmes conducted based on the results to track progress.

### PART 2: NTD STRATEGIC AGENDA

This part of the Master Plan articulates the strategic agenda, comprising the overall programme Mission, Vision, Strategic Goal, Programme focus, milestones, strategic priorities and the objectives for each NTD.

### 2.1. Overall NTD Programme Vision, Mission and Goals

#### Vision

- Eritrea free of neglected tropical diseases and related morbidity and disabilities **Mission** 
  - To provide cost-effective, sustainable, equitable, and community-owned interventions for the prevention, control and elimination and/or eradication of targeted NTDs through a coordinated, and where possible, integrated NTD control programme.

### 2.2. Guiding principles and strategic priorities

In developing this revised NTD master plan, the following guiding principles were observed.

Implementation of the programme will be guided by the following principles:

- **Inclusiveness:** Consultative process of the NTD programme unit with others relevant units, sectors and partners in agreeing on the need and the modalities for the review.
- **Transparency:** The entire process was transparent and open and everybody view was taken into consideration.
- **Community engagement**. This occurred in the field during the recent NTD mapping.
- **National ownership:** The ministry of health was on the driving and provided some logistic support for the exercise.

The focus of the National Master Plan for Neglected Tropical Diseases in Eritrea is directly informed by the situation analysis presented in Part 1. It is designed to elaborate the approach the programme will take to achieve its stipulated priorities in the next six years (2015-2020), namely:

- 1. Strengthening government ownership, advocacy, coordination and partnership
- 2. Improving planning for results, resource mobilization and financial sustainability of National NTD programmes
- 3. Scaling up access to effective NTD programme interventions and service delivery capacities
- 4. Strengthening NTD monitoring, evaluation, surveillance and operational research

 Table7: Strategic framework summary

| STRATEGIC<br>PRIORITIES   | STRATEGIC OBJECTIVES  |
|---|---|
| Strengthen<br>government<br>ownership,<br>advocacy,<br>coordination and | Undertake and enhance high level reviews of NTD program<br>performance and the use of lessons learnt to foster government<br>ownership and strengthening of advocacy, awareness and effective<br>implementation of targeted interventions.<br>Strengthen advocacy, visibility and profile of NTD prevention,<br>control, elimination and eradiaction interventions at all levels in |
| partnersnip   | Eritrea.  |
|   | Strengthen management and coordination mechanisms for the NTD control programme at, national, Zoba, Sub-Zoba and Kebabilevels in Eritrea  |
|   | Strengthen and foster partnerships for the prevention, control, elimination and eradication of targeted NTD at national, Zoba, Sub-Zoba and health station levels in Eritrea.   |
| Enhanceplanningforresults,resource                                      | Develop integrated gender-sensitive multi-year strategic plan and<br>annual operational plans for the prevention, control, elimination<br>and eradication of targeted NTDs.   |
| mobilisation and financial  | Enhance resource mobilization approaches and strategies at<br>international, national and sub-national levels for NTD   |
| sustainability of<br>National NTD                                       | Strengthen the integration/linkages of NTD programme and  |
| programmes  | Develop and update national NTD policies, guidelines and tools to support active policy and programme implementation.   |
| Scale up access to interventions,                                       | Scale up an integrated preventive chemotherapy, including access<br>to Schistosomiasis, STH, Lymphatic Filariasis, Leishmaniasis and<br>trachoma interventions  |
| system<br>capacity(service  | Strengthen case-management-based NTD interventions including integrated packages, for LF, Leprosy and Dengue fever  |
| delivery) building  | Strengthen integrated vector management for targeted NTDs<br>Strengthen capacity at national level for NTD programme<br>management and implementation and accelerate implementation of<br>disease burden assessment and integrated mapping of NTDs  |
| Enhance NTD<br>monitoring,<br>evaluation,<br>surveillence and           | Strengthen monitoring of national NTD programme performance<br>and outcome including monitoring of adverse drug reaction to<br>NTD medicines and insecticides (Pharmacovigilance)   |
| operations research   | Establish integrated data management systems and support impact<br>analysis for NTDs in Eritrea.  |
|   | and re-enforce the response to epidemic-prone NTDs in particular<br>Dengue Fever.   |

| Support operational research and documentation of evidence to |
|---|
| guide innovative approaches to NTD program interventions      |

# **2.3 NATIONAL NTD PROGRAMME GOALS, OBJECTIVES, STRATEGIES AND TARGETS**

#### Goal of NTD control

The goal of the NTDP is "to improve the health and socio-economic status of Eritreans by reducing significantly the morbidity, mortality and disability caused by the Neglected Tropical Diseases through cost-effective and integrated interventionsto control and eliminate all targeted NTDs".

#### **General Objective**

To significantly reduce the burden and subsequently eliminate the major NTDs (Schistosomiasis, Soil Transmitted Helminths, Lymphatic filariasis, Trachoma, Leprosy, Leshmaniasis, Dengue Fever Anthrax Brucelosis Rabies) in all affected sub –Zobas in Eritrea by 2020.

Table 8 provides a summary of the global and national disease-specific goals, objectives, strategies, national targets, indicators for the targeted NTDs and delivery channels.

| NTD<br>PROGRAMM | NATIONAL<br>TARGET | OBJECTIVES                                   | TARGETS                 | STRATEGIES                  | DELIVERY<br>CHANNEL | KEY<br>PERFORMANC     |
|-----------------|--------------------|--|-------------------------|-----------------------------|---------------------|-----------------------|
| E AND           | TARGET             |  |                         |                             | S                   | E INDICATORS          |
| GLOBAL          |                    |  |                         |                             |                     |                       |
| GOAL            |                    |  |                         |                             |                     |                       |
| Lymphatic       | То                 | 1. To implement                              | Global target:          | Mass drug                   | Community           | 1. ICT prevalence.    |
| Filariasis      | eliminate          | MDA in 100% of                               | Elimination of          | administration              |                     |                       |
| Elimination     | LF as a            | endemic sub zones                            | lymphatic filariasis as | with DEC and                |                     | 2. Program and        |
|                 | public             | by 2016.                                     | a public health         | Albendazole to              |                     | geographical          |
| Goal:           | health             |  | problem by 2020.        | all at risk                 |                     | coverage              |
| Elimination     | problem by         | 2. To achieve                                | Eritrean PELF           | Vector control              |                     |                       |
| as a board      | 2020.              | 100%   | targets: To reduce      | within Malaria              | Health Facility     |                       |
| public health   |                    | therapeutic                                  | the antigen prevalence  | Control                     |                     |                       |
| problem by      |                    | coverage by                                  | of LF to less than 1%   | Disability                  |                     |                       |
| 2020.           |                    | the end of                                   | among endemic           | management and              |                     |                       |
|                 |                    | 2015.  | populations and 0%      | prevention:                 |                     |                       |
|                 |                    | 3.10 reduce                                  | among children aged     | Personal hygiene            |                     |                       |
|                 |                    | morbidity and                                | below 5 years, and      | and exercises of            |                     |                       |
|                 |                    | disability due to LF $h_{\rm H} 250((2016))$ | reduce hydrocoele       | affected fimbs              |                     |                       |
|                 |                    | Dy 25%(2016)                                 | cases registered by     | alla<br>Uvdro colo stornico |                     |                       |
|                 |                    | 4. 10 interrupt                              | 80% as well as          | Hydrocelectomies            |                     |                       |
|                 |                    | hansinission of LF                           | lumphoodoma assos       |                             |                     |                       |
|                 |                    | by 2020.                                     | registered by 2016      |                             |                     |                       |
|                 |                    |  | registered by 2010.     |                             |                     |                       |
| Schistosomia    | То                 | 1. To implement                              | Global target:          | -Case                       | Health Facility     | 1. Scisto prevalence. |
| sis control     | Eliminate          | MDA in 100% of                               | • To treat 100% of      | management in               |                     | -                     |
|                 | as public          | sub zones by 2016.                           | cases in health         | health facilities           |                     | 3. Program and        |
| Goal:           | health             | 2. To achieve at                             | facilities              | -Mass Drug                  | Community           | geographical          |
| Elimination     | problem by         | least 75%                                    | • To achieve 75%        | Administration in           | -                   | coverage              |
| as public       | 2020               | therapeutic                                  | therapeutic             | the school-aged             |                     |                       |
| health          |                    | coverage during                              | coverage in             | children                    | School              |                       |
| problem by      |                    | annual MDA                                   | school age              | -Health education           |                     |                       |
| 2020            |                    | 3. To eliminate                              | children.               | and promotion of            |                     |                       |

**Table 8:** Summary of NTD disease specific goals and objectives

| NTD<br>PROGRAMM<br>E AND<br>GLOBAL<br>GOAL  | NATIONAL<br>TARGET  | OBJECTIVES  | TARGETS   | STRATEGIES   | DELIVERY<br>CHANNEL<br>S                                  | KEY<br>PERFORMANC<br>E INDICATORS   |
|---|---|---|---|--|---|---|
|   |   | infections of<br>Scistosomiasis in<br>school- age<br>children and high-<br>risk communities<br>by 2020.<br>4. To reduce the<br>prevalence of<br>schistosomiasis in<br>school- age<br>children to zero.  | <i>Eritrean targets:</i><br>Target and treat 80% of all school aged children in high risk areas.  | behavioral change<br>-Improvement in<br>water supply and<br>sanitation<br>-Vector control  |   |   |
| Soil<br>Transmitted<br>Helminths<br>Control<br>Goal:<br>To reduce<br>morbidity of<br>Soil<br>Transmitted<br>Helminths to<br>a level where<br>it is no longer<br>a public<br>health<br>problem | Elimination<br>as public<br>health<br>problem by<br>2020. | 1. To implement<br>MDA in 100% of<br>sub zones by 2016.   | <ul> <li>Global target:</li> <li>To treat 100% of cases in health facilities</li> <li>To achieve 75% therapeutic coverage in school age children.</li> <li>Eritrean targets: Target and treat 80% of all school aged children in high risk areas.</li> </ul>  | -Case<br>management in<br>health facilities<br>-Mass Drug<br>Administration in<br>the school-aged<br>children<br>-Health education<br>and promotion of<br>behavioural<br>change<br>-Improvement in<br>water supply and<br>sanitation   | Health facilities.<br>Community<br>Community<br>Community | <ol> <li>Geographical and<br/>therapeutic coverage<br/>achieved.</li> <li>Reduction in<br/>prevalence, intensity<br/>and morbidity</li> <li>Latrine coverage and<br/>use.</li> <li>Availability of safe<br/>water supply.</li> </ol>                            |
| Trachoma<br>Control<br>Goal:<br>Elimination<br>as blinding<br>disease by<br>2020.   | Elimination<br>as blinding<br>disease by<br>2020.         | 1. To reach 100%<br>of endemic<br>communities with<br>MDA by 2016.<br>2.To reduce the<br>prevalence of<br>Trichiasis trachoma<br>(TT) in affected<br>populations to less<br>than 1%.<br>3.To reduce the<br>prevalence of<br>trachoma<br>Follicular(TF) to<br>less than 10% in<br>affected<br>populations. | Global target: The<br>Global initiative is to<br>eliminate Trachoma<br>by the year 2020.<br>Eritrean trachoma<br>programme targets:<br>To reduce the<br>prevalence of active<br>trachoma to less than<br>5% among children<br>aged 1-9 years and the<br>prevalence of<br>trachomatoustrichiasis<br>to less than 1 case per<br>1000 population<br>above 15 years | Surgery of<br>trichiasis cases<br>Mass Drug<br>Administration<br>with<br>Azithromycin of<br>entire at risk<br>identified<br>communities.<br>Personal hygiene<br>reinforcing face<br>washing<br>Improved water<br>supply for<br>personal hygiene<br>Health education<br>and promotion of<br>behavioural<br>change | Health Facilities<br>Community<br>Community               | <ol> <li>Geographical and<br/>therapeutic coverage<br/>achieved.</li> <li>No. of people with<br/>TT operated</li> <li>Prevalence of TF.</li> <li>% of children with<br/>clean face.</li> <li>No. of health<br/>facilities offering TT<br/>surgeries.</li> </ol> |

| NTD<br>PROGRAMM  | NATIONAL<br>TARGET   | OBJECTIVES  | TARGETS   | STRATEGIES  | DELIVERY<br>CHANNEL                                       | KEY<br>PERFORMANC  |
|--|--|---|---|---|---|--|
| E AND  |  |   |   |   | S   | E INDICATORS   |
| GLOBAL<br>GOAL   |  |   |   |   |   |  |
| Leishmaniasi<br>s Control<br>Goal: Reduce<br>the incidence<br>of the disease<br>as soon as<br>possible,<br>strengthening<br>the network<br>of<br>surveillance. | To<br>determine<br>the burden<br>of<br>leishmanias<br>is .<br>Eventually<br>towards<br>elimination<br>program for<br>VL              | 1.Determinethe<br>distributionand<br>magnitudedistributionand<br>magnitudeof<br>leshmaniasis2.Establisheffectivediagnosis<br>and<br>treatment<br>capacitiescapacitiesfor<br>leshmaniasis3.Conduct<br>operational<br>researchoperational<br>research | Globaltarget:UltimateEliminationofLeishmaniais. (NB:EliminationprogrammhasbeenestablishedinsomecountriesforVLe.g. "VLeliminationprogrammeinprogrammeinIndia,BangladeshandNepal, 2005-2015)••To reducemorbidity andmortality due toLeishmaniasis•To reducetransmission ofleishmaniasis•To mapleishmaniasis inthe endemicregions•To prevent theemergentVL/HIV co-vIL/HIV co-infection | Early diagnosis<br>and treatment of<br>cases through<br>ACD<br>Integrated Vector<br>Control<br>Management<br>Reinforce<br>Operational<br>Research for<br>Leishmaniasis<br>Facilitate<br>combination<br>therapies after<br>WHO<br>recommendations<br>Early detection<br>VL/HIV and<br>follow-up<br>Health Education<br>and promotion for<br>community<br>awareness | Health Facility<br>Community                              | <ol> <li>No. of cases.</li> <li>HIV co infection rate.</li> </ol>  |
| Leprosy<br>Elimination<br>Goal:<br>Elimination<br>as public<br>health<br>problem by<br>2020.   | Leprosy<br>Sustain<br>Elimination<br>by 2020<br>(Achieved<br>at National<br>level, but<br>remaining<br>at sub-<br>national<br>level) | 1.To reduce the<br>prevalence of<br>leprosy in the<br>community.<br>2.To reduce the<br>disability due to<br>leprosy.  | <i>Global Target:</i><br>Reduction of the<br>prevalence to less<br>than 1 case per 10,000<br>inhabitants  | Early diagnosis<br>Adequate<br>treatment<br>(MDT)PB form:<br>6 months form:<br>12 months<br>Prevention of<br>disabilities<br>Health Education<br>(awareness<br>creation)  | Health Facility<br>Community                              | <ol> <li>No. of cases /10,000<br/>inhabitants.</li> <li>No. of leprosy cases<br/>with lesion.</li> </ol>                                     |
| Dengue<br>Fever:<br>Goal:<br>Control of<br>dengue<br>fever   | Dengue<br>fever<br>control by<br>the year<br>2020  | <ol> <li>To control the<br/>breeding sites.</li> <li>2.strengthen<br/>environmental<br/>sanitation</li> <li>3.building capacity<br/>of health workers at<br/>HFS.</li> </ol>  | To reduce morbidity<br>and mortality due to<br>dengue fever.  | <ol> <li>Attacking<br/>breeding sites of<br/>mosquitoes.</li> <li>Conducting<br/>environmental<br/>sanitation.</li> <li>Health<br/>education.</li> </ol>  | Health facility<br>Community                              | <ol> <li>No. of cases in<br/>endemic sub zones.</li> <li>Activities conducted<br/>attacking the breeding<br/>sites of mosquitoes.</li> </ol> |
| Guinea worm<br>Goal:<br>Eradication<br>by 2020   | Maintain<br>guinea<br>worm<br>disease free<br>status of the<br>country.  | <ol> <li>maintain zero<br/>transmission of<br/>gunea worm cases.</li> <li>100%<br/>containment of<br/>imported cases with<br/>in 24 hrs.</li> </ol>   | <ol> <li>Strengthening<br/>community based<br/>surveillance system in<br/>all formerly endemic<br/>and at risk sub zones.</li> <li>Capacity building<br/>for case containment<br/>for newly qualified<br/>health workers in all<br/>at risk sub zones.</li> </ol>   | 1.Conducting<br>continuous<br>surveillance<br>system in<br>suspected sub<br>zones.2. Strengthening<br>surveillance<br>monitoring and<br>evaluation.   | Health facility<br>and community<br>based<br>surveillance | <ol> <li>Rumour cases<br/>investigated within 24<br/>hrs.</li> <li>No. of imported<br/>cases.</li> </ol>                                     |

| NTD<br>PROGRAMM<br>E AND<br>GLOBAL<br>GOAL | NATIONAL<br>TARGET | OBJECTIVES | TARGETS  | STRATEGIES | DELIVERY<br>CHANNEL<br>S | KEY<br>PERFORMANC<br>E INDICATORS |
|--|--------------------|------------|--|------------|--------------------------|-----------------------------------|
|  |                    |            | <ol> <li>Advocacy and<br/>social mobilization of<br/>communities in<br/>formerly endemic<br/>villages.</li> <li>Strengthening<br/>surveillance<br/>monitoring and<br/>evaluation.</li> </ol> |            |                          |                                   |

### **2.4 National Milestones**

# LF ELIMINATION MILESTONES, 2015-2020

| Indicators  | 2015            | 2016        | 2017          | 2018          | 2019           | 2020          |
|---|-----------------|-------------|---------------|---------------|----------------|---------------|
| Completed mapping of LF and determined LF endemic areas and the population at risk  | 39/39<br>(100%) |             |               |               |                |               |
| Begun implementation of LF MDA in subzones requiring LF MDA   | 2/2 (100%)      |             |               |               |                |               |
| Achieving100% geographical coverage in LF endemic subzones  | 2/2 (100%)      | 2<br>(100%) | 2<br>(100%)   | 2 (100%)      | 2<br>(100%)    |               |
| Major urban areas with evidence of LF<br>transmission under adequate MDA<br>(Regional/State coverage more than 65%)   | NA              | NA          |               |               |                |               |
| Conducted more than 5 rounds of MDA in all<br>endemic IUs with regional/State coverage more<br>than 65% and stopped MDA in at least 50% of LF<br>endemic IUs under WHO criteria |                 |             |               |               | 2/2<br>(100%)  | 2/2<br>(100%) |
| Conducted first TAS activities in at least 50% of LF endemic IUs after at least 5 rounds of MDA   |                 |             |               |               | 2 /2<br>(100%) |               |
| Conducted and Passed at least 2 TAS activities in 75% of IUs  |                 |             |               |               | 2 /2<br>(100%) |               |
| Started passive surveillance and vector control activities in at least 75% of IUs.  |                 |             | 2/2<br>(100%) | 2/2<br>(100%) | 2/2<br>(100%)  | 2/2<br>(100%) |
| Present "the dossier " for in-country verification of absence of LF transmission  |                 |             |               |               | 2/2<br>(100%)  |               |
| Proportion and number of IUs where there is full coverage of morbidity- management services and access to basic care  |                 |             |               | 2/2<br>(100%) | 2/2<br>(100%)  | 2/2<br>(100%) |
| Proportion and number of IUs where 75% of hydrocele cases benefitted from appropriate surgery   |                 |             |               | 2/2<br>(100%) | 2/2<br>(100%)  | 2/2<br>(100%) |

# SCH ELIMINATION MILESTONES, 2015-2020

| Indicators  | 2015            | 2016            | 2017            | 2018            | 2019            | 2020            |
|---|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Completed mapping of SCH and determined areas above intervention threshold and the Endemic population                                       | 58(100%)        |                 |                 |                 |                 |                 |
| Begun implementation of school-<br>based/community-based treatments in<br>Endemic subzones  | 28/28<br>(100%) |                 |                 |                 |                 |                 |
| Achieving100% geographical coverage in SCH Endemic subzones   |                 | 28/28<br>(100%) |                 |                 |                 |                 |
| Conducted 3-5 years of consecutive treatments<br>in all Endemic subzones with zonal/national<br>coverage more than 75%                      |                 |                 |                 | 28(100%)        |                 |                 |
| Conducted first impact assessment activities in<br>at least 50% of SCH Endemic subzones after<br>at least 3 years of consecutive treatments |                 |                 | 28/28<br>(100%) |                 | 28/28<br>(100%) |                 |
| Endemic subzones achieving moderate morbidity control   | 21/28<br>(75%)  | 28/28<br>(100%) | 28/28<br>(100%) | 28/28<br>(100%) | 28/28<br>(100%) |                 |
| Endemic subzones achieving advanced morbidity control   |                 |                 | 28/28<br>(100%) | 28/28<br>(100%) | 28/28<br>(100%) |                 |
| Endemic subzones achieving elimination of transmission  |                 |                 |                 |                 | 28/28<br>(100%) | 28/28<br>(100%) |

# **STH ELIMINATION MILESTONES, 2015-2020**

| Indicators  | 2015            | 2016          | 2017          | 2018           | 2019           | 2020 |
|---|-----------------|---------------|---------------|----------------|----------------|------|
| Completed mapping of STH and determined areas above intervention threshold and the Endemic population                                 | 58<br>(100%)    |               |               |                |                |      |
| Begun implementation of school-based/community-<br>based treatments in Endemic subzones   | 0/0<br>(100%)   |               |               |                |                |      |
| Achieving100% geographical coverage in STH<br>Endemic subzones  | 21/21<br>(100%) |               |               |                |                |      |
| Conducted 3-5 years of consecutive treatments in all<br>Endemic subzones with regional/State coverage more<br>than 75%                |                 |               | 0/0<br>(100%) | 0 /0<br>(100%) |                |      |
| Conducted first impact assessment activities in at least 50% of STH Endemic subzones after at least 3 years of consecutive treatments |                 |               | 0/0<br>(100%) | 0 /0<br>(100%) |                |      |
| Endemic subzones achieving moderate morbidity control   |                 | 0/0<br>(100%) | 0/0<br>(100%) | 0 /0<br>(100%) | 0 /0<br>(100%) |      |

| Endemic | subzones | achieving | advanced | morbidity | 58 /58 | 58/58  | 58 /58 | 58 /58 |  |
|---------|----------|-----------|----------|-----------|--------|--------|--------|--------|--|
| control |          |           |          |           | (100%) | (100%) | (100%) | (100%) |  |

## TRACHOMA ELIMINATION MILESTONES, 2015-2020

| Indicators   | 2015           | 2016          | 2017          | 2018          | 2019          | 2020 |
|--|----------------|---------------|---------------|---------------|---------------|------|
| Completed mapping of trachoma and determined areas above intervention threshold and the target population                      | 58<br>(100%)   |               |               |               |               |      |
| Begun implementation of community-based treatments in target subzones  | 8/8<br>(100%)  |               |               |               |               |      |
| Achieved 100% geographical coverage in trachoma target subzones  | 8/8<br>(100%)  |               |               |               |               |      |
| Conducted 3-5 rounds of treatments in all target subzones with regional/State coverage more than 75%                           | 8/8<br>(100%)  |               |               |               |               |      |
| Conducted first impact assessment activities in at least 50% of trachoma target subzones after at least 3 rounds of treatments | 8/8<br>(87.5%) |               |               |               |               |      |
| Started passive surveillance in at least 75% of IUs.   |                | 6/8 (75%)     | 8/8<br>(100%) | 8/8<br>(100%) | 8/8<br>(100%) |      |
| Proportion and number of target subzones where there is full coverage of case-management services                              | 8/8<br>(100%)  | 8/8<br>(100%) |               |               |               |      |
| Target subzones achieved elimination of blinding trachoma  | 6/8<br>(75%)   |               |               | 8/8<br>(100%) |               |      |

# IDM CONTROL/ELIMINATION MILESTONES, 2015-2020

| Indicators   | 2015        | 2016        | 2017 | 2018 | 2019 | 2020 |
|--|-------------|-------------|------|------|------|------|
| Active Case detection in 100% of Highly endemic subzones | 8<br>(100%) | 8<br>(100%) |      |      |      |      |

| Passive case detection in 100% of other endemic subzones   | 8<br>(100%)  | 8<br>(100%)  |              |              |              |           |
|--|--------------|--------------|--------------|--------------|--------------|-----------|
| Manage all patients in peripheral health facilities  | 8<br>(100%)  | 8<br>(100%)  | 8<br>(100%)  |              |              |           |
| Refer severe and complicated cases for management at subzone hospitals and reference centres                               | 8<br>(100%)  | 8<br>(100%)  | 8<br>(100%)  |              |              |           |
| Achieved 100% geographical coverage of SAFE in trachoma target subzones  | 3<br>(37.5%) | 5<br>(62.5%) | 8<br>(100%)  | 8<br>(100%)  |              |           |
| Achieved 100% treatment coverage of identified leprosy cases   | 22<br>(100%) | 22<br>(100%) | 22<br>(100%) | 22<br>(100%) |              |           |
| Achieved 100% treatment coverage of identified cases for other CM-NTDs(Rabies, Leishmaniasis)                              | 5 (12%)      | 15<br>(37%)  | 30<br>(73%)  | 41<br>(100%) | 41<br>(100%) |           |
| Started passive surveillance in at least 50% of target subzones for CM-NTDs targeted for elimination (Leprosy)             | 5 (%)        | 10 (%)       | 15 (%)       | 22 (%)       | 22 (%)       |           |
| Started sentinel site surveillance in at least<br>50% of target subzones for CM-NTDs<br>targeted for elimination (Leprosy) | 5 (23%)      | 11<br>(50%)  | 15<br>(68%)  | 22<br>(100%) | 22<br>(100%) | 22 (100%) |
| Target subzones that sustained elimination of leprosy  | 0 (%)        | 5 (23%)      | 11<br>(50%)  | 15(68%)      | 22(100%)     | 22(100%)  |

## PHASE MILESTONES, 2017-2022

|   | Indicators  | 2017     | 2018        | 2019     | 2020     | 2021         | 2022         |
|---|---|----------|-------------|----------|----------|--------------|--------------|
| 1 | Proportion and number of Endemic<br>subzones with adequate* access to clean<br>water for SCH control                        | 10 (33%) | 15<br>(50%) | 20 (67%) | 25 (83%) | 30<br>(100%) | 30<br>(100%) |
| 2 | Proportion and number of Endemic subzones with adequate** sanitation manipulation for SCH control                           | 5 (17%)  | 10<br>(33%) | 15 (50%) | 20(67%)  | 25(83%)      | 30<br>(100%) |
| 3 | Proportion and number of Endemic subzones with adequate*** environmental manipulation for SCH control                       | 0 (%)    | 2 (7%)      | 5(17%)   | 10(33%)  | 15(50%)      | 20(67%)      |
| 4 | Proportion and number of Endemic<br>subzones with adequate access to clean<br>water and health education for STH<br>control | 10 (33%) | 15<br>(50%) | 20 (67%) | 25 (83%) | 30<br>(100%) | 30<br>(100%) |

| 5 | Proportion and number of Endemic subzones with adequate** sanitation for STH control                  | 5 (17%) | 10<br>(33%) | 15 (50%) | 20(67%) | 25(83%) | 30<br>(100%) |
|---|---|---------|-------------|----------|---------|---------|--------------|
| 6 | Proportion and number of Endemic subzones with adequate*** environmental manipulation for STH control | 0 (%)   | 2 (7%)      | 5(17%)   | 10(33%) | 15(50%) | 20(67%)      |

### PART 3: OPERATIONAL FRAMEWORK

This section of the Master Plan was developed in consultation with stakeholders to ensure harmonized and effective NTD program implementation. This section describes how the planned activities will be implemented using the available resources taking into account the potential risks in order to sustain and secure the achievements made.

# **3.1 Scaling up access to NTD Interventions, treatment and service delivery capacity**

With initiative of the Ministry of health, findings from studies that were conducted and based on the current WHO recommendations and guidelines; a detailed description of the activities for scaling up the NTD Program was developed. The three main packages of interventions addressed were:

- Preventive chemotherapy
- Case management/chronic case
- Integrated vector management and other "PHASE"\* interventions for the targeted NTDs.

### **3.1.1 Scaling up preventive chemotherapy interventions**

The most common NTDs that need Mass Drug Administration (MDA) are, Lymphatic Filariasis, Trachoma, STH and Schistosomiasis. The plan is to use Community and school based campaigns to address the sub zones that are mapped and found to be positive for these diseases. The type of MDAs to be implemented is detailed in table 9 and also in annexes 2.3 and 2.4. In addition to implementing the proposed MDAs and scaling up the interventions various activities such as training, sensitization, supervision and drug administration will be conducted (Table 10).

| Cross-cutting<br>MDA types | Delivery<br>channels | Timing of treatments | Disease<br>combination | Requirements | Target<br>(Sub<br>zobas) -<br>list | Other<br>mass<br>disease<br>control<br>interventi |
|----------------------------|----------------------|----------------------|------------------------|--------------|------------------------------------|---|
|                            |                      |                      |                        |              |                                    | ons   |

| Table 9 | : Types | of mass | drug | administratio | n |
|---------|---------|---------|------|---------------|---|
|         |         |         |      |               |   |

| Cross-cutting      | Delivery  | Timing of          | Disease      | Requirements                   | Target           | Other               |
|--------------------|-----------|--------------------|--------------|--------------------------------|------------------|---------------------|
| MDA types          | channels  | treatments         | combination  | 1                              | (Sub             | mass                |
| 51                 |           |                    |              |                                | zobas) -         | disease             |
|                    |           |                    |              |                                | list             | control             |
|                    |           |                    |              |                                | not              | interventi          |
|                    |           |                    |              |                                |                  | ons                 |
| MDA2 (One          |           | A novelly          | Izmphotio    | - Training of                  | Forto            | Vitomin A           |
| MDA2 (One          | • Communi | Annually           | filoriogia   | • Training Of                  | FUILU<br>Arreate | vitainin A          |
| DEC and            | ty-based  |                    | 111a11a515,  | Trainers                       | Alaala           | Campaigns           |
| DEC allu           | campaign  |                    |              | • Training of                  |                  | 111N<br>diataibatia |
| albendazole)       | S         |                    |              | health                         |                  | distributio         |
|                    | • School  |                    |              | personnel                      |                  | n                   |
|                    | based     |                    |              | • Training of                  |                  |                     |
|                    | campaign  |                    | ~            | community                      |                  |                     |
| T1(One annual      |           | Annually           | Schistosomia | volunteers                     | AdiTekele        |                     |
| round of           |           |                    | sis/STH      | • Training of                  | zan              |                     |
| prizaquintel +     |           |                    |              | teachers                       | Halhal           |                     |
| Albendazole)       |           |                    |              | Social                         | Hagaz            |                     |
|                    |           |                    |              | mobilization                   | Habero           |                     |
|                    |           |                    |              | of local                       | Hamelmal         |                     |
|                    |           |                    |              | administrato                   | 0                |                     |
|                    |           |                    |              | rs and                         | Keren            |                     |
|                    |           |                    |              | village                        | Kerkebet         |                     |
|                    |           |                    |              | elders;                        | Selaa            |                     |
|                    |           |                    |              | Mass media                     | AdiQuala         |                     |
|                    |           |                    |              | Supervision                    | AdiKeih          |                     |
|                    |           |                    |              | <ul> <li>Production</li> </ul> | Areza            |                     |
|                    |           |                    |              | • I founction                  | Debarwa          |                     |
|                    |           |                    |              | • Logistics for                | Dekemhare        |                     |
|                    |           |                    |              | Logistics for                  | Imnihaili        |                     |
|                    |           |                    |              | drug                           | Mai Aini         |                     |
|                    |           |                    |              | distribution                   | Mai mine         |                     |
|                    |           |                    |              | and                            | Mendefera        |                     |
|                    |           |                    |              | management                     | Segeneity        |                     |
|                    |           |                    |              |                                | Senafe           |                     |
|                    |           |                    |              |                                | Tsorona          |                     |
|                    |           |                    |              |                                | Berik            |                     |
|                    |           |                    |              |                                | Debubawi         |                     |
|                    |           |                    |              |                                | Mibrak           |                     |
|                    |           |                    |              |                                | Gala Nefhi       |                     |
|                    |           |                    |              |                                | Serejeka         |                     |
| MDA4 (One          | Community | Annually           | Trachoma     | • Training of                  | Debaruwa         |                     |
| annual round of    | hased     | <sup>1</sup> muuny | inchoma      | Trainers                       | Areza            |                     |
| with azithromycin  | Jubou     |                    |              | Training of                    | Mai Mine         |                     |
| + Tetracycline eve |           |                    |              | • Italining Of                 |                  |                     |
| ointment for under |           |                    |              | nealth                         |                  |                     |
| 2 children)        |           |                    |              | personnel;                     |                  |                     |
|                    |           |                    |              | • Training of                  |                  |                     |

| Cross-cutting<br>MDA types | Delivery<br>channels | Timing of<br>treatments | Disease<br>combination | Requirements  | Target<br>(Sub<br>zobas) -<br>list | Other<br>mass<br>disease<br>control<br>interventi<br>ons |
|----------------------------|----------------------|-------------------------|------------------------|---|------------------------------------|--|
|                            |                      |                         |                        | <ul> <li>community<br/>volunteers</li> <li>Social<br/>mobilization<br/>of local<br/>administrato<br/>rs and<br/>village<br/>elders;</li> <li>Mass media</li> <li>Supervision</li> </ul> |                                    |  |

MDA4 = Azithromycin and TTC eye ointment for under 2 children

T1= Praziquantil + AlbendazoleT2 = Praziquantel onlyT3 = Albendazole or mebendazole onlyMDA2 = DEC + Albendazole

| Cross-cutting<br>interventions  | NTDs targeted   | Requirements  | Other non-NTD<br>opportunities for<br>integration  |
|---|---|---|--|
| Hydrocele surgery<br>(hydrocelectomies)<br>Trichiasis surgery   | Lymphatic filariasis<br>hydrocele,<br>Trachomatous Trichiasis<br>(TT) | <ul> <li>Training of Medical Doctors and nurses</li> <li>Hospitals facilities or appropriate basic facilities with good surgical facilities</li> <li>Follow up/supervision</li> </ul> | Capacity building<br>for basic surgery at<br>the sub zoba level                                |
| -Daily hygienic<br>washing of affected<br>limbs.<br>-Exercise of<br>affected limbs<br>-Application of | Elephantiasis/lymphedema<br>Leprosy disability                        | <ul> <li>Washing kits (bucket, towel, soap, clean water, autoclave machines at local health facilities )</li> <li>Procuring prosthesis for disability due to leprosy</li> </ul>       | HIV/AIDS social<br>support groups.<br>Diabetes support<br>groups<br>Malaria home<br>management |

| antibiotic creams to |              |                | • | Antibiotics/Vaseline creams        | Community TB      |
|----------------------|--------------|----------------|---|------------------------------------|-------------------|
| affected limbs       |              |                | • | Training of first-line             | DOTs              |
| - skin care          |              |                |   | health/community workers,          |                   |
|                      |              |                |   | patients and family members        |                   |
|                      |              |                | • | Social support clubs/groups        |                   |
|                      |              |                | • | Follow up/ Supervision             |                   |
| Hospitalized         | Leprosy,     | Leishmaniasis, | • | Specific drugs (tablets and        | Malaria home case |
| treatment            | Rabies,      | Anthrax,       |   | injectable)                        | management        |
| (Leishmaniasis)      | Brucellosis, | Dengue fever,  | • | Hospitalization facilities         | Community TB      |
| Self-administering   | Hydrocele    |                | • | Close monitoring during            | DOTs              |
| MDT treatment        |              |                |   | treatment (in case of              | Women's           |
| (leprosy)            |              |                |   | Leishmaniasis)                     | associations (CL  |
|                      |              |                | • | Training of medical staff          | and MCL)          |
|                      |              |                | • | Follow up/ supervision             |                   |
|                      |              |                | • | Patient support (financial e.g.    |                   |
|                      |              |                |   | transportation to health facility) |                   |
|                      |              |                | • | Nutritional support                |                   |

| Strategic Objective 3.1.1: Scale up an integrated preventive chemotherapy, including access to     |                                    |                                |                                       |  |  |  |  |
|--|------------------------------------|--------------------------------|---------------------------------------|--|--|--|--|
| Lymphatic filariasis, STH, Schistosomiasis and trachoma interventions and reach elimination of the |                                    |                                |                                       |  |  |  |  |
| mentioned diseases by 2020   |                                    |                                |                                       |  |  |  |  |
| Activity   | Details (Sub-activities)           | Time                           | Resources needed                      |  |  |  |  |
|  |                                    | frame                          |                                       |  |  |  |  |
| 1.Training   | I Training at national level for   | 2015-2020                      | Personnel, meals, stationery, hall    |  |  |  |  |
|  | zoba focal persons                 |                                | hire, transport, per-diems            |  |  |  |  |
|  | ii. Training at Zoba level for     | 2015-2020                      | stationery, transport                 |  |  |  |  |
|  | the sub zoba                       |                                |                                       |  |  |  |  |
|  | iii. Training at sub-Zoba level    | 2015-2020                      |                                       |  |  |  |  |
|  | for health facilities              |                                |                                       |  |  |  |  |
|  | iv. Training of Teachers and       | 2015-2020                      |                                       |  |  |  |  |
|  | Supervisors/sub-Zoba health        |                                |                                       |  |  |  |  |
|  | staff (sub-Zoba level)             |                                |                                       |  |  |  |  |
|  | v. Training of community           | 2015-2020                      |                                       |  |  |  |  |
|  | health agents(CHA)                 |                                |                                       |  |  |  |  |
| 2.Community  | i. Sensitization of Zoba           | 2015-2020                      | Personnel, Perdiem, hall hire, meals, |  |  |  |  |
| Sensitization and  | leaders                            | ers stationery, transportation |                                       |  |  |  |  |
| mobilization   | ii. Community Sensitization        | 2015-2020                      | materials                             |  |  |  |  |
|  | iii. Health Education and          | 2015-2020                      |                                       |  |  |  |  |
|  | Mobilization                       |                                |                                       |  |  |  |  |
| 3.Distribution of  | i. Registration of Pupils and      | 2015-2020                      | Transport reimbursement,              |  |  |  |  |
| medicines  | Communities                        |                                | communication, registers,             |  |  |  |  |
|  | ii. Supervision of registration    |                                | stationery, allowances                |  |  |  |  |
|  | of pupils and communities          |                                |                                       |  |  |  |  |
|  | iii. Medicines delivery from       | 2015-2020                      | Personnel                             |  |  |  |  |
|  | the National pharmacy store to     |                                |                                       |  |  |  |  |
|  | Zoba                               |                                |                                       |  |  |  |  |
|  | iv. Distribution of medicines to   | 2015-2020                      | Personnel                             |  |  |  |  |
|  | sub-Zoba and to health             |                                |                                       |  |  |  |  |
|  | Stations or Clinics                |                                |                                       |  |  |  |  |
|  | v. Medicines Delivery (to          | 2015-2020                      | transportation, personnel and         |  |  |  |  |
|  | schools and communities)           | 2015 2020                      | allowances                            |  |  |  |  |
|  | vi. Supervision from National      | 2015-2020                      | Personnel, supervisors, IEC           |  |  |  |  |
|  | v11. From zobal level              |                                | materials, dose poles and treatment   |  |  |  |  |
|  |                                    | 0015 0000                      | charts                                |  |  |  |  |
|  | viii. Feedback meetings after      | 2015-2020                      | Perdiem, hall hire, meals,            |  |  |  |  |
|  | some interventions                 | 2015 2022                      | participants, transport               |  |  |  |  |
|  | x. Annual Review at national level | 2015-2020                      | reimbursement.                        |  |  |  |  |

### 3.1.2 Scaling up NTD Case management Interventions

The NTDs that require case management include LF, Trachoma, Leprosy, Leishmaniasis, Rabies, Dengue and Anthrax. The detailed activities that are proposed for scale-up of detection and management of these diseases are described in table 11.1 and annex 2.2.

| Strategic Objective3.1. 2: Eradicate LF and elim | inate trachoma, leprosy,  | rabies, anthr | ax and dengue by |
|--|---------------------------|---------------|------------------|
| 2020 by scaling up case management intervention  |                           | <b>T</b> .    | D                |
| Activity   | Sub-Activities            | Time          | Resources        |
|  |                           | Frame         | needed           |
| 1. Training of Trainers (TOTs)                   | i. National ToT           | 2015,         | Training         |
|  |                           | 2017,         | modules,         |
|  |                           | 2019          | allowances,      |
|  | ii. Zoba ToT              | 2015,         | LCD Projector    |
|  |                           | 2017,         | and stationery   |
|  |                           | 2019          |                  |
| 2. Training of HWs at sub-zoba level in case     | i. Training of clinicians | 2017-         | Allowances,      |
| management                                       | on TT surgery             | 2020          | Hall hire,       |
|  |                           |               | stationary,      |
|  |                           |               | access to local  |
|  |                           |               | hospital         |
|  |                           |               | operating rooms  |
|  | iii. Special training on  | 2017 –        | Allowances,      |
|  | lymphoedema               | 2020          | Hall hire,       |
|  | management                |               | Stationary       |
| 3. Training of Community Health Workers          | i. Develop training       | 2017          | Allowances,      |
| (CHWs) in case management NTDs                   | guide on CM-NTDs          |               | Hall hire,       |
|  |                           |               | stationery       |
|  | ii. Train CHWs on         | 2017-         |                  |
|  | detection and             | 2020          | Allowances,      |
|  | morbidity management      |               | Hall hire,       |
|  | of CM-NTDs and            |               | stationery.      |
|  | referrals                 |               | Transportation   |
| 4.Surgery for Trichiasis (Surgical camps)        | TT surgical camps in 7    | 2017-         |                  |
|  | sub-Zobas                 | 2020          |                  |
|  | Supportive                | 2017-         | Allowances,      |
|  | supervision by the        | 2020          | transportation,  |
|  | center during surgical    |               | and disposable   |
|  | camps                     |               | supplies         |
| 5.Lymphoedema management                         | Lymphoedema               | 2017-         | Allowances       |
|  | management in 2 sub-      | 2020          | transportation   |
|  |                           |               | and disposable   |

### Table 11.1: Activities for case management interventions

|  | Zobas                   |       | supplies         |
|--|-------------------------|-------|------------------|
|  |                         |       |                  |
|  |                         |       |                  |
| 6. Equip laboratories for Case detection | i. Training of          | 2017- | Kits for         |
|  | Laboratory staff in all | 2020  | leishmaniasis,   |
|  | sub-Zobas               |       | RDT for          |
|  | ii Propura lab          |       | dengue, test kit |
|  | equipment               |       | Microscopes      |
|  | and                     |       | haematocrit      |
|  | reagents                |       | centrifuges,     |
|  |                         |       | generators, lab  |
|  |                         |       | reagents         |
|  |                         |       | allowances,      |
| 7 Provision of drygg                     | : Dro ouromont          | 2017  | transportation   |
| 7. Provision of drugs                    | I. Procurement,         | 2017- | procurement of   |
|  | of drugs                | 2020  | IDM Drugs        |
| 8.Support supervision                    | i. Develop a support    | 2017- |                  |
|  | supervision             | 2020  |                  |
|  | tool/checklist          |       |                  |
|  | ii Conduct              |       |                  |
|  | II. Conduct             |       | Personnel,       |
|  | supervision             |       |                  |
|  | quarterly               |       |                  |
|  | 1 7                     |       |                  |
|  |                         |       | Allowance,       |
|  |                         | 2017  | transportation   |
| 9.Mapping                                | 1. Mapping of           | 2017  |                  |
|  | zobas                   |       |                  |
|  | ii. Active case finding | 2017- | -                |
|  | of Leprosy              | 2020  | Allowances ,     |
|  | Active case finding of  | 2017- | transportation,  |
|  | leishmaniasis           | 2020  | field and        |
|  | LF transmission         | 2017- | laboratory       |
|  | assessment survey       | 2020  | sundries         |

### **3.2 Scaling up NTD transmission control interventions**

In order to control and eliminate the NTDs, an integrated approach to vector control and other PHASE activities which are crosscutting, will be implemented in all the sub-Zobas. The Ministry has scaled up LLINs and IRS in malaria endemic Zobas. In addition to this, the MoH will intensify the implementation of the SAFE strategy for the control of

Trachoma. Already some villages across the country have achieved the outdoor defecation-free status. These cross cutting interventions are detailed in table 12 and in annexes 2.6 and 2.7, while the key activities that will be carried out to implement the transmission control packages are as shown in table 13.

| Cross-cutting interventions   | NTDs targeted   | Requirements   | Othernon-NTDopportunitiesforintegration   |
|---|---|--|---|
| <ul> <li>Mosquito and sand fly control using:</li> <li>insecticide treated nets (ITN)</li> <li>In-door residual spraying (IRS)</li> <li>Environmental management</li> <li>Biological control</li> <li>Health Education</li> </ul> | Lymphatic<br>filariasis<br>Leishmaniasis<br>Dengue            | <ul> <li>ITNs, and insecticide treated materials (ITM)</li> <li>Insecticide chemicals</li> <li>Larviciding chemicals</li> <li>Plastered walls, others</li> </ul> | Malaria vector control  |
| <ul> <li>Improved access and quality<br/>of water supply.</li> <li>Improved sanitations<br/>facilities</li> <li>Environmental management</li> <li>Health Education</li> <li>Personal Hygiene</li> </ul>                           | Schistosomiasis<br>Soil transmitted<br>helminthes<br>Trachoma | -Sinking bore-holes<br>-Building latrines<br>-Health Education<br>& Promotion.   | -Developmental<br>programmes (e.g. water<br>& sanitation)<br>-School health and<br>Nutrition programmes<br><u>Community Led Total</u><br><u>Sanitation (CLTS)</u><br>Environmental health |

Table 12: Intervention packages for Transmission control

 Table 13: Activities for disease transmission control

Strategic objective 3: Strengthening integrated vector management and other "PHASE"\* interventions for the targeted NTDs.

| joi inc iai geica i i i | of the talgeted 111D5.  |           |   |  |  |  |  |  |
|-------------------------|---|-----------|---|--|--|--|--|--|
| Activity                | Details (Sub-activities)  | Timeframe | <b>Resources needed</b>   |  |  |  |  |  |
| 1. Developing<br>tools  | i. Finalize the integrated vector management policy                           | 2017      | Stationary, allowances,<br>hall hire, transportation,<br>technical assistance |  |  |  |  |  |
|                         | ii. Develop guidelines for<br>integrated vector<br>management                 | 2017      | Stationary, allowances, hall hire, transportation                             |  |  |  |  |  |
|                         | iii. Development of training<br>modules and IEC<br>Materials (including radio | 2017      |   |  |  |  |  |  |

|                           | and TV spots)  |                             |   |
|---------------------------|--|-----------------------------|---|
| 2. Training               | i. Training of National trainers                                     | 2015, 2017,<br>2019<br>2020 | Training modules,<br>allowances, hall hire<br>stationary,                         |
|                           | ii. Training of Zoba and Sub-<br>Zoba level trainers                 | 2015, 2017,<br>2019, 2020   |   |
|                           | iii. Training of Spray<br>operators and WASH<br>persons              | 2017 – 2020                 |   |
|                           | iv. Training on entomology   | 2017- 2020                  | Training modules,<br>allowances, hall hire<br>stationary, technical<br>assistance |
| 3.Procurement of supplies | i. Procure integrated vector<br>management supplies and<br>equipment | 2017 – 2020                 | Spray pumps,<br>insecticides/larvicides,<br>personal protective gear              |
| 4.Community               | Conduct Zoba and Sub-Zoba  | 2017 - 2020                 | Personnel, Perdiem, hall  |
| integrated vector         | ii. Zoba and Sub-Zoba IRS  | 2017-2020                   | transportation, IEC   |
| management                | Advocacy meetings<br>iii. Sub-Zoba leaders'                          | 2017 - 2020                 | materials   |
|                           | sensitization meeting  | 2017 2020                   |   |
|                           | sensitization meetings   | 2017-2020                   |   |
|                           | v. Media sensitization and advocacy                                  | 2017 - 2020                 |   |
|                           | Vi. Develop and air radio and television NTD messages                | 2017-2020                   | Air time,   |
|                           | vii. Community mobilization for<br>IVM                               | 2017-2020                   | Transportation,<br>allowances, stationery,<br>hall hire                           |
| 5.                        | i. Conduct Sub-Zoba needs assessment for IRS                         | 2017 -2019                  | Transportation, allowances,   |
| Conduct<br>Operational    | ii. Micro planning and TOT workshop on IVM                           | 2017 - 2020                 | communication<br>,equipment   |
| Researches                | iii. Baseline entomological studies                                  | 2017                        |   |
|                           | iv. Baseline epidemiological studies                                 | 2017                        |   |
|                           | v. Chemical exposure assessment of spray operators                   | 2017 - 2020                 |   |
|                           | vii. Post-IRS entomological studies                                  | 2018 - 2020                 |   |
|                           | viii. Post-IRS epidemiological studies                               | 2018 - 2020                 |   |

| 6. Other PHASE interventions   | Conduct source reduction (filling<br>and destroying breeding sites)<br>Larviciding of breeding sites<br>Training on house hold<br>community water treatment using<br>sedimentation, filtration, etc<br>Health education on vector<br>behavior, sanitation and<br>environmental management | 2017 - 2020<br>2017 - 2020<br>2017 - 2020<br>2017 - 2020 | Transportation,<br>allowances ,equipment<br>and supplies,<br>communication    |
|--|---|--|---|
|  | Support construction of pit latrines  | 2017-2020  | Collaboration with<br>environmental health<br>division                        |
| 7. Monitor and<br>evaluate impact of<br>on-going IRS<br>PHASE activities | i. Monitor quality of IRS<br>using bio-assay tests  | 2017 - 2020  | Monitoring tools,<br>transportation,<br>allowances, equipment<br>and supplies |
|  | ii. Entomological evaluation studies  | 2019   | Evaluation tools,<br>transportation,<br>allowances.                           |
|  | iii. Epidemiological<br>evaluation studies  | 2019   | equipment and supplies  |
|  | iv. Latrine utilization surveys   | 2017   | Survey tools,<br>transportation,<br>allowances, equipment<br>and supplies     |
|  | v. KAP surveys on hygiene<br>and sanitation   | 2017   | Survey tools,<br>transportation,<br>allowances, equipment<br>and supplies     |
|  | vi Conduct dissemination work shops   | 2019-2020  | Stationery, allowances,<br>transportation, airtime                            |

• PHASE: Preventive chemotherapy, Health education, Access to safe drinking water, Sanitation and hygiene, and Environmental improvements

#### **3.3Pharcovigilance in NTD control activities**

This section provides information and details on preparedness of the national pharmacovigilance system and NTD programme management to ensure satisfactory reporting and management of adverse side effects/ events that may be linked to NTD interventions under the programme setting. Activities for strengthening relationship of NTDs with pharmacovigilance are listed in table 14.

| Table | 14: | Activities | for strengt | thening | pharmaco-vi | gilance in | NTD | programme. |
|-------|-----|------------|-------------|---------|-------------|------------|-----|------------|
|       |     |            | 0           | 0       |             | 0          |     |            |

| - 14 |                      |           |               | -          | -          |                       |            |
|------|----------------------|-----------|---------------|------------|------------|-----------------------|------------|
|      | Strategic Objective3 | .3.1 : To | strengthen th | e existing | functional | Pharmacovigilance(PV) | to include |
|      | NTD programme        |           |               |            |            |                       |            |
|      |                      |           |               |            |            |                       | -          |

| nib programme   |  |   |  |
|---|--|---|--|
| Activity  | Details (Sub-activities)   | Timeframe                                 | Resources needed   |
| Equip the National<br>Pharmacovigilance<br>Centre with<br>training materials<br>and the required<br>reporting tools | Support Pharmacovigilance<br>unit to Re-print and distribute<br>training materials, adverse<br>drug reaction (ADR)<br>reporting forms.   | 2017 - 2020                               | Consensusbuildingworkshop expenses, Printingcosts,workshop(Stationeries, venues, DSAandRefreshment,transportationcosts,communicationcosts)anddissemination                               |
| Sensitization<br>programme on the<br>role of<br>pharmacovigilance<br>in NTD Control                                 | Train all health professionals<br>on Pharmacovigilance<br>principles in the NTD<br>programme.  | 2017-2020                                 | Transportation, hotel<br>accommodations, DSA,<br>venues, refreshment, meals<br>and stationary materials.   |
| Monitoring and<br>Evaluation of the<br>Pharmacovigilance<br>system  | Annual National workshop<br>for the PV review  | 2017 – 2020                               | Accommodation,<br>transportation, allowance for<br>the monitoring group (4)<br>Accommodation,<br>transportation, allowance,<br>and stationary materials for<br>the workshop participants |
| Attend<br>international<br>meetings, trainings<br>and conferences   | Attend regional and<br>international meetings,<br>trainings and conferences<br>related to pharmacovigilance<br>activities in NTD Control | 2017 – 2020                               | Accommodation, airfare and DSA for participants  |
| Conduct Study<br>Tour   | Study tour of the PV and<br>NTD staff to experienced<br>countries  | 2017 or 2018                              | Accommodation, airfare and DSA for participants  |
| Workshop for<br>integrated work<br>plan   | Annual National workshop<br>for integrated work plan<br>between Pharmacovigilance<br>Unit and National NTD<br>programme                  | 2017 – 2020                               | Accommodation,<br>transportation, DSA, Venues<br>and stationary materials for<br>the workshop participants   |
| Quality Assurance<br>(QA) of Medicines<br>used for MDA in<br>WHO prequalified<br>Laboratories                       | Send samples of the<br>medicines used for MDA in<br>NTD Control to WHO<br>accredited laboratory for<br>quality test                      | Periodically<br>(once every two<br>years) | Quality test fee &<br>Transportation fee (DHL)   |
| Conduct   | Conduct Cohort Event   | 2017, 2019                                | Develop pre and post   |

| operational<br>research on patient<br>safety                | Monitoring of current<br>interment medicines during<br>MDA |      | questionnaires<br>Recruit 10% of the<br>population involved in<br>MDA<br>Follow patients with<br>telephone call and in<br>person<br>Data management and<br>dissemination |
|---|--|------|--|
| Develop Risk<br>Management and<br>Risk minimization<br>plan | Draft risk minimization plan during MDA                    | 2017 | No Resource needed   |

# **3.4** Strengthening Capacity at National Level for NTD programme management and implementation

This section focuses on activities that will be implemented and the resources required to strengthen the management and operational capacities of the NTD programme staff at various levels. This is required to scale up and achieve elimination goals. The details are as presented in table 15. Table 16 shows the scaling up/down of IDM and PCT NTDS.

 Table 15: Activities and resources needed for strengthening capacity for NTD programme

Strategic objective 3.4.1: Strengthening capacity at national level for NTD programme management and implementation.

| Activity             | Details (sub-<br>activities) | Time frame   | Resources needed                        |
|----------------------|------------------------------|--------------|---|
| Leadership and       |                              |              |   |
| management training  | Identification of            | 2017         | Financial                               |
|                      | trainees and trainers,       |              | Training institutions                   |
|                      | period, places and funds     |              |   |
| Office equipment and | Equip HQ and Zoba            | 2017         | Furniture (4 office                     |
| vehicles             | NTD offices with             |              | sets), lap tops (12),                   |
|                      | office equipment             |              | desk tops(12),                          |
|                      | (Lap tops, furniture,        |              | LCDs(8),                                |
|                      | LCDs, etc)                   |              | Specifications (12)                     |
|                      |                              |              | Printer and toners(12) $2$ values (land |
|                      |                              |              | 2 venicies (land                        |
|                      |                              |              |   |
| Laboratory diagnosis | 1.Identification of          | 2017-2020    |   |
|                      | trainees and trainers        |              |   |
|                      | 2., Conduct training         |              |   |
|                      | on how to maximize           |              |   |
|                      | detection                    |              |   |
|                      | 3.Procure lab                |              |   |
|                      | supplies and                 |              |   |
|                      | reagents,                    |              |   |
| Data management      | Identification of            | 2017,        | Computers, software,                    |
|                      | trainees and trainers,       | 2018         | training related costs                  |
|                      | period, places; funds        | (Refreshment | as above,                               |
|                      | identification;              | trainings)   |   |
|                      | consensus on                 |              |   |
|                      | software                     |              |   |

|           |           |           | 2015      | 2016          | 2017          | 2010          | 2010      | 2020      |
|-----------|-----------|-----------|-----------|---------------|---------------|---------------|-----------|-----------|
|           |           |           | 2015      | 2016          | 2017          | 2018          | 2019      | 2020      |
|           | Total     | Total at  | No. Sub   | No. Sub       | No. Sub       | No. Sub       | No. Sub   | No. Sub   |
| NTD       | No.       | risk      | zobas     | zobas         | zobas         | zobas         | zobas     | zobas     |
|           | sub       | populatio | and Total | and Total     | and Total     | and Total     | and Total | and Total |
|           | zobas     | n         | populatio | population    | population    | population    | populatio | populatio |
|           | requiri   |           | n to be   | to be treated | to be treated | to be treated | n to be   | n to be   |
|           | nguin     |           | in to be  |               |               |               | ii to be  | II to be  |
|           | ng<br>MDA |           | ireated   |               |               |               | llealed   | treated   |
|           | MDA       |           |           |               |               |               |           |           |
| PCT IMPLE | EMENTA    | TION (MD) | <u>A)</u> |               |               |               |           |           |
| LF        | 2         | 87250     | 87250     | 89431         | 91667         | 93958         | 96307.67  | 98715     |
|           |           |           |           |               |               |               |           |           |
| SCH       | 28        | 1,036,717 | 1,062,635 | 1,089,201     | 1,116,431     | 1,036,717     | 1,036,717 | 1,036,717 |
|           |           | , ,       | , ,       | , ,           | , ,           | , ,           | , ,       |           |
|           |           |           |           |               |               |               |           |           |
| STH       | 21        | 1,036,717 | 1,062,635 | 1,089,201     | 1,116,431     | 1,036,717     | 1,036,717 | 1,036,717 |
|           |           |           |           |               |               |               |           |           |
|           |           |           |           |               |               |               |           |           |
| Trachoma  |           |           |           |               |               |               |           |           |
|           |           |           |           |               |               |               |           |           |
| IDM IMPLI | EMENTA    | TION      |           | 1             | 1             | 1             | 1         | 1         |
| Dengue    |           |           |           |               |               | 1.0           |           | _         |
| fever     | 45        | 3,052,343 | 45        | 50            | 30            | 18            | 11        | 6         |
|           |           |           | 12 502    | 11252         | 6750          | 4051          | 2/21      | 1458      |
| LEIGH     | 11        | 1.057.500 | 12,303    | 11255         | 0752          | 4031          | 2431      | 1430      |
| LEISH     | 11        | 1,257,538 | 11        | 12            | /             | 4             | 3         | 2         |
|           |           |           | 182       | 200           | 120           | 72            | 43        | 26        |
| Leprosy   | 5         | 574,124   | 5         | 6             | 3             | 2             | 1         | 1         |
|           |           |           | 18        | 20            | 12            | 7             | 4         | 3         |

| Table 16: | Scaling  | up/scali | ing down | plan. |
|-----------|----------|----------|----------|-------|
|           | <u> </u> |          | <u> </u> |       |

# **3.5 Enhancing planning for results, Resource Mobilization and Financial Sustainability**

For successful implementation of the NTD Master Plan it is important to ensure development of practical strategies that will guarantee adequate resource mobilization for financial sustainability. Moreover a good accountability system for resource monitoring and control in a transparent manner based on justifiable evidence is of prime importance. In this document, some key activities have been identified to enable the achievement of the four strategic objectives for enhancing planning for results, resource mobilization and financial sustainability of the NTDP. These activities are shown in table 17.

Table 17: Activities for implementing Strategic Priority 2: Enhance planning for results, resource mobilization, and financial sustainability of national NTD programmes.

| operational plans for the co                                      | ntrol, elimination and era   | dication of targeted N | TDs   |
|---|--|------------------------|---|
| Activity  | Details (sub-activities)   | Time frame             | Resources needed  |
| 1. Review and launch<br>the new NTD<br>master plan                | i. Workshop to<br>Revise the<br>NTD Master<br>plan   | 2020                   | Allowances,<br>accommodation, hall<br>rental, meals,<br>stationaries.   |
|   | ii. Hold all NTDs<br>stake holders<br>meeting<br>including from<br>zones                         | 2017                   |   |
| 2. Development of<br>operation work<br>plans                      | i. hold meetings<br>to develop<br>national annual<br>gender<br>sensitive<br>operational<br>plans | 2017                   | Resource persons and<br>participants,<br>allowances,<br>accommodation, hall<br>rental, meals, assorted<br>stationary. |
| Strategic Objective 3.5.2: E national and zonal levels for        | hance resource mobiliza<br>NTD interventions.  | tion approaches and s  | trategies at international,   |
| 1. Develop an NTD<br>resource<br>mobilization<br>strategy.        | i. Hold meeting<br>to develop<br>resource<br>mobilization<br>strategy.                           | 2017                   | Resource persons and<br>participants,<br>allowances,<br>accommodation, hall<br>rental, meals, assorted<br>stationary  |
| 2. Implementation of<br>the resource<br>mobilization<br>strategy. | ii. Hold meeting<br>with multi-<br>lateral, bilateral<br>and all NTD<br>key<br>stakeholders.     | 2017-2020              | communication cost  |
|   | iii. Periodically<br>update the<br>resource<br>mobilization<br>strategy.                         | 2017-2020              | Personnel   |

Strategic objective 3.5.1: To develop integrated multiyear strategic plan and gender-sensitive annual operational plans for the control, elimination and eradication of targeted NTDs

Strategic objective 3.5. 3: Strengthen the integration and linkages of NTD programme and financial plans into sector-wide and national budgetary and financing mechanisms

| premis title seeter intere |       |                           |                      |                          |
|----------------------------|-------|---------------------------|----------------------|--------------------------|
| Advocacy                   | and   | i. Conduct advocacy       | 2017-2020            |                          |
| sensitisation              |       | visits to NTD relevant    |                      |                          |
|                            |       | stakeholders, including   |                      |                          |
|                            |       | Ministry of Finance       |                      |                          |
|                            |       | and Ministry of           |                      |                          |
|                            |       | Development.              |                      | Personnel                |
|                            |       |                           |                      |                          |
|                            |       | ii. Conduct               | 2017-2020            | Resource persons and     |
|                            |       | sensitization meetings    |                      | participants,            |
|                            |       | to NTD relevant           |                      | allowances, hall rental, |
|                            |       | stakeholders              |                      | meals, stationaries.     |
| Strategic Objective3.5.    | 4: L  | Develop and update nation | nal NTD policies and | elaborate guidelines and |
| tools to guide effective   | polic | y and program implement   | tation.              | -                        |
| 1. Review and up           | date  | Consult MoH to            | 2017                 |                          |
| the National he            | alth  | update the national       |                      |                          |
| policy to inclu            | ding  | NTD Policy                |                      |                          |
| the NTDs                   |       |                           |                      |                          |
| 2 Develop/resident         |       | Organiza mastings to      | 2017                 |                          |
| 2. Develop/update          |       | Organize meetings to      | 2017                 |                          |
| integrated r               |       | develop/update NID        |                      |                          |
| guide lines                | and   | guidelines and tools.     | 2017                 |                          |
| tools                      |       | Organize meetings to      | 2017                 | No resource needed       |
|                            |       | disseminate the           |                      |                          |
|                            |       | guidelines and tools      |                      |                          |

# **3.6 Strengthening Government Ownership, Advocacy, Coordination and Partnerships**

It is important to ensure government ownership of the programme and effective coordination of all partners with clear roles and responsibility of each one. NTD control strategies will be incorporated into the national and subnational health plan as well as into health service delivery in the facilities, education and other relevant areas. Community engagement and participation are critical to sustainability of the interventions. The NTD structure (Steering committees, task forces and secretariats) will review with stakeholders the progress. The role of the media is also very important in dissemination of accurate information on NTDs across the entire country. Table 18 list the activities that will be implemented to insure the achievements of the above strategic priorities. In order to insure

**Table 18:** Activities for implementing Strategic priority 1: Strengthen government ownership, advocacy, coordination, and partnership.

| Strategic objective 3.6.1: | Strengthen | coordination | mechanism fo | or the NTD | control programme at |
|----------------------------|------------|--------------|--------------|------------|----------------------|
| national and sub-national  | levels     |              |              |            |                      |
|                            |            |              |              |            |                      |

| Activity   | Details (sub-<br>activities)   | Time frame                         | Resources needed  |  |  |  |  |
|--|--|------------------------------------|---|--|--|--|--|
| 1. Strengthening<br>National coordination<br>mechanisms                    | Strengthen NTD<br>steering committees<br>and secretariat at<br>National level                                | 2017                               | Personnel   |  |  |  |  |
|  | Hold quarterly meetings  | 2017-2020                          | Allowances, accommodation, hall rental, meals, assorted stationary. |  |  |  |  |
| 2. National<br>Stakeholders NTD<br>review meeting                          | All stakeholders<br>meeting including<br>MoH high officials<br>and other line<br>ministry high<br>officials. | 2017-2020                          | Allowances, accommodation, hall rental, meals, assorted stationary. |  |  |  |  |
| Strategic objective 3.6.2 eradication of targeted N                        | 2: Strengthen and fost<br>TDs at national, sub zol   | er partnerships<br>ba and communit | for the control, elimination and y levels                           |  |  |  |  |
| 1. Update potential  | i. Identify NTD  | 2017                               | Personnel   |  |  |  |  |
| NTD partners list in the country.  | related partners.  |                                    |   |  |  |  |  |
| 2.Strengthen partnership   | i. Make advocacy<br>meetings to involve<br>more partners in<br>NTD control                                   | 2017                               | Hall rental, meals, assorted stationary.                            |  |  |  |  |
| Strategic objective 3.6.3:   | Enhance high level revi  | iews of NTD prog                   | ramme performance and the use of                                    |  |  |  |  |
| lessons learnt to enhance advocacy, awareness and effective implementation |  |                                    |   |  |  |  |  |

| 1.    | Conduct     | annual | i. Annual            |           | 2017 -2020 | allowances, accommodation, hall     |
|-------|-------------|--------|----------------------|-----------|------------|-------------------------------------|
| revie | ew meeting. |        | stakeholders meeting |           |            | rental, meals, assorted stationary. |
|       |             |        | for                  | reviewing |            |                                     |
|       |             |        | program              |           |            |                                     |
|       |             |        | performance          |           |            |                                     |
|       |             |        | ii. Documentation of |           | 2017 -2020 | Personnel, stationery,              |
|       |             |        | program              |           |            | communication cost, postal          |
|       |             |        | performan            | nce and   |            | services, printing and              |
|       |             |        | dissemina            | tion      |            | dissemination                       |

#### **3.7 MONITORING & EVALUATION**

Monitoring and evaluation activities are critical steps in tracking progress of programme implementation. It requires continuous observation and data collection on NTD programme and systematic and critical analysis of the adequacy, efficiency and effectiveness of the programme and its strategies. Continuous supervision is required and programme evaluation at midterm and at the end of the programme will be conducted to assess performance in relation to the goals, objectives and set targets. Table 19 below describes the activities, sub-activities, time frame and resources needed to achieve the four strategic objectives.

Table 19: Strategic priority 4: Enhance NTD monitoring and evaluation, surveillance and operation research.

| Strategic Objective 3.7.1: Develop and promote an integrated M&E framework and improve |   |                    |                               |  |  |  |  |
|--|---|--------------------|-------------------------------|--|--|--|--|
| monitoring of NTDs, w  | monitoring of NTDs, within the context of national health information systems |                    |                               |  |  |  |  |
| Activity   | Details (sub-activities)  | Time Frame         | Resources Needed              |  |  |  |  |
| Develop an   | Develop an M&E tool   | 2017               | Training, Experts/honorarium, |  |  |  |  |
| integrated NTD   | Field testing, training on  | 2017               | Stationeries, venues, DSA and |  |  |  |  |
| M&E framework  | the forms   |                    | Refreshment, communications   |  |  |  |  |
|  |   |                    | cost, transportation costs,   |  |  |  |  |
|  | Printing of M&E tool  | 2017               | Funds                         |  |  |  |  |
| Monitor drug   |   | Annually           | Experts/honorarium,           |  |  |  |  |
| management   |   |                    | Stationeries, venues, DSA and |  |  |  |  |
| inventory and  |   |                    | Refreshment, communication    |  |  |  |  |
| logistics  |   |                    | cost transportation costs,    |  |  |  |  |
| Strategic Objective 3  | .7.2: Strengthen and fost   | er partnership for | the control, elimination and  |  |  |  |  |
| eradication of targeted  | NTDs at national, zonal, si   | ub-zonal and comm  | unities.                      |  |  |  |  |
| Monitor the  | Develop checklist for   | 2017-2020          | develop and print checklist,  |  |  |  |  |
| coordination and   | monitoring indicators,  |                    | Stationeries, DSA and         |  |  |  |  |
| implementation   | conduct annual  |                    | Refreshment, transportation   |  |  |  |  |
| activity of NTD unit   | monitoring of activities  |                    | costs, communication costs,   |  |  |  |  |
|  | against set indicators  |                    |                               |  |  |  |  |
| Monitoring resource  | Tracking of appropriate   | Annually           | transportation costs,         |  |  |  |  |
| use  | availability and use of   |                    | communication costs,          |  |  |  |  |
|  | resources: financial report   |                    |                               |  |  |  |  |

Strategic Objective 3.7.3: Strengthen surveillance of NTDs and strengthen response and control of epidemic prone NTDs, in particular Dengue and Leishmaniasis, and other IDM NTDs

| 1 1                   | 1 0                      | -    |                               |
|-----------------------|--------------------------|------|-------------------------------|
| Strengthen existing   | Set up NTD lab in        | 2017 | Experts/honorarium,           |
| reference lab for     | Asmara                   |      | Commodities/equipment,        |
| NTDs                  |                          |      | reagents and supplies,        |
|                       |                          |      | transportation costs,         |
| Strengthen cross      | Cross border advocacy,   | 2017 | transportation costs,         |
| border surveillance   | Identify joint sentinel  |      | communication costs, venues,  |
| activities            | sites for NTD            |      | DSA, refreshment,             |
|                       | surveillance; Joint      |      |                               |
|                       | community sensitization; |      |                               |
|                       | joint supervision,       |      |                               |
| Strengthen integrated | Integrate NTDs in the    | 2017 | Stationeries, venues, DSA and |
| NTD surveillance      | IDSR guidelines          |      | Refreshment, transportation   |
| structures and        |                          |      | costs, communication costs    |
| mechanisms            |                          |      | (mobile phones, internet      |
|                       |                          |      | connections, computers)       |

Strategic Objective 3.7.4: Establish integrated data management systems and support impact analysis for NTD in the WHO African Region as part of the global NTD data management system and global NTD plan

| TTE press  |  |           |   |
|--|--|-----------|---|
| Establish/strengthen<br>integrated data<br>management system | Develop and produce<br>reporting forms, software,<br>field test, conduct<br>trainings,   | 2017      | Trainings, field testing,<br>Experts/honorarium, printing<br>forms, Stationeries, venues,<br>DSA and Refreshment,<br>transportation costs, software,<br>communication costs,                                  |
|  | Identify and train NTD<br>Data focal persons   | 2017      | Trainings, field testing,<br>Experts/honorarium, printing<br>forms, Stationeries, venues,<br>DSA and Refreshment,<br>transportation costs, software,<br>communication costs,                                  |
| Conduct impact<br>assessment for NTDs                        | Develop integrated<br>protocol for impact<br>assessment; conduct<br>treatment coverage<br>impact survey, share best<br>practices | 2018      | Training, Experts/honorarium,<br>Commodities, workshop<br>(Stationeries, venues, DSA<br>and Refreshment,<br>transportation costs,<br>communication costs); survey<br>cost; dissemination costs of<br>results, |
| Report and provide<br>NTD data to AFRO                       | Compile report and submit to WHO and MoH   | 2017-2020 | No resource needed  |

# **3.8.** Post intervention surveillance and integration within Primary Health Care

It is important to ensure that the gains made are sustained by establishing a strong postintervention surveillance and integration of the NTD programme into the primary health care. This Master plan will integrate the activities at the subnational levels of the health care delivery system to ensure routine practice. Surveillance activities will also be integrated into the national HMIS.

The activities to be implemented and the resources needed are elaborated in table 20.

| control epidemic – Prone IDM NTDs( dengue, leishmaniasis leprosy, Rabies, brucellosis and anthrax |                               |           |   |  |  |  |  |
|---|-------------------------------|-----------|---|--|--|--|--|
| Activity  | Details (Sub-<br>activities)  | Timeframe | Resources needed                          |  |  |  |  |
| Build capacity  | review and<br>update training |           |   |  |  |  |  |
|   | manuals                       | 2018      | personel                                  |  |  |  |  |
| Strengthen cross  | Meeting with                  | 2017-2020 |   |  |  |  |  |
| border  | NTD affected                  |           | Meeting cost ( stationeries ,Venues, DSA  |  |  |  |  |
| collaboration   | neighboring                   |           | and refreshment transportation costs,     |  |  |  |  |
|   | countries                     |           | Communication costs                       |  |  |  |  |
| Conduct   | Identify sentinel             | 2017-2020 | DSA and refreshment, transportation cost, |  |  |  |  |
| supportive  | sites for periodic            |           | communication cost, printing cost         |  |  |  |  |
| supervision   | spots checks                  |           |   |  |  |  |  |

Table 20: Activities for surveillance and sustainability

Strategic objectives: 3.8.1 Strengthen and sustain the surveillance of NTDs and the response and control epidemic – Prone IDM NTDs( dengue, leishmaniasis leprosy, Rabies, brucellosis and anthrax

## **Contact addresses:**

Communicable Diseases Control (CDC) Division Office Department of Public Health Ministry of Health Street 174.3 P.O Box 212 Asmara, Eritrea Tel: +291-1- 12 21 29 Fax: +291-1- 12 21 29 Contact Persons: 1. Dr. Araia Berhane, CDC Division Director

<u>araiabm@gmail.com</u>2. Mehreteab Abraha, NTD Manager

mehreteabmas@yahoo.com

### ANNEXES Annex 1.1 Summary population table National population data, schools, and health facilities at sub zoba level

| Zone   | Sub-Zone               | No. of<br>villages | Total<br>population | Under-<br>fives<br>(13.7) | 5-14 years<br>(29.2%) | No. of<br>primary<br>schools | No. of<br>peripheral<br>health<br>facilities |
|--------|------------------------|--------------------|---------------------|---------------------------|-----------------------|------------------------------|--|
| Anseba | Elabered               | 55                 | 68,119              | 9332                      | 19891                 | 22                           | 4  |
|        | Geleb                  | 39                 | 48,417              | 6633                      | 14138                 | 10                           | 2  |
|        | Keren                  | 52                 | 106,602             | 14604                     | 31128                 | 30                           | 7  |
|        | Hagaz                  | 81                 | 90,342              | 12377                     | 26380                 | 18                           | 67   |
|        | Halhal                 | 29                 | 71,441              | 9787                      | 20861                 | 9                            | 3  |
|        | Habero                 | 36                 | 65,328              | 8950                      | 19076                 | 10                           | 4  |
|        | Asmat                  | 27                 | 49,130              | 6731                      | 14346                 | 8                            | 3  |
|        | Kerkebet               | 55                 | 40,147              | 5500                      | 11723                 | 9                            | 4  |
|        | Sela                   | 22                 | 13,742              | 1883                      | 4013                  | 7                            | 1  |
|        | AdiTekelizan           | 37                 | 45,655              | 6255                      | 13331                 | 9                            | 1  |
|        | Hamelmalo              | 41                 | 37,738              | 5170                      | 11019                 | 11                           | 3  |
|        | Zonal population       |                    | 636,661             | 87223                     | 185905                |                              | 38   |
| Debub  | Debarwa                | 81                 | 124,667             | 17079                     | 36403                 | 25                           | 8  |
|        | Areza                  | 104                | 114,635             | 15705                     | 33473                 | 25                           | 7  |
|        | Mendefera              | 68                 | 80,041              | 10966                     | 23372                 | 16                           | 4  |
|        | Dekemhare              | 46                 | 70,312              | 9633                      | 20531                 | 26                           | 6  |
|        | Segeneiti              | 39                 | 69,454              | 9515                      | 20281                 | 21                           | 6  |
|        | Adi Keyih              | 99                 | 112,111             | 15359                     | 32736                 | 21                           | 6  |
|        | Senafe                 | 120                | 51,845              | 7103                      | 15139                 | 27                           | 8  |
|        | Tsorona                | 88                 | 116,724             | 15991                     | 34083                 | 13                           | 7  |
|        | Adiquala               | 109                | 81,245              | 11131                     | 23724                 | 20                           | 4  |
|        | Emni-Haili             | 100                | 81245               | 11131                     | 23724                 | 22                           | 3  |
|        | Mai-Aynee              | 59                 | 54156               | 7419                      | 15814                 | 12                           | 3  |
|        | Mai-Mine               | 73                 | 91074               | 12477                     | 26594                 | 14                           | 3  |
|        | Zonal population       |                    | 1,047,509           | 143509                    | 305873                |                              | 65   |
| DKB    | Areta                  | 48                 | 27,434              | 3758                      | 8011                  | 8                            | 4  |
|        | Makelay Keyih<br>Bahri | 21                 | 19,152              | 2624                      | 5592                  | 3                            | 3  |
|        | Debub Denkalia         | 34                 | 16,209              | 2221                      | 4733                  | 6                            | 5  |
|        | Asseb                  | 6                  | 29,600              | 4055                      | 8643                  | 5                            | 2  |
|        | Zonal population       |                    | 92,395              | 12658                     | 26979                 |                              | 14   |
| Gash   |                        |                    |                     |                           |                       |                              |  |
| Barka  | Agurdet                | 103                | 43,326              | 5936                      | 12651                 | 15                           | 6  |
|        | Barentu                | 39                 | 29,018              | 3975                      | 8473                  | 16                           | 7  |
|        | Dighe                  | 88                 | 57,239              | 7842                      | 16714                 | 11                           | 6  |
|        | Forto                  | 84                 | 59,816              | 8195                      | 17466                 | 14                           | 5  |

|        | Gogne                | 54 | 59,269    | 8120   | 17307   | 13 | 2   |
|--------|----------------------|----|-----------|--------|---------|----|-----|
|        | Haycota              | 91 | 62,883    | 8615   | 18362   | 13 | 4   |
|        | LogoAnseba           | 22 | 53,055    | 7269   | 15492   | 16 | 5   |
|        | Mensura              | 26 | 80,143    | 10980  | 23402   | 16 | 5   |
|        | Mogolo               | 21 | 31,457    | 4310   | 9185    | 11 | 3   |
|        | Guluj                | 48 | 76,673    | 10504  | 22389   | 20 | 9   |
|        | Shambuko             | 38 | 47,655    | 6529   | 13915   | 19 | 4   |
|        | Mulki                | 61 | 49,517    | 6784   | 14459   | 13 | 5   |
|        | Teseney              | 62 | 59,665    | 8174   | 17422   | 18 | 6   |
|        | Laalay Gash          | 89 | 76,673    | 10504  | 22389   | 24 | 6   |
|        | Zonal population     |    | 786,389   | 107735 | 229626  |    | 73  |
| Maakel | Serejeka             | 28 | 77,028    | 10553  | 22492   | 17 | 8   |
|        | Berikh               | 22 | 62,331    | 8539   | 18201   | 16 | 3   |
|        | Ghalanefhi           | 32 | 66,537    | 9116   | 19429   | 23 | 6   |
|        | North east<br>Asmara | 4  | 159,896   | 21906  | 46690   | 13 | 4   |
|        | North west<br>Asmara | 3  | 156,395   | 21426  | 45667   | 14 | 3   |
|        | South west<br>Asmara | 3  | 117,217   | 16059  | 34227   | 8  | 9   |
|        | South East<br>Asmara | 3  | 111,016   | 15209  | 32417   | 18 | 4   |
|        | Zonal population     |    | 750,420   | 102808 | 219123  |    | 37  |
| SKB    | Ghelealo             | 46 | 34,790    | 4766   | 10159   | 18 | 5   |
|        | Foro                 | 58 | 66792     | 9151   | 19503   | 12 | 4   |
|        | Dahlak               | 12 | 4,254     | 583    | 1242    | 6  | 3   |
|        | Massawa              | 15 | 49,608    | 6796   | 14486   | 11 | 10  |
|        | Ghindae              | 25 | 89,433    | 12252  | 26114   | 19 | 10  |
|        | Shieb                | 10 | 76,520    | 10483  | 22344   | 8  | 2   |
|        | Afabet               | 49 | 145,644   | 19953  | 42528   | 14 | 5   |
|        | Nakfa                | 33 | 76,872    | 10531  | 22447   | 11 | 4   |
|        | Adobha               | 18 | 33,645    | 4609   | 9824    | 3  | 3   |
|        | Karora               | 22 | 61,856    | 8474   | 18062   | 8  | 4   |
|        | Zonal population     |    | 639,414   | 87600  | 186709  |    | 50  |
|        | National population  |    | 3,952,788 | 541532 | 1154214 |    | 277 |

| Asmara |           |       |           |      |        |       |         |         |          |        |       |         |       |
|--------|-----------|-------|-----------|------|--------|-------|---------|---------|----------|--------|-------|---------|-------|
| 60     | Mendefera |       |           |      |        |       |         |         |          |        |       |         |       |
|        |           | Adi   |           |      |        |       |         |         |          |        |       |         |       |
| 92     | 32        | quala |           |      |        |       |         |         |          |        |       |         |       |
| 40     | 44        | 76    | Dekemhare |      |        |       |         |         |          |        |       |         |       |
|        |           |       |           | Adi  |        |       |         |         |          |        |       |         |       |
| 110    | 114       | 146   | 70        | keyh |        |       |         |         |          |        |       |         |       |
| 135    | 139       | 171   | 95        | 25   | Senafe |       |         |         |          |        |       |         |       |
| 91     | 151       | 183   | 131       | 201  | 226    | Keren |         |         |          |        |       |         |       |
| 172    | 232       | 264   | 212       | 282  | 307    | 81    | Akurdet |         |          |        |       |         |       |
| 202    | 262       | 294   | 242       | 312  | 337    | 30    | 30      | Barentu |          |        |       |         |       |
| 357    | 417       | 449   | 397       | 467  | 492    | 266   | 185     | 155     | Tesseney |        |       |         |       |
| 157    | 217       | 249   | 197       | 267  | 292    | 66    | 147     | 96      | 514      | Afabet |       |         |       |
| 227    | 287       | 319   | 267       | 337  | 362    | 136   | 217     | 166     | 584      | 70     | Nakfa |         |       |
| 155    | 215       | 247   | 195       | 265  | 290    | 246   | 327     | 357     | 512      | 312    | 382   | Massawa |       |
| 705    | 765       | 797   | 745       | 815  | 840    | 796   | 877     | 907     | 1062     | 862    | 932   | 550     | Assab |

Annex 1.2. Distances between Asmara and major cities in the country

#### Annex 1.3: Organizational chart of the MoH and the NTD National Programme



| <b>Province</b> or | District or   | LF  | SCH | STH | Trachoma |
|--------------------|---------------|-----|-----|-----|----------|
| region             | community*    |     |     |     |          |
| Anseba             |               |     |     |     |          |
|                    | Hagaz         | NO  | NO  | YES | YES      |
|                    | Adi-Tekelezan | NO  | YES | YES | YES      |
|                    | Asmat         | NO  | NO  | NO  | ND       |
|                    | Elaberd       | NO  | NO  | NO  | YES      |
|                    | Geleb         | NO  | NO  | NO  | YES      |
|                    | Habero        | NO  | NO  | YES | YES      |
|                    | Halhal        | NO  | YES | YES | YES      |
|                    | Hamelmalo     | NO  | NO  | YES | YES      |
|                    | Keren         | NO  | NO  | YES | YES      |
|                    | Kerkebet      | NO  | NO  | YES | ND       |
|                    | Selea         | NO  | NO  | YES | ND       |
| Total Anseba       |               | 0   | 2   | 8   | 8        |
| Debub              |               |     |     |     |          |
|                    | Adequala      | NO  | YES | YES | YES      |
|                    | Adikeih       | NO  | YES | YES | YES      |
|                    | Areza         | NO  | YES | YES | YES      |
|                    | Dbarwa        | NO  | YES | YES | YES      |
|                    | Dekemhare     | NO  | YES | YES | YES      |
|                    | Imnihaili     | NO  | YES | YES | YES      |
|                    | Maiaini       | NO  | YES | YES | YES      |
|                    | Maimine       | NO  | YES | YES | YES      |
|                    | Mendefera     | NO  | YES | YES | YES      |
|                    | Segeniti      | NO  | YES | YES | YES      |
|                    | Senafe        | NO  | YES | YES | YES      |
|                    | Tsorona       | NO  | YES | YES | YES      |
| Total Debub        |               | 0   | 12  | 12  | 12       |
|                    | Areta         | YES | No  | No  | YES*     |
|                    | Makel         | NO  | No  | No  | YES*     |
| DKB                | Denkalia      |     |     |     | VES*     |
|                    | Denkalia      | NO  | No  | No  | 1125     |
|                    | Asseb         | NO  | No  | No  | YES*     |
| Total DKB          |               | 1   |     |     | 4        |
|                    | Agurdet       | NO  | ND  | ND  | YES      |
|                    | Barentu       | NO  | ND  | ND  | YES      |
|                    | Dighe         | NO  | ND  | ND  | NO       |
| Coch Dorles        | Forto         | YES | ND  | ND  | YES      |
| Gasii Багка        | Gogne         | NO  | ND  | ND  | YES      |
|                    | Haycota       | NO  | ND  | ND  | YES      |
|                    | Logo Anseba   | NO  | ND  | ND  | YES      |
|                    | Mensura       | NO  | ND  | ND  | YES      |

Annex 1.4: Summary on available data of PCT-NTD distribution
|                      | Mogolo              | NO | ND  | ND | NO   |
|----------------------|---------------------|----|-----|----|------|
|                      | Gulug               | NO | ND  | ND | YES  |
|                      | Shambuko            | NO | ND  | ND | YES  |
|                      | Mulki               | NO | ND  | ND | YES  |
|                      | Teseney             | NO | ND  | ND | YES  |
|                      | Laalay Gash         | NO | ND  | ND | YES  |
| Total Gash-<br>Barka |                     | 1  |     |    | 12   |
| Maakel               |                     |    |     |    |      |
|                      | Berik               | NO | YES | NO | YES* |
|                      | Debubawi Mbrak      | NO | YES | NO | YES* |
|                      | Debubawi-<br>me'rab | NO | NO  | NO | YES* |
|                      | Gaa-Nefhi           | NO | YES | NO | YES* |
|                      | Semenawi-<br>me'rab | NO | YES | NO | YES* |
|                      | Semenawi-<br>mibrak | NO | NO  | NO | YES* |
|                      | Serejeka            | NO | YES | NO | YES* |
| Total Maakel         |                     | 0  | 5   | 0  | 7    |
|                      | Ghelealo            | NO | ND  | ND | YES  |
|                      | Foro                | NO | ND  | ND | NO   |
|                      | Dahlak              | NO | ND  | ND | YES  |
|                      | Massawa             | NO | ND  | ND | YES  |
| SVD                  | Ghindae             | NO | ND  | ND | YES  |
| SKD                  | Shieb               | NO | ND  | ND | YES  |
|                      | Afabet              | NO | ND  | ND | YES  |
|                      | Nakfa               | NO | ND  | ND | YES  |
|                      | Adobha              | NO | ND  | ND | YES  |
|                      | Karora              | NO | ND  | ND | YES  |
| Total SKB            |                     | 0  |     |    | 9    |
| Total                |                     |    |     |    |      |
| Country              |                     | 2  | 19  | 20 | 33   |

#### Legend:

 $\boldsymbol{N}\boldsymbol{D}$  (No data): if no information is available

No: Not endemic or below PCT intervention threshold

Yes or known Prevalence rate if endemic

\* Areas where rapid assessment was used to derive data for Trachoma (only one village was assessed per sub-Zoba).

| Province or region | District or community* | LEISH | Leprosy | Trac<br>hiasis | Rabies | Dengue | Brucellosis | Anthrax |
|--------------------|------------------------|-------|---------|----------------|--------|--------|-------------|---------|
| Anseba             | Elabered               | Yes   | No      | No             | Yes    | Yes    | No          | Yes     |
|                    | Geleb                  | No    | No      | No             | No     | No     | No          | No      |
|                    | Keren                  | Yes   | Yes     | No             | Yes    | Yes    | Yes         | Yes     |
|                    | Hagaz                  | No    | No      | NO             | Yes    | Yes    | No          | No      |
|                    | Halhal                 | Yes   | No      | No             | Yes    | Yes    | Yes         | No      |
|                    | Habero                 | Yes   | No      | No             | Yes    | Yes    | Yes         | Yes     |
|                    | Asmat                  | No    | No      | ND             | Yes    | Yes    | No          | No      |
|                    | Kerkebet               | No    | No      | ND             | Yes    | Yes    | No          | No      |
|                    | Sela                   | No    | No      | ND             | No     | No     | No          | No      |
|                    | AdiTekelizan           | No    | No      | No             | Yes    | No     | Yes         | No      |
|                    | Hamelmalo              | No    | No      | No             | Yes    | Yes    | No          | Yes     |
| Total<br>Anseba    | 11                     | 4     | 1       | 0              | 9      | 8      | 4           | 4       |
| Debub              | Debarwa                | Yes   | No      | NO             | Yes    | No     | No          | Yes     |
|                    | Areza                  | Yes   | No      | NO             | Yes    | Yes    | No          | Yes     |
|                    | Mendefera              | Yes   | Yes     | YES            | Yes    | No     | Yes         | Yes     |
|                    | Dekemhare              | Yes   | Yes     | YES            | Yes    | Yes    | Yes         | Yes     |
|                    | Segeneiti              | Yes   | No      | NO             | Yes    | Yes    | Yes         | Yes     |
|                    | AdiKeyih               | Yes   | Yes     | YES            | Yes    | Yes    | Yes         | Yes     |
|                    | Senafe                 | Yes   | No      | YES            | Yes    | Yes    | No          | Yes     |
|                    | Tsorona                | No    | No      | NO             | Yes    | No     | No          | Yes     |
|                    | Adiquala               | Yes   | No      | NO             | Yes    | Yes    | No          | Yes     |
|                    | Emni-Haili             | Yes   | No      | NO             | Yes    | Yes    | No          | Yes     |
|                    | Mai-Aynee              | No    | No      | YES            | Yes    | Yes    | No          | Yes     |

### Annex 1.5: Summary on available data on CM-NTD distribution

|                         | Mai-Mine          | Yes | No  | YES | Yes | Yes | Yes | Yes |
|-------------------------|-------------------|-----|-----|-----|-----|-----|-----|-----|
| Total<br>Debub          | 12                | 10  | 3   | 6   | 12  | 9   | 5   | 12  |
| DKB                     | Araata            | No  | Yes | NO  | Yes | Yes | No  | No  |
|                         | Makel Dankalia    | No  | No  | NO  | Yes | Yes | No  | No  |
|                         | Debub Dankalia    | No  |
|                         | Asseb             | Yes |
| Total<br>DKB            | 4                 | 1   | 2   | 1   | 3   | 3   | 1   | 1   |
| Gash<br>Barka           | Agurdet           | Yes | Yes | NO  | Yes | Yes | Yes | Yes |
|                         | Barentu           | Yes |
|                         | Dighe             | Yes | No  | NO  | Yes | Yes | No  | No  |
|                         | Forto             | No  | No  | NO  | Yes | Yes | Yes | Yes |
|                         | Gogne             | No  | No  | NO  | Yes | Yes | No  | No  |
|                         | Haycota           | Yes | No  | NO  | Yes | No  | No  | No  |
|                         | Logo Anseba       | No  | No  | YES | Yes | Yes | No  | No  |
|                         | Mensura           | Yes | No  | NO  | Yes | Yes | No  | Yes |
|                         | Mogolo            | Yes | Yes | NO  | Yes | Yes | No  | Yes |
|                         | Gulug             | Yes | Yes | YES | Yes | No  | Yes | Yes |
|                         | Shambuko          | Yes | No  | YES | Yes | No  | Yes | Yes |
|                         | Mulki             | Yes | No  | YES | Yes | Yes | No  | Yes |
|                         | Teseney           | Yes |
|                         | Laalay Gash       | Yes | No  | NO  | Yes | Yes | No  | Yes |
| Total<br>Gash-<br>Barka | 14                | 11  | 5   | 6   | 14  | 11  | 6   | 10  |
| Maakel                  | Serejeka          | Yes | Yes | NO  | Yes | Yes | No  | Yes |
|                         | Berikh            | No  | No  | NO  | Yes | Yes | No  | No  |
|                         | Ghalanefhi        | Yes | No  | YES | Yes | Yes | No  | Yes |
|                         | North east Asmara | Yes | Yes | NO  | Yes | Yes | Yes | Yes |

|                  | North west Asmara | Yes | Yes | NO  | Yes | Yes | Yes | Yes |
|------------------|-------------------|-----|-----|-----|-----|-----|-----|-----|
|                  | South west Asmara | Yes | Yes | NO  | Yes | Yes | Yes | Yes |
|                  | South East Asmara | Yes | Yes | NO  | Yes | Yes | Yes | Yes |
| Total<br>Maakel  | 7                 | 6   | 5   | 1   | 7   | 7   | 4   | 6   |
| SKB              | Ghelealo          | Yes | Yes | NO  | Yes | Yes | Yes | No  |
|                  | Foro              | No  | No  | NO  | Yes | Yes | No  | No  |
|                  | Dahlak            | Yes | Yes | ND  | Yes | Yes | No  | No  |
|                  | Massawa           | Yes | Yes | NO  | Yes | Yes | Yes | Yes |
|                  | Ghindae           | Yes | Yes | NO  | Yes | Yes | Yes | Yes |
|                  | Shieb             | Yes | No  | YES | Yes | Yes | No  | No  |
|                  | Afabet            | Yes | Yes | YES | Yes | Yes | No  | Yes |
|                  | Nakfa             | Yes | Yes | NO  | Yes | Yes | No  | Yes |
|                  | Adobha            | Yes | No  | YES | Yes | Yes | No  | No  |
|                  | Karora            | Yes | No  | NO  | Yes | Yes | No  | No  |
| Total<br>SKB     | 10                | 9   | 6   | 3   | 10  | 10  | 3   | 4   |
| Total<br>Country | 58                | 41  | 22  | 17  | 55  | 48  | 23  | 37  |

### Legend:

ND (No data): if no information is available No for Not endemic or below elimination threshold Yes or known **Prevalence rate** if endemic

| Province or  | Sub zoba or        | LF  | SCH     | STH     | Trachoma |
|--------------|--------------------|-----|---------|---------|----------|
| region       | community*         | 14  | Suit    |         | machoma  |
| Anseba       |                    |     |         |         |          |
|              | Hagaz              | NO  | NO      | YES     | NO       |
|              | Adi-Tekelezan      | NO  | PCT (1) | PCT (1) | NO       |
|              | Asmat              | NO  | NO      | NO      | ND       |
|              | Elaberd            | NO  | NO      | NO      | NO       |
|              | Geleb              | NO  | NO      | NO      | NO       |
|              | Habero             | NO  | NO      | YES     | NO       |
|              | Halhal             | NO  | YES     | YES     | NO       |
|              | Hamelmalo          | NO  | NO      | PCT (1) | NO       |
|              | Keren              | NO  | NO      | YES     | NO       |
|              | Kerkebet           | NO  | NO      | YES     | ND       |
|              | Selea              | NO  | NO      | YES     | ND       |
| Total Anseba |                    | 0   | 2       | 8       |          |
| Debub        |                    |     |         |         |          |
|              | Adequala           | NO  | PCT (1) | PCT (1) | PCT(3)   |
|              | Adikeih            | NO  | YES     | YES     | NO       |
|              | Areza              | NO  | YES     | YES     | PCT(3)   |
|              | Dbarwa             | NO  | YES     | YES     | PCT(3)   |
|              | Dekemhare          | NO  | YES     | YES     | NO       |
|              | Imnihaili          | NO  | YES     | YES     | PCT(3)   |
|              | Maiaini            | NO  | YES     | YES     | NO       |
|              | Maimine            | NO  | YES     | YES     | PCT(4)   |
|              | Mendefera          | NO  | YES     | YES     | PCT(3)   |
|              | Segeniti           | NO  | YES     | YES     | NO       |
|              | Senafe             | NO  | YES     | YES     | PCT(3)   |
|              | Tsorona            | NO  | YES     | YES     | NO       |
| Total Debub  |                    | 0   | 12      | 12      | 7        |
| DKB          | Areta              | YES | MAP     | MAP     | MAP      |
|              | Maakle<br>Dankalia | NO  | MAP     | MAP     | MAP      |
|              | Debub<br>Dankalia  | NO  | MAP     | МАР     | MAP      |
|              | Asseb              | NO  | MAP     | MAP     | MAP      |
| Total DKB    |                    | 1   |         |         |          |
| Gash Barka   | Agurdet            | NO  | MAP     | MAP     | NO       |
|              | Barentu            | NO  | MAP     | MAP     | NO       |
|              | Dighe              | NO  | MAP     | MAP     | NO       |
|              | Forto              | YES | MAP     | MAP     | NO       |
|              | Gogne              | NO  | MAP     | MAP     | NO       |
|              | Haycota            | NO  | MAP     | MAP     | NO       |
|              | LogoAnseba         | NO  | MAP     | MAP     | NO       |

Annex 1.6: Summary on status of implementation of PCT NTD interventions in sub zobas

| Mensura             | NO  | MAP   | MAP  | NO  |
|---------------------|---|---|--|---|
| Mogolo              | NO  | MAP   | MAP  | NO  |
| Gulug               | NO  | MAP   | MAP  | NO  |
| Shambuko            | NO  | MAP   | MAP  | NO  |
| Mulki               | NO  | MAP   | MAP  | NO  |
| Teseney             | NO  | MAP   | MAP  | NO  |
| Laalay Gash         | NO  | MAP   | MAP  | NO  |
|                     | 1   |   |  |   |
|                     |   |   |  |   |
| Berik               | NO  | YES   | NO   | MAP   |
| Debubawi Mbrak      | NO  | YES   | NO   | MAP   |
| Debubawi-<br>me'rab | NO  | NO  | NO   | MAP   |
| Gaa-Nefhi           | NO  | YES   | NO   | MAP   |
| Semenawi-<br>me'rab | NO  | YES   | NO   | MAP   |
| Semenawi-<br>mibrak | NO  | NO  | NO   | MAP   |
| Serejeka            | NO  | YES   | NO   | MAP   |
|                     |   | 5   | 0  |   |
| Ghelealo            | NO  | MAP   | MAP  | NO  |
| Foro                | NO  | MAP   | MAP  | NO  |
| Dahlak              | NO  | MAP   | MAP  | NO  |
| Massawa             | NO  | MAP   | MAP  | NO  |
| Ghindae             | NO  | MAP   | MAP  | NO  |
| Shieb               | NO  | MAP   | MAP  | NO  |
| Afabet              | NO  | MAP   | MAP  | NO  |
| Nakfa               | NO  | MAP   | MAP  | PCT(2)  |
| Adobha              | NO  | MAP   | MAP  | NO  |
| Karora              | NO  | MAP   | MAP  | NO  |
|                     | 0   |   |  | 1   |
|                     | 2   | 19  | 20   | 8   |
|                     | Mensura<br>Mogolo<br>Gulug<br>Shambuko<br>Mulki<br>Teseney<br>Laalay Gash<br>Laalay Gash<br>Berik<br>Debubawi Mbrak<br>Debubawi Mbrak<br>Debubawi-<br>me'rab<br>Gaa-Nefhi<br>Semenawi-<br>me'rab<br>Semenawi-<br>me'rab<br>Semenawi-<br>me'rab<br>Gaa-Nefhi<br>Semenawi-<br>me'rab<br>Gaa-Nefhi<br>Semenawi-<br>me'rab<br>Gaa-Nefhi<br>Semenawi-<br>me'rab<br>Gaa-Nefhi<br>Semenawi-<br>me'rab<br>Gaa-Nefhi<br>Semenawi-<br>mibrak<br>Serejeka<br>Ghindae<br>Shieb<br>Afabet<br>Nakfa<br>Adobha<br>Karora | MensuraNOMogoloNOGulugNOShambukoNOMulkiNOTeseneyNOLaalay GashNOLaalay GashNOBerikNODebubawi MbrakNODebubawi-<br>me'rabNOGaa-NefhiNOSemenawi-<br>me'rabNOSemenawi-<br>mibrakNOSerejekaNOGhelealoNOForoNODahlakNOShiebNOAfabetNOShiebNOAfabetNOXaroraNOQQ | MensuraNOMAPMogoloNOMAPGulugNOMAPGulugNOMAPShambukoNOMAPMulkiNOMAPTeseneyNOMAPLaalay GashNOMAPLaalay GashNOMAPBerikNOYESDebubawi MbrakNOYESDebubawi-<br>me'rabNOYESSemenawi-<br>me'rabNOYESSemenawi-<br>mibrakNOYESSemenawi-<br>mibrakNOYESGhelealoNOMAPDahlakNOMAPMassawaNOMAPShiebNOMAPAfabetNOMAPAdobhaNOMAPAdobhaNOMAPAdobhaNOMAPIndaeNOMAPShiebNOMAPShiebNOMAPShiebNOMAPShiebNOMAPShiebNOMAPShiebNOMAPShiebNOMAPAdobhaNOMAPAdobhaNOMAPNakfaNOMAPNakfaNOMAPSubshaNOMAPSubshaNOMAPSubshaNOMAPSubshaNOMAPSubshaNOMAP | MensuraNOMAPMAPMogoloNOMAPMAPGulugNOMAPMAPGulugNOMAPMAPShambukoNOMAPMAPMulkiNOMAPMAPTeseneyNOMAPMAPLaalay GashNOMAPMAPBerikNOYESNODebubawi MbrakNOYESNODebubawi-<br>me'rabNONONOGaa-NefhiNOYESNOSemenawi-<br>mibrakNOYESNOSerejekaNOYESNOGhelealoNOMAPMAPForoNOMAPMAPMassawaNOMAPMAPMassawaNOMAPMAPShiebNOMAPMAPMakfaNOMAPMAPAdobhaNOMAPMAPAdobhaNOMAPMAPAdobhaNOMAPMAPAdobhaNOMAPMAPAdobhaNOMAPMAP |

**Legend:** ND (No data): if no information is available

No: if no intervention is required

MAP: if mapping is planned or on-going

**PCT (1),PCT (2)** ... **PCT (10)**: if MDA. In bracket is the number of round being conducted. Examples: MDA1 (1) =  $1^{st}$  round of MDA1 (IVM+ALB), T2 (3) =  $3^{rd}$  round of T2 (PZQ in SAC).

| Province or region | District or<br>community* | LEISH | Leprosy | Trachiasis | Rabies | Dengue | Brucellosis | Anthrax |
|--------------------|---------------------------|-------|---------|------------|--------|--------|-------------|---------|
| Anseba             | Elabered                  | CM2   | No      | No         | CM2    | CM1    | No          | CM2     |
|                    | Geleb                     | No    | No      | No         | No     | No     | No          | No      |
|                    | Keren                     | CM2   | CM2     | No         | CM2    | CM1    | CM2         | CM2     |
|                    | Hagaz                     | No    | No      | NO         | CM2    | CM1    | No          | No      |
|                    | Halhal                    | CM2   | No      | No         | CM2    | CM1    | CM2         | No      |
|                    | Habero                    | CM2   | No      | No         | CM2    | CM1    | CM2         | CM2     |
|                    | Asmat                     | No    | No      | ND         | CM2    | CM1    | No          | No      |
|                    | Kerkebet                  | No    | No      | ND         | CM2    | CM1    | No          | No      |
|                    | Sela                      | No    | No      | ND         | No     | No     | No          | No      |
|                    | AdiTekelizan              | No    | No      | No         | CM2    | No     | CM2         | No      |
|                    | Hamelmalo                 | No    | No      | No         | CM2    | CM1    | No          | CM2     |
| Total Anseba       | 11                        |       |         |            |        |        |             |         |
| Debub              | Debarwa                   | CM2   | No      | NO         | CM2    | No     | No          | CM2     |
| 2                  | Areza                     | CM2   | No      | NO         | CM2    | CM1    | No          | CM2     |
|                    | Mendefera                 | CM2   | CM2     | YES        | CM2    | No     | CM2         | CM2     |
|                    | Dekemhare                 | CM2   | CM2     | YES        | CM2    | CM1    | CM2         | CM2     |
|                    | Segeneiti                 | CM2   | No      | NO         | CM2    | CM1    | CM2         | CM2     |
|                    | AdiKeyih                  | CM2   | CM2     | YES        | CM2    | CM1    | CM2         | CM2     |
|                    | Senafe                    | CM2   | No      | YES        | CM2    | CM1    | No          | CM2     |
|                    | Tsorona                   | No    | No      | NO         | CM2    | No     | No          | CM2     |
|                    | Adiquala                  | CM2   | No      | NO         | CM2    | CM1    | No          | CM2     |
|                    | Emni-Haili                | CM2   | No      | NO         | CM2    | CM1    | No          | CM2     |
|                    | Mai-Aynee                 | No    | No      | YES        | CM2    | CM1    | No          | CM2     |
|                    | Mai-Mine                  | CM2   | No      | YES        | CM2    | CM1    | CM2         | CM2     |

## Annex 1.7: Summary on status of implementation of CM interventions in sub Zobas

|                      | 12                    |     |     |     |     |     |     |     |
|----------------------|-----------------------|-----|-----|-----|-----|-----|-----|-----|
| Total Debub          | Anata                 | NT  | CMO | NO  | CMO | CM1 | Nia | Na  |
| DKB                  | Areta                 | No  | CM2 | NO  | CM2 | CMI | NO  | No  |
|                      | MakelayKeyihBa<br>hri | No  | No  | NO  | CM2 | CM1 | No  | No  |
|                      | DebubDenkalia         | No  |
|                      | Asseb                 | CM2 | CM2 | YES | CM2 | CM1 | CM2 | CM2 |
| Total DKB            | 4                     |     |     |     |     |     |     |     |
| Gash Barka           | Agurdet               | CM2 | CM2 | NO  | CM2 | CM1 | CM2 | CM2 |
|                      | Barentu               | CM2 | CM2 | YES | CM2 | CM1 | CM2 | CM2 |
|                      | Dighe                 | CM2 | No  | NO  | CM2 | CM1 | No  | No  |
|                      | Forto                 | No  | No  | NO  | CM2 | CM1 | CM2 | CM2 |
|                      | Gogne                 | No  | No  | NO  | CM2 | CM1 | No  | No  |
|                      | Haycota               | CM2 | No  | NO  | CM2 | No  | No  | No  |
|                      | Logo Anseba           | No  | No  | YES | CM2 | CM1 | No  | No  |
|                      | Mensura               | CM2 | No  | NO  | CM2 | CM1 | No  | CM2 |
|                      | Mogolo                | CM2 | CM2 | NO  | CM2 | CM1 | No  | CM2 |
|                      | Gulug                 | CM2 | CM2 | YES | CM2 | No  | CM2 | CM2 |
|                      | Shambuko              | CM2 | No  | YES | CM2 | No  | CM2 | CM2 |
|                      | Mulki                 | CM2 | No  | YES | CM2 | CM1 | No  | CM2 |
|                      | Teseney               | CM2 | CM2 | YES | CM2 | CM1 | CM2 | CM2 |
|                      | Laalay Gash           | CM2 | No  | NO  | CM2 | CM1 | No  | CM2 |
| Total Gash-<br>Barka | 14                    |     |     |     |     |     |     |     |
| Maakel               | Serejeka              | CM2 | CM2 | NO  | CM2 | CM1 | No  | CM2 |
|                      | Berikh                | No  | No  | NO  | CM2 | CM1 | No  | No  |
|                      | Ghalanefhi            | CM2 | No  | YES | CM2 | CM1 | No  | CM2 |
|                      | North east<br>Asmara  | CM2 | CM2 | NO  | CM2 | CM1 | CM2 | CM2 |

|                  | North west<br>Asmara | CM2 | CM2 | NO  | CM2 | CM1 | CM2 | CM2 |
|------------------|----------------------|-----|-----|-----|-----|-----|-----|-----|
|                  | South west<br>Asmara | CM2 | CM2 | NO  | CM2 | CM1 | CM2 | CM2 |
|                  | South East<br>Asmara | CM2 | CM2 | NO  | CM2 | CM1 | CM2 | CM2 |
| Total Maakel     | 7                    |     |     |     |     |     |     |     |
| SKB              | Ghelealo             | CM2 | CM2 | NO  | CM2 | CM1 | CM2 | No  |
|                  | Foro                 | No  | No  | NO  | CM2 | CM1 | No  | No  |
|                  | Dahlak               | CM2 | CM2 | ND  | CM2 | CM1 | No  | No  |
|                  | Massawa              | CM2 | CM2 | NO  | CM2 | CM1 | CM2 | CM2 |
|                  | Ghindae              | CM2 | CM2 | NO  | CM2 | CM1 | CM2 | CM2 |
|                  | Shieb                | CM2 | No  | YES | CM2 | CM1 | No  | No  |
|                  | Afabet               | CM2 | CM2 | YES | CM2 | CM1 | No  | CM2 |
|                  | Nakfa                | CM2 | CM2 | NO  | CM2 | CM1 | No  | CM2 |
|                  | Adobha               | CM2 | No  | YES | CM2 | CM1 | No  | No  |
|                  | Karora               | CM2 | No  | NO  | CM2 | CM1 | No  | No  |
| Total SKB        | 10                   |     |     |     |     |     |     |     |
| Total<br>Country | 58                   |     |     |     |     |     |     |     |

Legend: ND (No data): if no information is available

No: if no active case finding is required (elimination goal is achieved at sub zoba level) ACF: if active case finding is planned or on-going for assessing the disease burden and treating CM1: if routine case finding and treatment are on-going in peripheral health facilities CM2: if routine case finding and treatment are on-going and reference to higher levels (hospitals) is organised for confirmation of diagnosis, treatment and prevention of complications and disabilities

## **PART 2: OPERATIONAL FRAMEWORK**

| Annex | 2. | 1: | Package | of | Preventive | Chemotherapy | (PCT) | - | Mass | drug | administration |
|-------|----|----|---------|----|------------|--------------|-------|---|------|------|----------------|
| (MDA) |    |    |         |    |            |              |       |   |      |      |                |

| Activity                              |                        | LF | Schisto | STH | Trachoma |
|---------------------------------------|------------------------|----|---------|-----|----------|
| Program coor                          | dination               | X  | X       | Х   | Х        |
| Advocacy                              |                        | Х  | Х       | Х   | Х        |
| Resource mob                          | oilization             | X  | X       | Х   | Х        |
| Social Mobili                         | zation                 | X  | X       | Х   | Х        |
| Training                              |                        | X  | X       | Х   | Х        |
| Mapping                               |                        | X  | X       | Х   | Х        |
|                                       | School                 |    | X       | Х   |          |
|                                       | MDA Campaign           | X  | X       | Х   |          |
| Drug                                  | Child immunization day |    | X       | Х   | Х        |
| Distribution Health and Nutrition day |                        |    | X       | Х   | Х        |
| HSAM                                  |                        | X  | Х       | Х   | Х        |
| M&E                                   |                        | Х  | Х       | Х   | Х        |

### Annex 2.2: Package of Case management (CM) and chronic care

| Key interventions  | Leprosy | LEISH | LF<br>complications | Trachiasis | Rabies | Dengue | Brucellosis | Anthrax |
|--|---------|-------|---------------------|------------|--------|--------|-------------|---------|
| Advocacy/resource<br>mobilization                        | Х       | Х     | X                   | X          | Х      | Х      | X           | Х       |
| Strengthening partnership                                | Х       | Х     | Х                   | X          | х      | Х      | Х           | Х       |
| Inter-sectoral collaboration                             | Х       | Х     | Х                   | X          | х      | Х      | X           | X       |
| Health promotion   | Х       | Х     | Х                   | Х          | х      | Х      | Х           | Х       |
| Capacity building  | Х       | Х     | Х                   | Х          | х      | Х      | Х           | Х       |
| Mapping  |         |       |                     |            |        |        |             |         |
| Passive case finding                                     | Х       | Х     | Х                   | Х          | х      | Х      | Х           | Х       |
| Active case finding                                      | Х       | Х     | Х                   | X          |        | Х      | Х           | Х       |
| Medical treatment  | Х       | Х     | Х                   | Х          | х      | Х      | Х           | Х       |
| Surgery  |         |       | Х                   | Х          |        |        |             |         |
| Prevention of disability                                 | Х       | Х     | Х                   | X          |        |        |             |         |
| Integrated vector<br>management/<br>reservoir<br>control |         | X     | X                   | X          | X      | X      |             |         |
| Surveillance   | Х       | Х     | Х                   | X          | х      | X      | X           | X       |

#### Annex 2. 3: PCT algorithm 1



#### Annex 2.4: PCT algorithm 2

Algorithm 2: Coordinated implementation of preventive chemotherapy intervention





Annex 2.5: Algorithm for Co-endemicity of CM-NTDs (Lepros y and Leishmaniasis) in Eritrea

## Annex 2.6 Package of Transmission control - vector/reservoir control

|   |               | Vector     | s and Associa | ociated NTDs |       |  |  |
|---|---------------|------------|---------------|--------------|-------|--|--|
|   |               |            | Other Vectors |              |       |  |  |
| Activity                                  |               | Mosquitoes | Snails        | Sand fly     |       |  |  |
|   | $\mathbf{LF}$ | Dengue     | Malaria       | Schisto      | Leish |  |  |
| LLINs                                     | X             | X          | X             |              |       |  |  |
| IRS                                       | Х             | Х          | Х             |              |       |  |  |
| Space spraying                            |               |            |               |              |       |  |  |
| Larviciding                               | Х             | Х          | Х             | X            | Х     |  |  |
| Prevention/treatment<br>of breeding sites | Х             | X          | Х             | X            | X     |  |  |

# Annex 2.7: Package of Improvement of Environment, Supply of safe drinking water, sanitation, and operational research

| Activity                                 | LF | SCH | STH | Trach | LEP | Leish | Dengue | Rabies | BRUC |
|--|----|-----|-----|-------|-----|-------|--------|--------|------|
| Partnership for water supply improvement |    | Х   | Х   | Х     |     |       |        |        |      |
| Partnership for sanitation improvement   | Х  | Х   | Х   | Х     |     |       | Х      |        |      |
| Social mobilization                      | Х  | Х   | Х   | Х     | Х   | Х     | X      |        |      |
| Health promotion                         | Х  | Х   | X   | Х     | Х   | Х     | Х      |        |      |
| Operational research                     | X  | X   | Х   | X     | X   | X     | X      |        |      |

## Annex 2.8: "WHAT to do" by sub zoba (operational unit) by operational package

| Province or<br>region | Sub-zoba or<br>community* | PCT- | NTDs           | CM-NTDs |           | PCT & CM NTDs |     | NTDs | NTDs T<br>for Elim<br>or Erad | argeted<br>ination<br>ication |
|-----------------------|---------------------------|------|----------------|---------|-----------|---------------|-----|------|-------------------------------|-------------------------------|
|                       |                           | МАР  | РСТ            | ACF     | CM1+<br>2 | IVM           | SWS | ІоЕ  | SURV                          | VERI<br>F                     |
| Anseba                | Hagaz                     |      | X              | X       | X         | Х             | X   | X    | X                             | X                             |
|                       | Adi-                      |      | v              | v       | v         | Х             | X   | Х    | X                             | Х                             |
|                       | l ekelezan                |      | Λ              |         |           | x             | x   | X    | x                             | x                             |
|                       | Flaberd                   |      |                |         |           | X             | X   | X    | X                             | X                             |
|                       |                           |      |                |         |           | X             | X   | X    | X                             | X                             |
|                       | Geleb                     |      | V              | X       |           | X             |     | X    | X                             | X                             |
|                       |                           |      | X              | X       |           |               |     |      | X<br>X                        | X                             |
|                       | Hamalmala                 |      | X              | X       | X         |               |     |      |                               |                               |
|                       | Hamelmalo                 |      | X              | X       | X         |               |     |      |                               |                               |
|                       | Keren                     |      | X              | X       | X         |               |     |      |                               |                               |
|                       | Kerkebet                  |      | X              | X       | X         |               |     |      |                               |                               |
| T-4-1                 | Selea                     |      | X              | X       | X         | Λ             |     | Λ    | Λ                             | Λ                             |
| l otal<br>A nseba     |                           |      |                |         |           |               |     |      |                               |                               |
|                       |                           |      |                |         |           |               |     |      |                               |                               |
| 20040                 | Adequala                  |      | X              | x       | x         | X             | X   | X    | X                             | X                             |
|                       | Adikeih                   |      | X              | X       | X         | X             | X   | X    | X                             | X                             |
|                       | Areza                     |      | X<br>V         |         |           | X             | X   | X    | X                             | X                             |
|                       | Dharwa                    |      |                |         |           | X             | X   | X    | X                             | X                             |
|                       | Dekembare                 |      |                |         |           | X             | X   | X    | X                             | X                             |
|                       | Imnihaili                 |      |                |         |           | X             | X   | X    | X                             | X                             |
|                       | Majajni                   |      |                |         |           | X             | X   | X    | X                             | X                             |
|                       | Maimine                   |      | $\Lambda$<br>V |         |           | X             | X   | X    | X                             | X                             |
|                       | Mondofora                 |      |                |         |           | X             | X   | X    | X                             | X                             |
|                       | Sogoniti                  |      |                |         |           | X             | X   | X    | X                             | X                             |
|                       | Segeniu                   |      | X              | X       |           | X             |     | X    | X                             | X                             |
|                       | Teerere                   |      | X              | X       | X         | X<br>V        |     | x    | X<br>V                        | X<br>V                        |
| Total                 | Tsorona                   |      | X              | X       | X         | Λ             | Λ   | Δ    |                               |                               |
| Debub                 |                           |      |                |         |           |               |     |      | Λ                             | Λ                             |
| DKB                   | Areta                     | X    | X              | X       | X         | X             | X   | X    | X                             | X                             |
|                       | Maakel                    |      |                |         |           | X             | X   | X    | X                             | X                             |
|                       | Dankalia                  | Х    |                | Χ       | X         |               |     |      |                               |                               |
|                       | Debub                     | • •  |                | T       |           | X             | X   | Х    | X                             | Х                             |
|                       | Dankalia                  | X    |                | X       | X         | v             | v   | v    | v                             | v                             |
| T-4-1 DVP             | Asseb                     | X    |                | X       | X         |               |     |      |                               |                               |
| 1 otal DKB            |                           |      |                |         |           | Λ             | Λ   | Λ    |                               |                               |
| Gasn<br>Barka         | Agurdet                   | X    |                | X       | X         |               |     |      | Λ                             | Λ                             |
|                       | Barentu                   | X    |                | X       | X         | X             | X   | X    | X                             | X                             |
|                       | Dighe                     | X    |                | X       | X         | X             | X   | X    | X                             | X                             |
|                       | Forto                     | X    | X              | X       | X         | X             | X   | X    | X                             | X                             |
|                       | Gogne                     | X    |                | Χ       | X         | X             | X   | X    | X                             | X                             |

|                      | Haycota             | X |   | Х | Х | X | Х | Х | X | Х |
|----------------------|---------------------|---|---|---|---|---|---|---|---|---|
|                      | LogoAnseba          | Х |   | Х | Х | Х | X | Х | Х | Х |
|                      | Mensura             | Х |   | Х | Х | Х | Х | Х | Х | Х |
|                      | Mogolo              | Х |   | Χ | Х | Х | X | Х | X | Х |
|                      | Gulug               | Х |   | Х | Х | Х | Х | Х | Х | Х |
|                      | Shambuko            | Х |   | Х | Х | Х | Х | Х | Х | Х |
|                      | Mulki               | Х |   | Χ | Х | Х | Х | Х | X | Х |
|                      | Teseney             | Х |   | Χ | Х | Х | Х | Х | X | Х |
|                      | Laalay Gash         | Х |   | Χ | Х | Х | Х | Х | X | Х |
| Total Gash-<br>Barka |                     |   |   |   |   |   |   |   |   |   |
| Maakel               |                     |   |   |   |   |   |   |   |   |   |
|                      | Berik               | Х | Х | Χ | Х | Х | Х | Х | X | Х |
|                      | Debubawi<br>Mbrak   | Х | X | Х | X | Х | Х | Х | Х | Х |
|                      | Debubawi-<br>me'rab | X |   | Х | X | Х | X | Х | X | X |
|                      | Gaa-Nefhi           | Х | Х | Χ | Х | X | X | Х | Х | X |
|                      | Semenawi-<br>me'rab | X | X | Х | X | Х | X | X | Х | X |
|                      | Semenawi-<br>mibrak | X |   | Х | X | Х | Х | X | Х | X |
|                      | Serejeka            | Х | Х | Х | Х | Х | Х | Х | Х | Х |
| Total<br>Maakel      |                     |   |   |   |   |   |   |   |   |   |
| SKB                  | Ghelealo            | Х |   | Χ | Х |   |   |   |   |   |
|                      | Foro                | Х |   | Χ | Х | Х | Х | Х | X | Х |
|                      | Dahlak              | Х |   | Χ | Х | Х | Х | Х | X | Х |
|                      | Massawa             | Х |   | Χ | Х | Х | Х | Х | X | Х |
|                      | Ghindae             | Х |   | Χ | Х | X | Х | Х | X | Х |
|                      | Shieb               | Х |   | Χ | Х | Х | Х | Х | Х | Х |
|                      | Afabet              | Х |   | Х | Х | Х | Х | Х | Х | Х |
|                      | Nakfa               | Х | Х | Х | Х | Х | Х | Х | Х | Х |
|                      | Adobha              | Х |   | Χ | Х | Х | X | X | X | X |
|                      | Karora              | Х |   | X | Х | Х | Х | Х | Х | Х |
| Total SKB            |                     |   |   |   |   |   |   |   |   |   |
| Total                |                     |   |   |   |   |   |   |   |   |   |
| country              |                     |   |   |   |   |   |   |   |   |   |

#### **LEGEND:**

MAP= Mapping; PCT= MDA, CDTI and Targeted Treatment; ACF= Active Case finding; CM1+2= Routine case finding and treatment in HF1 (peripheral) and HF2 (reference hospitals); IVM= Integrated Vector Management; SSWS= Sanitation and Safe drinking Water Supply; IoE= Improvement of Environment; SURV= Surveillance; VERIF= Verification

#### Annex 2.9: Drug estimates and logistics

| NTD programme | Drug              | Source drug   | Status of   | Minimum lead | In-country consignee  |
|---------------|-------------------|---------------|-------------|--------------|-----------------------|
|               |                   |               | procurement | time before  |                       |
|               |                   |               | (donated or | delivery     |                       |
|               |                   |               | purchased)  |              |                       |
| LFE           | DEC               | WHO/GOV       | Donated     | 6 months     | Central Medical Store |
| LEPROSY       | MDT blister packs | WHO, Novartis | Donated     | 6 months     | Central Medical Store |
| SCH           | PZQ               | WHO/GOV       | Donated     | 6 months     | Central Medical Store |
| STH           | ALB               | WHO/GOV       | Donated     | 6 months     | Central Medical Store |
| Trachoma      | AZI               | ITI           | Donated     | 6 months     | Central Medical Store |

#### Annex 2.10: Drug forecasting and logistics

| Drug | Source of drug | Status of procurement | Minimum Lead         | In-country Consignee  |
|------|----------------|-----------------------|----------------------|-----------------------|
|      |                | (donate/purchased)    | time before delivery |                       |
| DEC  | WHO            | Donated               | 6 months             | Central Medical Store |
| ALB  | WHO            | Donated               | 6 months             | Central Medical Store |
| MEB  | WHO            | Donated               | 6 months             | Central Medical Store |
| PZQ  | WHO            | Donated               | 6 months             | Central Medical Store |
| AZI  | ITI            | Donated               | 6 months             | Central Medical Store |

• Complete the following table to describe how essential NTD drug supplies will be obtained.

• Identify sources of drugs (procured or donated)

• Describe management, logistics and monitoring system for delivering drugs to field distributions sites.

Annex 2.11: Summary of progressive scale up and phase out of PCT interventions package

|   | Status of interventions   | Other PCT-NTD specific activities to be added                      |
|---|---------------------------|--|
| 1 | LF MDA planned in Forto & | • Map schisotosomiais and STH                                      |
|   | Araata sub zones          | • Collect baseline for LF, schistosomiasis and STH                 |
|   |                           | • Coordinate timing of delivery of MDA through community-based and |
|   |                           | school-based approaches appropriately.                             |
| 2 | LF not endemic            | • Map schisotosomiais and STH                                      |
|   |                           | • Coordinate timing of delivery of MDA through community-based and |
|   |                           | school-based approaches appropriately.                             |

| Strategic priorities  | Strategic objectives   | Core indicators   |
|---|--|---|
| 1 Strengthen<br>advocacy,<br>coordination and<br>partnerships   | <ul> <li>I. Strengthen coordination mechanisms for the NTD control programme at regional, national and subnational levels in the African Region;</li> <li>II. Strengthen and foster partnerships for the control, elimination and eradication of targeted NTDs at regional, national, district and community levels;</li> <li>III. Enhance high level reviews of NTD programme performance and the use of lessons learnt to enhance advocacy, awareness and effective implementation of targeted interventions;</li> <li>IV. Strengthen advocacy, visibility and profile of NTD control elimination and eradication interventions at all levels in the African Region.</li> </ul>  | <ul> <li>Minutes of high-level NTD coordination meeting;</li> <li>Minutes of partnership events on NTDs;</li> <li>Number of high level advocacy events on NTDs;</li> <li>Number of partners involved in NTD programme.</li> </ul>   |
| 2 Enhance<br>resource<br>mobilization and<br>planning for results<br>in NTD control   | <ul> <li>I. Support countries to update integrated<br/>multiyear strategic plans and gender-sensitive<br/>annual operational plans for the control,<br/>elimination and eradication of targeted NTDs</li> <li>II. Enhance resource mobilization approaches<br/>and strategies at regional, national and sub-<br/>national levels for NTD interventions</li> <li>III. Strengthen the integration and linkages of<br/>NTD programme and financial plans into<br/>sector-wide and national budgetary and<br/>financing mechanisms</li> <li>IV. Support countries to develop and update<br/>national NTD policies and elaborate<br/>guidelines and tools to guide effective policy<br/>and programme implementation</li> </ul> | <ul> <li>Number of countries with<br/>updated national integrated<br/>NTD strategic plans;</li> <li>Number of NTD guidelines and<br/>NTD planning and<br/>implementation tools<br/>developed;</li> <li>Number of countries with<br/>adapted national guidelines and<br/>tools;</li> <li>Presence of NTD budget line;</li> <li>Total amount of financial<br/>resources available for NTD<br/>activities;</li> <li>Percentage of planned NTD<br/>funds received.</li> </ul> |
| 3 Scaleup<br>access to<br>interventions,<br>treatment and NTD<br>service delivery<br>capacity, within the<br>overall health<br>system | <ul> <li>I. Scale up an integrated preventive<br/>chemotherapy, including access to<br/>interventions forlymphatic filariasis, soil<br/>transmitted helminthiasis,onchocerciasis,<br/>schistosomiasis and trachoma;</li> <li>II. Scale up integrated case-management-based<br/>disease interventions, especially do the<br/>following: <ul> <li>a. Intensify guinea worm surveillance;</li> <li>b. Enhance HAT control interventions for<br/>human African trypanosomiasis;</li> <li>c. Strengthen national programme to control<br/>Buruli ulcer;</li> <li>d. Strengthen leishmaniasis control and human</li> </ul> </li> </ul>   | <ul> <li>Number of districts mapped for<br/>NTDs;</li> <li>Drug administration coverage;</li> <li>National coverage;</li> <li>Parasitological prevalence;</li> <li>Percentage of disease-specific<br/>targets achieved.</li> </ul>  |

## Annex 2.12: Results framework for the WHO-HQ-AFRO-APOC Strategic Plan, 2015–2020

| Strategic priorities  | Strategic objectives   | Core indicators   |
|---|--|---|
|   | <ul> <li>rabies prevention;</li> <li>e. Strengthen national programme to eliminate tungiasis and control podoconiosis;</li> <li>III. Strengthening integrated vector management for targeted NTDs.</li> <li>IV. Strengthen capacity at the national level for NTD programme management and implementation and accelerate implementation of disease burden assessments and integrated mapping of NTDs;</li> </ul>   |   |
| 4 Enhance<br>NTD monitoring<br>and evaluation,<br>surveillance and<br>operations research | <ul> <li>I. Develop and promote an integrated NTD<br/>M&amp;E framework and improve monitoring of<br/>NTDs, within the context of national health<br/>information systems. This will include<br/>strengthening the reporting and response to<br/>severe adverse events (SAEs) by leveraging<br/>on-going efforts to strengthen<br/>pharmacovigilance systems;</li> <li>II. Strengthen surveillance of NTDs and<br/>strengthen response and control of epidemic-<br/>prone NTDs, in particular leishmaniasis;</li> <li>III. Support operational research, documentation<br/>and evidence to guide innovative approaches<br/>to NTD programme interventions;</li> <li>IV. Establish integrated data management<br/>systems and support impact analysis for<br/>NTD.</li> </ul> | <ul> <li>NTD data completeness and timeliness;</li> <li>Number of evaluation studies conducted and results disseminated;</li> <li>Number of operational research studies conducted and results disseminated;</li> <li>A functional data management system.</li> </ul> |

## **Bibliography**

- 1. Eritrean Ministry of health (2007). Summary report of National trachoma prevalence survey.
- 2. Eritrea HMIS guideline, 2008)
- 3. Eritrean (2014). Ministry of health National Blindness Prevention and control programme. Trachoma control programme MDA progressive report, 1st – 4th round.
- 4. Eritrea Ministry of health (2012). Nationwide latrine coverage survey and knowledge, attitude, behavior and practice (KABP) study on water, sanitation and hygiene (wash)
- 5. Eritrea Ministry of health (2010). National Health Policy.
- 6. Erutrean Ministry of health (2013). National master plan Neglected Tropical Diseases
- 7. Ministry of Health, Health sector strategic development plan (HSSDP: 2012-2016), 2011.
- 8. Ministry of Health, National Blindness Prevention and Control Program Trachoma Control Project, 2011.
- 9. Ministry of Health, Summary report of National Trachoma Prevalence survey, 2007.
- 10. Ministry of Education, Report on schist soma Treatment in schools in Halhal and Aditekelezan sub- Zobas, 2011-2012.
- 11. Ministry of Health, Country Plan for Safe Strategy- Eritrea, 2009-2011.
- 12. Ministry of Health, Country Plan for Safe Strategy- Eritrea, 2008-2010.
- 13. Ministry of Health, National Blindness Prevention Program (NBPP), Guide line for Azithromycin control for Eritrea Safe program,2010
- 14. Ministry of Health, Primary Eye Care Manual, 2006.
- 15. Ministry of Health, Department of Health Services, Second National Strategic Plan of Action 2010-2015.
- 16. National Statistics Office, Demographic and Health Survey, 1995.
- 17. World Health Organization, State of the world's Sight Vision 2020: the Right to Sight, 1999-2005.
- 18. WHO 2012 Guide for preparing a Master Plan for Neglected Tropical Diseases Programme in the African Region,
- 19. WHO (2014). Guide for preparing master plan for national neglected tropical diseases programmes in the African region. WHO regional office for Africa.
- 20. Who (2013). Regional strategic plan for Neglected Tropical Diseases in the African region 2014-2020. WHO regional office for Africa.